data_1g1p_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1g1p _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.2 p . . . . . 0 N--CA 1.428 -1.549 1 N-CA-C 97.849 -4.871 . . . . 0.0 97.849 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.5 mt -92.09 148.22 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 104.862 -2.274 . . . . 0.0 104.862 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.6 tttt . . . . . 0 N--CA 1.437 -1.092 0 C-N-CA 127.127 2.171 . . . . 0.0 107.747 -168.095 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 . . . . . 0 N--CA 1.444 -0.773 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.26 173.98 25.74 Favored Glycine 0 C--N 1.354 1.568 0 N-CA-C 105.802 -2.919 . . . . 0.0 105.802 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -85.08 131.78 34.41 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-N 118.372 1.086 . . . . 0.0 108.907 -174.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p . . . . . 0 CA--C 1.493 -1.226 0 C-N-CA 123.783 0.833 . . . . 0.0 108.925 -178.353 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 CA--C 1.498 -1.036 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.95 -33.23 75.13 Favored 'General case' 0 C--N 1.354 0.772 0 CA-C-O 121.134 0.493 . . . . 0.0 110.491 176.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -90.18 9.69 27.47 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 121.696 -0.628 . . . . 0.0 110.124 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.83 -69.34 1.18 Allowed Glycine 0 CA--C 1.492 -1.348 0 O-C-N 121.142 -0.974 . . . . 0.0 112.995 165.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.87 153.56 20.55 Favored 'General case' 0 CA--C 1.494 -1.187 0 CA-C-N 118.202 1.001 . . . . 0.0 108.768 -160.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 50.6 t -130.83 133.91 46.36 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 102.428 -3.175 . . . . 0.0 102.428 -176.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.5 p -137.26 37.27 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 102.671 -3.085 . . . . 0.0 102.671 175.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.04 -55.36 0.97 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 106.072 -2.811 . . . . 0.0 106.072 -176.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 m -94.85 156.53 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 165.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 57.0 m -73.62 129.7 38.5 Favored 'General case' 0 CA--C 1.486 -1.495 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.48 -156.8 0.7 Allowed 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 . . . . . 0 N--CA 1.418 -2.031 1 N-CA-C 98.569 -4.604 . . . . 0.0 98.569 -170.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.43 -1.474 1 N-CA-C 98.933 -4.469 . . . . 0.0 98.933 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.6 mt -93.58 136.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 176.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.5 ttpp . . . . . 0 N--CA 1.435 -1.186 0 C-N-CA 127.847 2.459 . . . . 0.0 108.584 -166.287 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 . . . . . 0 N--CA 1.441 -0.918 0 CA-C-O 120.824 0.345 . . . . 0.0 111.26 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.86 160.22 13.44 Favored Glycine 0 CA--C 1.491 -1.448 1 N-CA-C 102.548 -4.221 . . . . 0.0 102.548 167.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -74.34 149.91 40.38 Favored 'General case' 0 CA--C 1.503 -0.833 0 CA-C-N 118.094 0.947 . . . . 0.0 111.636 -165.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 30.1 p . . . . . 0 N--CA 1.436 -1.131 1 N-CA-C 98.884 -4.488 . . . . 0.0 98.884 170.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.7 m . . . . . 0 CA--C 1.485 -1.544 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.3 m -63.19 -37.56 87.71 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 121.327 0.584 . . . . 0.0 111.052 -171.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.8 p -90.52 7.07 40.86 Favored 'General case' 0 N--CA 1.443 -0.821 0 C-N-CA 124.695 1.198 . . . . 0.0 111.741 178.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.21 -69.91 0.27 Allowed Glycine 0 C--N 1.35 1.334 0 O-C-N 121.171 -0.956 . . . . 0.0 111.505 170.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.3 145.16 31.03 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-N 118.227 1.013 . . . . 0.0 110.986 -167.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.3 t -128.31 129.66 46.64 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 101.339 -3.578 . . . . 0.0 101.339 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.8 p -133.24 -138.6 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -0.982 1 N-CA-C 97.837 -4.875 . . . . 0.0 97.837 165.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.99 -4.68 56.17 Favored Glycine 0 C--N 1.348 1.236 0 O-C-N 118.657 -2.527 . . . . 0.0 112.322 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.45 164.09 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.954 1 N-CA-C 98.794 -4.521 . . . . 0.0 98.794 174.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 73.3 m -77.57 141.03 39.77 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 167.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.5 -146.1 0.19 Allowed 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 104.165 -2.531 . . . . 0.0 104.165 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.425 -1.706 1 N-CA-C 96.989 -5.189 . . . . 0.0 96.989 173.033 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.0 p . . . . . 0 CA--C 1.491 -1.314 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -92.97 140.63 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 101.543 -3.502 . . . . 0.0 101.543 172.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.7 tttm . . . . . 0 N--CA 1.44 -0.959 0 CA-C-O 117.382 -1.294 . . . . 0.0 108.276 -162.738 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 . . . . . 0 CA--C 1.507 -0.676 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.91 168.39 26.1 Favored Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 105.889 -2.884 . . . . 0.0 105.889 172.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -85.46 146.4 26.97 Favored 'General case' 0 CA--C 1.504 -0.805 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -177.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.7 p . . . . . 0 N--CA 1.434 -1.261 0 N-CA-C 103.432 -2.803 . . . . 0.0 103.432 -177.309 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.3 m . . . . . 0 CA--C 1.5 -0.96 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -62.13 -42.65 99.45 Favored 'General case' 0 C--N 1.358 0.938 0 CA-C-N 118.805 0.73 . . . . 0.0 110.024 -177.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.4 p -87.53 17.63 4.45 Favored 'General case' 0 N--CA 1.441 -0.916 0 C-N-CA 123.716 0.806 . . . . 0.0 111.314 177.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.99 -71.49 0.89 Allowed Glycine 0 CA--C 1.49 -1.494 0 O-C-N 120.552 -1.342 . . . . 0.0 111.595 164.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.18 144.73 25.6 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 121.755 -0.85 . . . . 0.0 111.09 -163.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.9 t -111.38 133.43 53.7 Favored 'General case' 0 N--CA 1.432 -1.348 0 N-CA-C 101.212 -3.625 . . . . 0.0 101.212 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.77 41.47 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.173 0 N-CA-C 102.86 -3.015 . . . . 0.0 102.86 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.31 -61.19 1.06 Allowed Glycine 0 C--N 1.352 1.431 0 N-CA-C 105.434 -3.066 . . . . 0.0 105.434 -174.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.1 m -95.07 160.6 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 166.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 67.1 m -78.86 135.4 37.02 Favored 'General case' 0 CA--C 1.495 -1.17 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 172.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.89 -140.7 0.11 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 103.436 -2.802 . . . . 0.0 103.436 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 . . . . . 0 N--CA 1.423 -1.821 1 N-CA-C 96.893 -5.225 . . . . 0.0 96.893 174.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.435 -1.224 0 N-CA-C 103.396 -2.816 . . . . 0.0 103.396 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . 0.41 ' HB ' ' SG ' ' A' ' 20' ' ' CYS . 57.0 mt -89.45 150.69 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 102.835 -3.024 . . . . 0.0 102.835 165.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.1 tttm . . . . . 0 N--CA 1.439 -1.006 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 -164.31 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.257 86.9 m-85 . . . . . 0 CA--C 1.503 -0.84 0 CA-C-O 121.301 0.572 . . . . 0.0 110.499 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.9 163.0 19.32 Favored Glycine 0 CA--C 1.491 -1.449 0 N-CA-C 105.335 -3.106 . . . . 0.0 105.335 166.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -79.92 145.58 32.58 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.433 -1.294 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 -170.671 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.41 ' SG ' ' HB ' ' A' ' 4' ' ' ILE . 84.8 m . . . . . 0 CA--C 1.484 -1.585 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.0 m -64.6 -36.78 85.34 Favored 'General case' 0 C--N 1.351 0.645 0 CA-C-O 121.242 0.544 . . . . 0.0 110.183 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.6 p -87.69 1.15 54.54 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.17 0.988 . . . . 0.0 110.316 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.9 -79.67 1.5 Allowed Glycine 0 N--CA 1.437 -1.249 0 O-C-N 121.421 -0.799 . . . . 0.0 111.939 173.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.57 123.31 28.54 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 113.421 0.897 . . . . 0.0 113.421 -149.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -96.64 127.09 42.3 Favored 'General case' 0 CA--C 1.5 -0.954 0 C-N-CA 125.435 1.494 . . . . 0.0 107.309 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.79 42.22 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.061 -2.941 . . . . 0.0 103.061 175.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.88 -56.12 1.14 Allowed Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 106.118 -2.793 . . . . 0.0 106.118 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.7 m -103.91 156.78 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 103.019 -2.956 . . . . 0.0 103.019 163.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -89.58 143.89 26.45 Favored 'General case' 0 CA--C 1.482 -1.67 0 CA-C-O 121.172 0.511 . . . . 0.0 109.905 179.323 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.26 -146.75 0.19 Allowed 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 102.421 -3.177 . . . . 0.0 102.421 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.431 -1.406 1 N-CA-C 95.876 -5.601 . . . . 0.0 95.876 166.329 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.428 -1.559 1 N-CA-C 99.276 -4.342 . . . . 0.0 99.276 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.1 mt -88.66 145.98 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 -172.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.5 tttt . . . . . 0 N--CA 1.437 -1.08 0 C-N-CA 126.766 2.026 . . . . 0.0 109.762 -162.179 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.269 96.3 m-85 . . . . . 0 CA--C 1.504 -0.81 0 CA-C-O 120.911 0.386 . . . . 0.0 111.847 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.81 171.05 27.01 Favored Glycine 0 C--N 1.352 1.446 0 N-CA-C 104.473 -3.451 . . . . 0.0 104.473 163.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -90.13 159.36 16.82 Favored 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 175.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.433 -1.323 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 -174.228 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 93.1 m . . . . . 0 CA--C 1.485 -1.542 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 59.2 m -66.87 -36.35 82.11 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.905 0.383 . . . . 0.0 110.929 -173.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.6 p -90.15 9.65 27.53 Favored 'General case' 0 N--CA 1.438 -1.058 0 C-N-CA 123.925 0.89 . . . . 0.0 111.158 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.48 -74.84 0.21 Allowed Glycine 0 C--N 1.353 1.478 0 O-C-N 121.294 -0.879 . . . . 0.0 111.439 168.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.02 141.1 30.54 Favored 'General case' 0 CA--C 1.494 -1.205 0 O-C-N 121.753 -0.851 . . . . 0.0 109.555 -162.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 25.8 t -119.81 126.62 51.43 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 98.492 -4.633 . . . . 0.0 98.492 171.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.3 p -146.47 48.29 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 101.924 -3.361 . . . . 0.0 101.924 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.69 -62.67 2.65 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.151 -2.779 . . . . 0.0 106.151 -174.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.9 m -89.25 158.36 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 167.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.0 m -82.1 128.96 34.65 Favored 'General case' 0 CA--C 1.49 -1.347 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 168.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.78 -142.77 0.2 Allowed 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 -178.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.422 -1.843 1 N-CA-C 97.734 -4.913 . . . . 0.0 97.734 -176.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.6 p . . . . . 0 CA--C 1.492 -1.264 0 N-CA-C 102.888 -3.004 . . . . 0.0 102.888 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 38.0 mt -111.75 149.63 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 101.791 -3.411 . . . . 0.0 101.791 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 tptp . . . . . 0 N--CA 1.441 -0.897 0 C-N-CA 125.002 1.321 . . . . 0.0 108.184 -164.946 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.258 75.0 m-85 . . . . . 0 CA--C 1.505 -0.766 0 CA-C-O 120.679 0.276 . . . . 0.0 111.605 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.97 169.41 29.56 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 105.544 -3.023 . . . . 0.0 105.544 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -85.23 154.17 22.13 Favored 'General case' 0 CA--C 1.5 -0.962 0 N-CA-C 106.804 -1.554 . . . . 0.0 106.804 178.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 CA--C 1.492 -1.281 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -173.539 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.0 m . . . . . 0 CA--C 1.496 -1.1 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.5 -31.42 69.66 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.093 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.3 p -87.26 9.5 20.07 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.749 1.22 . . . . 0.0 111.086 173.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.68 -78.96 0.49 Allowed Glycine 0 C--N 1.351 1.37 0 O-C-N 120.866 -1.147 . . . . 0.0 110.495 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.44 146.7 32.63 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 117.431 0.615 . . . . 0.0 111.368 -161.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.6 t -125.78 131.51 52.47 Favored 'General case' 0 N--CA 1.429 -1.499 1 N-CA-C 97.741 -4.911 . . . . 0.0 97.741 173.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -149.16 51.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.137 0 N-CA-C 101.407 -3.553 . . . . 0.0 101.407 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.01 -60.73 1.64 Allowed Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.235 -2.746 . . . . 0.0 106.235 -176.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.4 m -100.28 161.34 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.007 -2.219 . . . . 0.0 105.007 167.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 54.1 m -80.65 136.74 36.26 Favored 'General case' 0 CA--C 1.49 -1.357 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 174.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.01 -165.29 2.13 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -176.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.436 -1.128 0 N-CA-C 103.643 -2.725 . . . . 0.0 103.643 170.424 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.426 -1.638 1 N-CA-C 97.086 -5.153 . . . . 0.0 97.086 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.1 mt -107.59 148.43 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.322 0 N-CA-C 102.083 -3.303 . . . . 0.0 102.083 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.2 tptt . . . . . 0 N--CA 1.439 -1.008 0 C-N-CA 126.061 1.745 . . . . 0.0 108.343 -162.48 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 . . . . . 0 CA--C 1.507 -0.708 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.4 167.01 22.16 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 169.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.19 142.44 32.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -175.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p . . . . . 0 CA--C 1.501 -0.918 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 178.967 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 91.5 m . . . . . 0 CA--C 1.492 -1.269 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.25 -29.5 69.15 Favored 'General case' 0 C--N 1.352 0.71 0 CA-C-N 118.713 0.688 . . . . 0.0 111.414 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -90.03 -3.05 58.19 Favored 'General case' 0 N--CA 1.438 -1.071 0 O-C-N 121.292 -0.88 . . . . 0.0 109.841 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 115.48 -79.28 0.28 Allowed Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 109.829 -1.309 . . . . 0.0 109.829 170.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.19 151.4 24.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 O-C-N 122.596 -0.356 . . . . 0.0 110.585 -163.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -123.82 131.2 53.54 Favored 'General case' 0 CA--C 1.489 -1.39 1 N-CA-C 98.553 -4.61 . . . . 0.0 98.553 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.67 39.03 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 103.33 -2.841 . . . . 0.0 103.33 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.61 -55.68 1.03 Allowed Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.251 -2.74 . . . . 0.0 106.251 -176.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.5 m -98.21 164.3 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 163.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 63.7 m -81.69 139.55 34.85 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 171.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.35 -152.93 0.46 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 -177.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 N--CA 1.424 -1.742 1 N-CA-C 97.337 -5.06 . . . . 0.0 97.337 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p . . . . . 0 CA--C 1.484 -1.574 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.1 mt -97.97 149.49 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 175.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.354 0.771 0 C-N-CA 125.132 1.373 . . . . 0.0 108.496 -163.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.263 97.2 m-85 . . . . . 0 CA--C 1.503 -0.857 0 CA-C-O 121.108 0.48 . . . . 0.0 112.057 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.64 170.8 28.47 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 105.414 -3.074 . . . . 0.0 105.414 164.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -88.23 140.36 29.56 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 -176.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.9 p . . . . . 0 CA--C 1.498 -1.027 0 CA-C-O 122.275 1.036 . . . . 0.0 109.142 -174.044 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -72.64 -28.5 62.78 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.598 -0.689 . . . . 0.0 109.957 -178.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.5 p -90.66 11.63 21.53 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 124.36 1.064 . . . . 0.0 110.404 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.65 -77.72 0.93 Allowed Glycine 0 CA--C 1.491 -1.465 0 O-C-N 121.065 -1.022 . . . . 0.0 110.989 171.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.63 142.0 31.12 Favored 'General case' 0 CA--C 1.497 -1.092 0 CA-C-N 117.948 0.874 . . . . 0.0 109.999 -159.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 t -118.44 130.26 55.86 Favored 'General case' 0 CA--C 1.485 -1.544 1 N-CA-C 99.796 -4.15 . . . . 0.0 99.796 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -142.46 42.91 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.34 -60.41 1.31 Allowed Glycine 0 C--N 1.352 1.455 0 N-CA-C 106.232 -2.747 . . . . 0.0 106.232 -176.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.82 157.6 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 164.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 m -79.4 133.25 36.56 Favored 'General case' 0 CA--C 1.486 -1.504 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 174.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.55 -164.44 1.41 Allowed 'General case' 0 N--CA 1.428 -1.547 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 -176.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.5 p30 . . . . . 0 N--CA 1.423 -1.794 0 N-CA-C 100.752 -3.795 . . . . 0.0 100.752 179.147 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 6.2 p . . . . . 0 CA--C 1.499 -1.016 0 N-CA-C 102.223 -3.251 . . . . 0.0 102.223 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 35.5 mt -94.54 141.64 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt . . . . . 0 N--CA 1.442 -0.872 0 C-N-CA 127.334 2.254 . . . . 0.0 110.579 -163.005 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.443 -0.823 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.2 166.46 21.05 Favored Glycine 0 CA--C 1.493 -1.324 0 N-CA-C 105.056 -3.218 . . . . 0.0 105.056 164.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -66.6 148.2 52.23 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 125.399 1.48 . . . . 0.0 107.167 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.4 p . . . . . 0 CA--C 1.483 -1.612 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 178.058 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 94.0 m . . . . . 0 CA--C 1.489 -1.393 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 33.7 m -71.58 -30.4 65.79 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -175.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.09 -1.9 58.02 Favored 'General case' 0 N--CA 1.439 -0.991 0 C-N-CA 124.83 1.252 . . . . 0.0 110.245 177.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.86 -70.26 0.21 Allowed Glycine 0 CA--C 1.49 -1.503 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 172.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.61 145.68 27.9 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -161.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.2 t -132.22 133.03 43.68 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 100.726 -3.805 . . . . 0.0 100.726 -177.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.68 -125.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.885 1 N-CA-C 98.563 -4.606 . . . . 0.0 98.563 161.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.58 -9.17 86.25 Favored Glycine 0 C--N 1.349 1.276 0 O-C-N 118.316 -2.74 . . . . 0.0 110.801 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 m -148.12 161.58 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.755 1 N-CA-C 99.482 -4.266 . . . . 0.0 99.482 -172.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 97.8 m -78.7 136.57 37.47 Favored 'General case' 0 CA--C 1.489 -1.376 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 -165.46 1.5 Allowed 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 . . . . . 0 N--CA 1.421 -1.9 1 N-CA-C 99.108 -4.404 . . . . 0.0 99.108 -174.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 CA--C 1.488 -1.429 0 N-CA-C 100.513 -3.884 . . . . 0.0 100.513 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.5 mt -100.68 154.47 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 173.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? . . . . . 0 N--CA 1.44 -0.966 0 C-N-CA 125.294 1.437 . . . . 0.0 108.53 -161.577 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 CA--C 1.502 -0.896 0 CA-C-O 122.044 0.926 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.57 173.28 16.44 Favored Glycine 0 C--N 1.35 1.334 1 N-CA-C 102.348 -4.301 . . . . 0.0 102.348 162.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -89.86 145.86 24.85 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -175.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.8 p . . . . . 0 N--CA 1.433 -1.279 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 -177.501 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 CA--C 1.488 -1.404 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.29 -28.56 66.39 Favored 'General case' 0 C--N 1.35 0.617 0 CA-C-O 121.12 0.486 . . . . 0.0 110.183 -176.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 7.2 p -90.31 11.17 22.16 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 124.622 1.169 . . . . 0.0 110.833 175.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.69 -68.75 0.88 Allowed Glycine 0 CA--C 1.492 -1.359 0 O-C-N 120.672 -1.268 . . . . 0.0 111.704 165.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.78 142.66 28.8 Favored 'General case' 0 CA--C 1.496 -1.099 0 O-C-N 121.272 -1.134 . . . . 0.0 109.698 -164.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.3 t -132.93 127.48 34.38 Favored 'General case' 0 CA--C 1.486 -1.487 1 N-CA-C 99.653 -4.202 . . . . 0.0 99.653 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.44 62.8 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.161 0 N-CA-C 101.712 -3.44 . . . . 0.0 101.712 172.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.18 -63.41 2.76 Favored Glycine 0 C--N 1.351 1.414 0 N-CA-C 106.993 -2.443 . . . . 0.0 106.993 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.0 m -91.65 155.33 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.21 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 168.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.2 m -80.24 122.67 27.16 Favored 'General case' 0 CA--C 1.487 -1.445 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 166.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.55 -147.56 0.37 Allowed 'General case' 0 N--CA 1.432 -1.365 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 . . . . . 0 N--CA 1.42 -1.965 1 N-CA-C 95.58 -5.711 . . . . 0.0 95.58 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.427 -1.621 1 N-CA-C 96.47 -5.381 . . . . 0.0 96.47 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mt -89.43 140.6 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 -177.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 74.6 tttt . . . . . 0 N--CA 1.441 -0.877 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -158.558 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.306 68.3 m-85 . . . . . 0 N--CA 1.443 -0.806 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.36 168.65 16.66 Favored Glycine 0 N--CA 1.437 -1.298 0 N-CA-C 103.345 -3.902 . . . . 0.0 103.345 158.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -87.86 143.89 26.88 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.002 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.433 -1.308 0 N-CA-C 102.488 -3.153 . . . . 0.0 102.488 174.35 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 88.1 m . . . . . 0 CA--C 1.489 -1.386 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 38.9 m -66.9 -36.11 81.53 Favored 'General case' 0 C--N 1.351 0.637 0 CA-C-O 121.026 0.441 . . . . 0.0 111.516 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.6 p -90.34 15.04 11.27 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 123.846 0.858 . . . . 0.0 111.114 177.308 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.47 -67.7 0.69 Allowed Glycine 0 CA--C 1.489 -1.545 0 O-C-N 121.128 -0.983 . . . . 0.0 110.722 167.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.03 133.07 35.26 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 121.639 -0.918 . . . . 0.0 110.252 -166.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 12.5 t -123.61 122.48 38.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 100.487 -3.894 . . . . 0.0 100.487 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -151.21 65.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 103.228 -2.879 . . . . 0.0 103.228 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.25 -62.84 3.78 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 107.069 -2.412 . . . . 0.0 107.069 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -99.65 159.44 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 104.756 -2.312 . . . . 0.0 104.756 171.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 66.1 m -83.42 128.43 34.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 170.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.45 -152.36 0.41 Allowed 'General case' 0 N--CA 1.432 -1.333 0 N-CA-C 104.502 -2.406 . . . . 0.0 104.502 -174.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.424 -1.743 1 N-CA-C 97.371 -5.048 . . . . 0.0 97.371 173.071 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p . . . . . 0 CA--C 1.495 -1.138 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.3 mt -95.52 146.37 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 -175.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 ttpp . . . . . 0 N--CA 1.443 -0.807 0 C-N-CA 127.074 2.149 . . . . 0.0 110.197 -167.279 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 . . . . . 0 N--CA 1.444 -0.727 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.16 167.18 23.66 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 103.784 -3.726 . . . . 0.0 103.784 160.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -82.66 141.44 32.48 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 176.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p . . . . . 0 N--CA 1.435 -1.205 0 CA-C-O 122.403 1.097 . . . . 0.0 109.933 -169.429 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 N--CA 1.428 -1.561 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 55.8 m -70.16 -31.93 69.66 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -173.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.41 9.79 27.68 Favored 'General case' 0 N--CA 1.442 -0.834 0 C-N-CA 124.268 1.027 . . . . 0.0 110.43 175.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.27 -72.82 0.38 Allowed Glycine 0 CA--C 1.489 -1.554 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 170.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.79 151.95 25.9 Favored 'General case' 0 CA--C 1.498 -1.021 0 O-C-N 122.192 -0.593 . . . . 0.0 111.286 -162.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 1.9 t -138.23 133.61 33.41 Favored 'General case' 0 CA--C 1.485 -1.528 1 N-CA-C 97.315 -5.069 . . . . 0.0 97.315 -175.151 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -158.19 55.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 102.975 -2.972 . . . . 0.0 102.975 175.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.67 -64.23 2.16 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 106.113 -2.795 . . . . 0.0 106.113 -176.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.3 m -92.43 159.85 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 168.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.6 m -79.92 139.54 37.05 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 168.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.62 -149.39 0.28 Allowed 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 104.38 -2.452 . . . . 0.0 104.38 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.425 -1.695 1 N-CA-C 96.513 -5.366 . . . . 0.0 96.513 173.188 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.425 -1.7 1 N-CA-C 99.738 -4.171 . . . . 0.0 99.738 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -93.37 144.4 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.158 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 -177.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.3 tttm . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 127.853 2.461 . . . . 0.0 108.604 -170.582 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 . . . . . 0 CA--C 1.503 -0.848 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.67 166.49 13.67 Favored Glycine 0 C--N 1.349 1.296 0 N-CA-C 104.293 -3.523 . . . . 0.0 104.293 163.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -81.35 134.37 35.56 Favored 'General case' 0 CA--C 1.503 -0.834 0 CA-C-N 118.253 1.026 . . . . 0.0 108.251 -175.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.5 p . . . . . 0 CA--C 1.504 -0.816 0 CA-C-O 122.518 1.151 . . . . 0.0 108.44 -179.434 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.1 m . . . . . 0 CA--C 1.489 -1.372 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.4 m -66.77 -36.11 81.65 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 121.182 0.515 . . . . 0.0 110.749 -175.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 p -90.38 10.21 25.93 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.53 0.732 . . . . 0.0 111.518 178.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.21 -47.92 1.07 Allowed Glycine 0 C--N 1.35 1.327 0 O-C-N 121.24 -0.912 . . . . 0.0 112.954 163.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.82 143.16 33.51 Favored 'General case' 0 CA--C 1.489 -1.371 0 CA-C-N 119.042 1.421 . . . . 0.0 107.524 -167.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 11.9 t -123.86 136.48 54.39 Favored 'General case' 0 CA--C 1.484 -1.584 1 N-CA-C 98.463 -4.643 . . . . 0.0 98.463 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.6 43.57 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 103.111 -2.922 . . . . 0.0 103.111 176.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.49 -56.05 1.43 Allowed Glycine 0 C--N 1.354 1.529 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 m -99.51 160.44 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 164.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 89.9 m -80.12 148.06 31.13 Favored 'General case' 0 CA--C 1.488 -1.411 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 172.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.62 -146.62 0.2 Allowed 'General case' 0 N--CA 1.431 -1.388 0 N-CA-C 102.62 -3.104 . . . . 0.0 102.62 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.427 -1.594 1 N-CA-C 96.372 -5.418 . . . . 0.0 96.372 175.06 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.422 -1.85 1 N-CA-C 95.539 -5.726 . . . . 0.0 95.539 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.5 mt -100.21 143.96 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 104.622 -2.362 . . . . 0.0 104.622 176.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt . . . . . 0 N--CA 1.439 -0.989 0 C-N-CA 126.678 1.991 . . . . 0.0 108.22 -164.783 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 31.6 m-85 . . . . . 0 CA--C 1.504 -0.789 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.37 165.25 28.7 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 169.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -88.33 138.67 31.23 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.1 p . . . . . 0 CA--C 1.49 -1.358 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -170.92 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 N--CA 1.432 -1.353 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -74.03 -15.19 61.09 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 122.316 -0.24 . . . . 0.0 110.911 178.098 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.4 p -86.35 -25.33 25.43 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 176.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.06 -75.01 0.36 Allowed Glycine 0 CA--C 1.485 -1.81 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -176.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.13 34.79 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 122.189 -0.595 . . . . 0.0 110.202 -168.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.1 t -119.02 130.41 55.64 Favored 'General case' 0 CA--C 1.481 -1.69 1 N-CA-C 96.186 -5.487 . . . . 0.0 96.186 173.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.5 p -146.88 44.78 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.96 -60.63 1.99 Allowed Glycine 0 C--N 1.353 1.488 0 N-CA-C 106.639 -2.584 . . . . 0.0 106.639 -176.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.57 164.17 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.135 0 N-CA-C 104.511 -2.403 . . . . 0.0 104.511 164.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 83.3 m -80.85 134.54 35.78 Favored 'General case' 0 CA--C 1.488 -1.435 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.37 -163.42 1.6 Allowed 'General case' 0 CA--C 1.485 -1.54 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 -174.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.423 -1.81 1 N-CA-C 95.284 -5.821 . . . . 0.0 95.284 173.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.6 p . . . . . 0 N--CA 1.424 -1.728 1 N-CA-C 99.091 -4.411 . . . . 0.0 99.091 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.1 mt -97.56 148.59 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 103.212 -2.884 . . . . 0.0 103.212 171.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp . . . . . 0 N--CA 1.44 -0.943 0 C-N-CA 125.508 1.523 . . . . 0.0 109.092 -162.644 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 . . . . . 0 CA--C 1.5 -0.962 0 CA-C-O 121.679 0.752 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.61 170.51 18.31 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 103.556 -3.818 . . . . 0.0 103.556 161.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -82.26 156.21 24.46 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -176.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p . . . . . 0 CA--C 1.489 -1.393 1 N-CA-C 98.723 -4.547 . . . . 0.0 98.723 170.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.0 m . . . . . 0 CA--C 1.49 -1.365 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -67.92 -28.38 67.44 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 119.687 1.13 . . . . 0.0 110.229 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.9 p -90.28 10.42 24.85 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 125.336 1.454 . . . . 0.0 110.407 174.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.25 -69.28 1.83 Allowed Glycine 0 CA--C 1.491 -1.408 0 O-C-N 120.941 -1.1 . . . . 0.0 111.152 168.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.77 141.9 35.86 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 -162.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.1 t -137.07 145.78 44.37 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 97.811 -4.885 . . . . 0.0 97.811 -175.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.5 p -160.69 -140.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.427 -1.609 1 N-CA-C 92.667 -6.79 . . . . 0.0 92.667 175.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.7 -4.44 61.64 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 122.92 2.6 . . . . 0.0 113.019 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 m -143.72 163.53 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 100.436 -3.913 . . . . 0.0 100.436 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.69 133.46 33.68 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 105.965 -1.865 . . . . 0.0 105.965 168.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.22 -154.93 0.54 Allowed 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 -179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.427 -1.621 1 N-CA-C 96.281 -5.451 . . . . 0.0 96.281 174.332 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.423 -1.82 1 N-CA-C 96.661 -5.311 . . . . 0.0 96.661 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.19 150.64 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.582 0 N-CA-C 104.081 -2.562 . . . . 0.0 104.081 169.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.1 tptt . . . . . 0 N--CA 1.436 -1.157 0 C-N-CA 127.6 2.36 . . . . 0.0 108.504 -166.551 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 . . . . . 0 CA--C 1.506 -0.737 0 CA-C-O 121.13 0.49 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.27 168.81 12.68 Favored Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 103.368 -3.893 . . . . 0.0 103.368 165.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -87.53 147.96 25.11 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 CA--C 1.497 -1.082 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 -178.572 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.5 m . . . . . 0 CA--C 1.493 -1.234 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.03 -28.31 65.37 Favored 'General case' 0 C--N 1.353 0.737 0 CA-C-N 118.779 0.718 . . . . 0.0 111.144 -177.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.0 p -90.01 3.89 51.82 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 124.618 1.167 . . . . 0.0 109.301 176.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.94 -75.23 0.24 Allowed Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 169.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.66 144.67 29.25 Favored 'General case' 0 CA--C 1.496 -1.104 0 CA-C-O 120.859 0.362 . . . . 0.0 111.254 -160.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.9 t -123.07 130.39 52.72 Favored 'General case' 0 N--CA 1.428 -1.53 1 N-CA-C 99.449 -4.278 . . . . 0.0 99.449 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.5 p -150.61 56.54 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.08 0 N-CA-C 102.548 -3.13 . . . . 0.0 102.548 170.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.84 -67.03 1.87 Allowed Glycine 0 CA--C 1.491 -1.41 0 N-CA-C 106.133 -2.787 . . . . 0.0 106.133 -177.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.5 m -87.5 157.5 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.099 0 N-CA-C 105.313 -2.106 . . . . 0.0 105.313 167.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 m -84.02 127.15 33.68 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 167.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.79 -141.63 0.13 Allowed 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 102.676 -3.083 . . . . 0.0 102.676 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.425 -1.701 1 N-CA-C 96.589 -5.337 . . . . 0.0 96.589 171.252 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p . . . . . 0 N--CA 1.427 -1.598 1 N-CA-C 97.476 -5.009 . . . . 0.0 97.476 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.3 mt -109.02 154.65 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 -175.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 128.229 2.611 . . . . 0.0 107.44 -157.197 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 . . . . . 0 N--CA 1.446 -0.663 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.36 165.09 28.61 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.65 -2.58 . . . . 0.0 106.65 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -76.44 144.35 39.98 Favored 'General case' 0 CA--C 1.497 -1.06 0 CA-C-N 118.135 0.967 . . . . 0.0 108.813 -175.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.6 p . . . . . 0 CA--C 1.482 -1.65 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 177.82 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.5 m . . . . . 0 CA--C 1.484 -1.561 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.7 m -69.98 -27.26 64.57 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.757 0.313 . . . . 0.0 110.505 -176.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.52 4.66 50.52 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 123.997 0.919 . . . . 0.0 111.221 173.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.85 -74.89 0.27 Allowed Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 172.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.58 153.07 25.67 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 118.146 0.973 . . . . 0.0 110.191 -163.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.7 t -142.42 152.02 42.38 Favored 'General case' 0 N--CA 1.429 -1.496 1 N-CA-C 98.166 -4.753 . . . . 0.0 98.166 -171.759 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.8 p -160.31 -142.92 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.146 1 N-CA-C 92.693 -6.78 . . . . 0.0 92.693 176.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.57 -15.11 65.81 Favored Glycine 0 C--N 1.35 1.308 0 CA-C-N 124.126 3.148 . . . . 0.0 113.008 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 m -138.14 163.75 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.691 0 N-CA-C 100.927 -3.731 . . . . 0.0 100.927 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.7 m -79.96 136.44 36.62 Favored 'General case' 0 CA--C 1.484 -1.589 0 C-N-CA 124.871 1.268 . . . . 0.0 108.172 176.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.23 -155.17 0.58 Allowed 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 -174.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 . . . . . 0 N--CA 1.423 -1.815 1 N-CA-C 95.416 -5.772 . . . . 0.0 95.416 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.3 p . . . . . 0 N--CA 1.433 -1.305 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -100.29 141.2 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 N-CA-C 104.447 -2.427 . . . . 0.0 104.447 -174.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp . . . . . 0 N--CA 1.446 -0.653 0 C-N-CA 126.271 1.828 . . . . 0.0 110.589 -166.868 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 . . . . . 0 CA--C 1.5 -0.974 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.59 165.9 18.1 Favored Glycine 0 CA--C 1.487 -1.67 1 N-CA-C 102.481 -4.248 . . . . 0.0 102.481 161.026 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -71.87 152.13 42.84 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -177.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.9 p . . . . . 0 N--CA 1.432 -1.372 1 N-CA-C 98.664 -4.569 . . . . 0.0 98.664 169.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 57.1 m . . . . . 0 CA--C 1.483 -1.609 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 m -72.81 -16.89 61.61 Favored 'General case' 0 C--N 1.352 0.693 0 CA-C-O 120.675 0.274 . . . . 0.0 110.63 -172.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -88.43 -17.24 30.87 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 125.688 1.595 . . . . 0.0 110.158 176.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.1 -78.58 0.29 Allowed Glycine 0 N--CA 1.436 -1.309 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 -175.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.87 150.41 29.1 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.83 -0.806 . . . . 0.0 111.418 -166.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.6 t -131.11 137.14 48.94 Favored 'General case' 0 N--CA 1.425 -1.719 1 N-CA-C 97.868 -4.864 . . . . 0.0 97.868 -177.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.19 -129.87 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.189 1 N-CA-C 98.027 -4.805 . . . . 0.0 98.027 164.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.16 -5.01 87.1 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 117.705 -3.122 . . . . 0.0 110.713 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.1 m -145.78 164.42 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.728 1 N-CA-C 99.14 -4.393 . . . . 0.0 99.14 -177.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.9 m -79.07 137.64 37.61 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 169.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.11 -151.23 0.37 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 -174.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.647 1 N-CA-C 98.007 -4.812 . . . . 0.0 98.007 175.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 102.207 -3.257 . . . . 0.0 102.207 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 1.4 p30 178.85 -170.98 0.12 Allowed 'General case' 0 N--CA 1.429 -1.476 1 N-CA-C 96.198 -5.482 . . . . 0.0 96.198 -169.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.2 p -148.97 173.5 13.28 Favored 'General case' 0 N--CA 1.428 -1.549 1 N-CA-C 97.849 -4.871 . . . . 0.0 97.849 168.306 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.5 mt -92.09 148.22 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 104.862 -2.274 . . . . 0.0 104.862 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.6 tttt -74.63 141.59 44.63 Favored 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 127.127 2.171 . . . . 0.0 107.747 -168.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 72.07 20.45 4.3 Favored 'General case' 0 C--N 1.354 0.798 0 C-N-CA 126.394 1.878 . . . . 0.0 111.869 -173.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.26 173.98 25.74 Favored Glycine 0 C--N 1.354 1.568 0 N-CA-C 105.802 -2.919 . . . . 0.0 105.802 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -85.08 131.78 34.41 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-N 118.372 1.086 . . . . 0.0 108.907 -174.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p -125.6 9.37 7.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 C-N-CA 123.783 0.833 . . . . 0.0 108.925 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 12.8 p -77.35 68.49 3.47 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 69.3 mt -98.2 122.05 55.29 Favored Pre-proline 0 N--CA 1.433 -1.323 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 -178.167 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.63 68.78 8.19 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.845 2.364 . . . . 0.0 108.43 174.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.2 141.93 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.764 1 N-CA-C 94.287 -6.19 . . . . 0.0 94.287 176.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.5 mt -92.27 136.3 33.3 Favored 'General case' 0 CA--C 1.489 -1.388 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 -174.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.3 mtmm 66.09 59.15 0.7 Allowed 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 125.799 1.64 . . . . 0.0 108.335 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -159.32 -172.86 3.91 Favored 'General case' 0 N--CA 1.42 -1.945 1 N-CA-C 97.203 -5.11 . . . . 0.0 97.203 -178.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.75 37.2 8.74 Favored Glycine 0 C--N 1.346 1.118 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -170.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 54.1 mt -89.2 91.16 8.67 Favored 'General case' 0 CA--C 1.502 -0.871 0 C-N-CA 123.786 0.834 . . . . 0.0 110.272 -166.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.0 m -83.75 144.09 29.56 Favored 'General case' 0 CA--C 1.498 -1.036 0 C-N-CA 123.671 0.788 . . . . 0.0 109.922 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.95 -33.23 75.13 Favored 'General case' 0 C--N 1.354 0.772 0 CA-C-O 121.134 0.493 . . . . 0.0 110.491 176.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -90.18 9.69 27.47 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 121.696 -0.628 . . . . 0.0 110.124 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.83 -69.34 1.18 Allowed Glycine 0 CA--C 1.492 -1.348 0 O-C-N 121.142 -0.974 . . . . 0.0 112.995 165.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.87 153.56 20.55 Favored 'General case' 0 CA--C 1.494 -1.187 0 CA-C-N 118.202 1.001 . . . . 0.0 108.768 -160.206 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 50.6 t -130.83 133.91 46.36 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 102.428 -3.175 . . . . 0.0 102.428 -176.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.5 p -137.26 37.27 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 102.671 -3.085 . . . . 0.0 102.671 175.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.04 -55.36 0.97 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 106.072 -2.811 . . . . 0.0 106.072 -176.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 m -94.85 156.53 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 165.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 57.0 m -73.62 129.7 38.5 Favored 'General case' 0 CA--C 1.486 -1.495 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.48 -156.8 0.7 Allowed 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -153.69 169.63 22.85 Favored 'General case' 0 N--CA 1.418 -2.031 1 N-CA-C 98.569 -4.604 . . . . 0.0 98.569 -170.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.8 tp -161.03 166.28 28.46 Favored 'General case' 0 N--CA 1.419 -1.981 1 N-CA-C 94.272 -6.196 . . . . 0.0 94.272 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.851 0 O-C-N 123.842 0.714 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 . . . . . 0 N--CA 1.493 1.69 0 N-CA-C 100.54 -3.874 . . . . 0.0 100.54 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -66.63 -26.77 67.24 Favored 'General case' 0 C--N 1.352 0.717 0 C-N-CA 124.163 0.985 . . . . 0.0 110.225 175.354 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.9 p -140.83 170.43 15.77 Favored 'General case' 0 N--CA 1.43 -1.474 1 N-CA-C 98.933 -4.469 . . . . 0.0 98.933 163.641 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.6 mt -93.58 136.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 176.574 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.5 ttpp -69.7 146.22 51.72 Favored 'General case' 0 N--CA 1.435 -1.186 0 C-N-CA 127.847 2.459 . . . . 0.0 108.584 -166.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 69.24 29.54 4.56 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 125.951 1.7 . . . . 0.0 111.26 -177.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.86 160.22 13.44 Favored Glycine 0 CA--C 1.491 -1.448 1 N-CA-C 102.548 -4.221 . . . . 0.0 102.548 167.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -74.34 149.91 40.38 Favored 'General case' 0 CA--C 1.503 -0.833 0 CA-C-N 118.094 0.947 . . . . 0.0 111.636 -165.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 30.1 p -160.06 -173.47 4.08 Favored 'General case' 0 N--CA 1.436 -1.131 1 N-CA-C 98.884 -4.488 . . . . 0.0 98.884 170.468 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.3 p -121.32 -80.11 0.62 Allowed 'General case' 0 CA--C 1.507 -0.709 0 CA-C-N 119.652 1.114 . . . . 0.0 109.179 -174.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 66.7 mt -150.19 163.14 25.51 Favored Pre-proline 0 N--CA 1.431 -1.423 1 N-CA-C 98.093 -4.78 . . . . 0.0 98.093 172.117 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -64.43 112.26 1.88 Allowed 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.715 2.277 . . . . 0.0 112.207 176.923 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 20.3 tt -161.66 161.54 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.424 -1.742 1 N-CA-C 96.836 -5.246 . . . . 0.0 96.836 176.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.9 mt 52.63 -121.37 1.85 Allowed 'General case' 0 C--N 1.354 0.798 0 C-N-CA 125.838 1.655 . . . . 0.0 108.842 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 46.6 mmtm -137.19 45.63 2.21 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . 0.259 0.1 OUTLIER -90.73 -35.69 14.74 Favored 'General case' 0 C--N 1.362 1.142 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 175.304 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -81.94 60.64 4.76 Favored Glycine 0 C--N 1.354 1.581 0 O-C-N 120.901 -1.124 . . . . 0.0 110.597 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 89.7 mt -118.66 72.65 0.89 Allowed 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 101.175 -3.639 . . . . 0.0 101.175 168.189 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 138.22 31.7 Favored 'General case' 0 CA--C 1.485 -1.544 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.3 m -63.19 -37.56 87.71 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 121.327 0.584 . . . . 0.0 111.052 -171.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.8 p -90.52 7.07 40.86 Favored 'General case' 0 N--CA 1.443 -0.821 0 C-N-CA 124.695 1.198 . . . . 0.0 111.741 178.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.21 -69.91 0.27 Allowed Glycine 0 C--N 1.35 1.334 0 O-C-N 121.171 -0.956 . . . . 0.0 111.505 170.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.3 145.16 31.03 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-N 118.227 1.013 . . . . 0.0 110.986 -167.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.3 t -128.31 129.66 46.64 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 101.339 -3.578 . . . . 0.0 101.339 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.8 p -133.24 -138.6 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -0.982 1 N-CA-C 97.837 -4.875 . . . . 0.0 97.837 165.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -70.99 -4.68 56.17 Favored Glycine 0 C--N 1.348 1.236 0 O-C-N 118.657 -2.527 . . . . 0.0 112.322 -179.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.45 164.09 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.954 1 N-CA-C 98.794 -4.521 . . . . 0.0 98.794 174.855 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 73.3 m -77.57 141.03 39.77 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 167.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.5 -146.1 0.19 Allowed 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 104.165 -2.531 . . . . 0.0 104.165 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -142.02 164.47 30.08 Favored 'General case' 0 N--CA 1.425 -1.706 1 N-CA-C 96.989 -5.189 . . . . 0.0 96.989 173.033 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.1 mt -150.07 166.13 30.67 Favored 'General case' 0 N--CA 1.425 -1.689 1 N-CA-C 94.611 -6.07 . . . . 0.0 94.611 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.912 0 O-C-N 124.36 1.037 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 . . . . . 0 CA--C 1.487 -1.472 1 N-CA-C 100.146 -4.02 . . . . 0.0 100.146 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -88.65 -147.78 0.16 Allowed 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 170.251 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.0 p -111.71 172.55 6.83 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 -179.448 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -92.97 140.63 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 101.543 -3.502 . . . . 0.0 101.543 172.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -75.39 139.17 42.19 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 117.382 -1.294 . . . . 0.0 108.276 -162.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 75.56 11.72 3.23 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 126.204 1.801 . . . . 0.0 111.637 -171.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.91 168.39 26.1 Favored Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 105.889 -2.884 . . . . 0.0 105.889 172.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -85.46 146.4 26.97 Favored 'General case' 0 CA--C 1.504 -0.805 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -177.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.7 p -145.41 -179.22 6.51 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 103.432 -2.803 . . . . 0.0 103.432 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 154.89 -89.06 0.0 OUTLIER 'General case' 0 CA--C 1.495 -1.151 1 N-CA-C 97.91 -4.848 . . . . 0.0 97.91 177.451 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mp -88.91 152.24 48.29 Favored Pre-proline 0 CA--C 1.498 -1.039 0 N-CA-C 102.511 -3.144 . . . . 0.0 102.511 161.498 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -73.36 148.24 43.01 Favored 'Trans proline' 0 CA--C 1.5 -1.203 0 CA-C-N 121.556 1.591 . . . . 0.0 109.191 -173.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 45.8 mm -62.6 -41.77 93.4 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 C-N-CA 123.953 0.901 . . . . 0.0 108.703 -175.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.6 mt -109.63 59.54 0.6 Allowed 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.1 mttp 73.68 -58.24 0.6 Allowed 'General case' 0 C--N 1.357 0.899 0 C-N-CA 126.103 1.761 . . . . 0.0 114.602 160.396 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -137.77 120.19 15.94 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 -175.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.89 179.79 46.82 Favored Glycine 0 CA--C 1.479 -2.193 1 N-CA-C 99.098 -5.601 . . . . 0.0 99.098 178.416 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.1 tp -150.58 165.27 33.82 Favored 'General case' 0 N--CA 1.427 -1.616 1 N-CA-C 95.687 -5.672 . . . . 0.0 95.687 175.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.3 m -72.67 142.48 48.26 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -62.13 -42.65 99.45 Favored 'General case' 0 C--N 1.358 0.938 0 CA-C-N 118.805 0.73 . . . . 0.0 110.024 -177.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.4 p -87.53 17.63 4.45 Favored 'General case' 0 N--CA 1.441 -0.916 0 C-N-CA 123.716 0.806 . . . . 0.0 111.314 177.388 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.99 -71.49 0.89 Allowed Glycine 0 CA--C 1.49 -1.494 0 O-C-N 120.552 -1.342 . . . . 0.0 111.595 164.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.18 144.73 25.6 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 121.755 -0.85 . . . . 0.0 111.09 -163.36 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.9 t -111.38 133.43 53.7 Favored 'General case' 0 N--CA 1.432 -1.348 0 N-CA-C 101.212 -3.625 . . . . 0.0 101.212 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.77 41.47 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.173 0 N-CA-C 102.86 -3.015 . . . . 0.0 102.86 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.31 -61.19 1.06 Allowed Glycine 0 C--N 1.352 1.431 0 N-CA-C 105.434 -3.066 . . . . 0.0 105.434 -174.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.1 m -95.07 160.6 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 166.018 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 67.1 m -78.86 135.4 37.02 Favored 'General case' 0 CA--C 1.495 -1.17 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 172.64 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.89 -140.7 0.11 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 103.436 -2.802 . . . . 0.0 103.436 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -145.49 170.51 16.25 Favored 'General case' 0 N--CA 1.423 -1.821 1 N-CA-C 96.893 -5.225 . . . . 0.0 96.893 174.594 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.3 mt -138.86 156.19 47.5 Favored 'General case' 0 N--CA 1.423 -1.803 1 N-CA-C 93.963 -6.31 . . . . 0.0 93.963 171.046 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.886 0 O-C-N 124.355 1.035 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 36.1 t70 . . . . . 0 N--CA 1.487 1.41 1 N-CA-C 98.956 -4.461 . . . . 0.0 98.956 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -71.82 -45.45 61.44 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 168.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 7.5 p -118.75 -169.75 1.78 Allowed 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 103.396 -2.816 . . . . 0.0 103.396 171.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . 0.41 ' HB ' ' SG ' ' A' ' 20' ' ' CYS . 57.0 mt -89.45 150.69 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 102.835 -3.024 . . . . 0.0 102.835 165.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.1 tttm -76.05 139.29 41.34 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 -164.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.257 86.9 m-85 71.61 24.99 3.4 Favored 'General case' 0 CA--C 1.503 -0.84 0 C-N-CA 126.248 1.819 . . . . 0.0 110.499 -173.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.9 163.0 19.32 Favored Glycine 0 CA--C 1.491 -1.449 0 N-CA-C 105.335 -3.106 . . . . 0.0 105.335 166.145 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -79.92 145.58 32.58 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.3 p -142.1 177.68 8.06 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 -170.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 p 172.29 -158.76 0.01 OUTLIER 'General case' 0 N--CA 1.423 -1.784 1 N-CA-C 94.817 -5.994 . . . . 0.0 94.817 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -113.86 96.18 40.33 Favored Pre-proline 0 N--CA 1.441 -0.889 0 N-CA-C 101.25 -3.611 . . . . 0.0 101.25 167.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.29 147.96 29.88 Favored 'Trans proline' 0 CA--C 1.501 -1.132 0 C-N-CA 122.399 2.066 . . . . 0.0 107.63 175.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 25.6 pt -92.02 -38.32 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.839 0 CA-C-N 118.231 0.469 . . . . 0.0 110.903 -171.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 72.7 mt -71.47 -37.66 71.33 Favored 'General case' 0 CA--C 1.492 -1.253 0 C-N-CA 124.279 1.031 . . . . 0.0 111.493 -160.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -133.81 143.46 48.38 Favored 'General case' 0 N--CA 1.421 -1.915 1 N-CA-C 94.119 -6.252 . . . . 0.0 94.119 164.536 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -149.52 161.27 42.46 Favored 'General case' 0 N--CA 1.423 -1.798 1 N-CA-C 98.639 -4.578 . . . . 0.0 98.639 -168.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.15 -165.08 30.68 Favored Glycine 0 N--CA 1.425 -2.096 1 N-CA-C 95.279 -7.128 . . . . 0.0 95.279 -168.642 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -129.3 -165.14 1.48 Allowed 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 102.192 -3.262 . . . . 0.0 102.192 173.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.41 ' SG ' ' HB ' ' A' ' 4' ' ' ILE . 84.8 m -87.52 157.94 19.05 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 -177.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.0 m -64.6 -36.78 85.34 Favored 'General case' 0 C--N 1.351 0.645 0 CA-C-O 121.242 0.544 . . . . 0.0 110.183 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.6 p -87.69 1.15 54.54 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.17 0.988 . . . . 0.0 110.316 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.9 -79.67 1.5 Allowed Glycine 0 N--CA 1.437 -1.249 0 O-C-N 121.421 -0.799 . . . . 0.0 111.939 173.322 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.57 123.31 28.54 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 113.421 0.897 . . . . 0.0 113.421 -149.463 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -96.64 127.09 42.3 Favored 'General case' 0 CA--C 1.5 -0.954 0 C-N-CA 125.435 1.494 . . . . 0.0 107.309 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.79 42.22 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.061 -2.941 . . . . 0.0 103.061 175.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.88 -56.12 1.14 Allowed Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 106.118 -2.793 . . . . 0.0 106.118 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.7 m -103.91 156.78 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 103.019 -2.956 . . . . 0.0 103.019 163.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -89.58 143.89 26.45 Favored 'General case' 0 CA--C 1.482 -1.67 0 CA-C-O 121.172 0.511 . . . . 0.0 109.905 179.323 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.26 -146.75 0.19 Allowed 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 102.421 -3.177 . . . . 0.0 102.421 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -130.41 160.28 34.49 Favored 'General case' 0 N--CA 1.431 -1.406 1 N-CA-C 95.876 -5.601 . . . . 0.0 95.876 166.329 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 31.2 tp -160.69 162.73 32.67 Favored 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 95.765 -5.643 . . . . 0.0 95.765 -174.145 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.879 0 O-C-N 124.595 1.185 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.497 1.881 0 N-CA-C 103.438 -2.801 . . . . 0.0 103.438 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -159.01 171.58 19.76 Favored 'General case' 0 N--CA 1.429 -1.479 1 N-CA-C 95.546 -5.724 . . . . 0.0 95.546 176.281 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.3 p -159.44 169.81 23.12 Favored 'General case' 0 N--CA 1.428 -1.559 1 N-CA-C 99.276 -4.342 . . . . 0.0 99.276 -175.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.1 mt -88.66 145.98 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 -172.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -74.84 138.72 42.72 Favored 'General case' 0 N--CA 1.437 -1.08 0 C-N-CA 126.766 2.026 . . . . 0.0 109.762 -162.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.269 96.3 m-85 70.56 19.61 6.12 Favored 'General case' 0 C--N 1.355 0.827 0 C-N-CA 126.678 1.991 . . . . 0.0 111.847 -176.708 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.81 171.05 27.01 Favored Glycine 0 C--N 1.352 1.446 0 N-CA-C 104.473 -3.451 . . . . 0.0 104.473 163.097 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -90.13 159.36 16.82 Favored 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 175.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.2 p -140.5 152.47 45.62 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 -174.228 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.3 p -155.18 168.78 25.92 Favored 'General case' 0 N--CA 1.421 -1.912 1 N-CA-C 96.749 -5.278 . . . . 0.0 96.749 164.462 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 11.2 mt -157.64 172.31 6.31 Favored Pre-proline 0 N--CA 1.425 -1.681 1 N-CA-C 95.834 -5.617 . . . . 0.0 95.834 166.516 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -61.26 132.93 43.74 Favored 'Trans proline' 0 CA--C 1.504 -1.012 0 C-N-CA 123.062 2.508 . . . . 0.0 107.201 164.311 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 40.3 pt -72.52 29.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.351 0.659 0 N-CA-C 115.637 1.718 . . . . 0.0 115.637 -149.445 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.5 mt -89.44 -19.05 25.61 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.654 1.582 . . . . 0.0 107.083 173.0 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -140.39 156.04 46.54 Favored 'General case' 0 N--CA 1.424 -1.774 1 N-CA-C 96.477 -5.379 . . . . 0.0 96.477 164.566 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -93.33 -22.29 19.05 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 -178.124 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.68 166.68 35.2 Favored Glycine 0 N--CA 1.416 -2.698 1 N-CA-C 98.923 -5.671 . . . . 0.0 98.923 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 tp -118.13 90.85 3.42 Favored 'General case' 0 CA--C 1.488 -1.409 1 N-CA-C 99.534 -4.247 . . . . 0.0 99.534 165.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 93.1 m -90.17 145.39 25.06 Favored 'General case' 0 CA--C 1.485 -1.542 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 59.2 m -66.87 -36.35 82.11 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.905 0.383 . . . . 0.0 110.929 -173.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.6 p -90.15 9.65 27.53 Favored 'General case' 0 N--CA 1.438 -1.058 0 C-N-CA 123.925 0.89 . . . . 0.0 111.158 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.48 -74.84 0.21 Allowed Glycine 0 C--N 1.353 1.478 0 O-C-N 121.294 -0.879 . . . . 0.0 111.439 168.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.02 141.1 30.54 Favored 'General case' 0 CA--C 1.494 -1.205 0 O-C-N 121.753 -0.851 . . . . 0.0 109.555 -162.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 25.8 t -119.81 126.62 51.43 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 98.492 -4.633 . . . . 0.0 98.492 171.653 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.3 p -146.47 48.29 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 101.924 -3.361 . . . . 0.0 101.924 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.69 -62.67 2.65 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.151 -2.779 . . . . 0.0 106.151 -174.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.9 m -89.25 158.36 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 167.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.0 m -82.1 128.96 34.65 Favored 'General case' 0 CA--C 1.49 -1.347 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 168.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.78 -142.77 0.2 Allowed 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 -178.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.62 168.43 24.98 Favored 'General case' 0 N--CA 1.422 -1.843 1 N-CA-C 97.734 -4.913 . . . . 0.0 97.734 -176.993 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -89.49 69.36 7.94 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 -174.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 . . . . . 0 N--CA 1.484 1.266 0 N-CA-C 101.961 -3.348 . . . . 0.0 101.961 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -109.27 -113.38 0.3 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 103.444 -2.799 . . . . 0.0 103.444 179.275 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.6 p -122.03 -179.69 4.23 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 102.888 -3.004 . . . . 0.0 102.888 171.745 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 38.0 mt -111.75 149.63 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 101.791 -3.411 . . . . 0.0 101.791 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -76.43 137.42 39.71 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 125.002 1.321 . . . . 0.0 108.184 -164.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.258 75.0 m-85 74.77 15.72 3.15 Favored 'General case' 0 C--N 1.355 0.839 0 C-N-CA 127.421 2.288 . . . . 0.0 111.605 -174.051 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.97 169.41 29.56 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 105.544 -3.023 . . . . 0.0 105.544 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -85.23 154.17 22.13 Favored 'General case' 0 CA--C 1.5 -0.962 0 N-CA-C 106.804 -1.554 . . . . 0.0 106.804 178.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 p -148.17 -173.5 4.33 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.4 p -149.83 179.54 7.94 Favored 'General case' 0 N--CA 1.423 -1.792 1 N-CA-C 96.562 -5.347 . . . . 0.0 96.562 176.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -113.84 100.98 53.39 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 100.821 -3.77 . . . . 0.0 100.821 175.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -70.83 144.87 49.45 Favored 'Trans proline' 0 N--CA 1.453 -0.91 0 CA-C-N 122.029 1.76 . . . . 0.0 107.998 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.3 tt -77.95 -49.23 22.05 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.948 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 -169.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 73.9 mt -89.64 102.21 14.9 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 100.888 -3.745 . . . . 0.0 100.888 163.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.5 mtpt -59.75 106.36 0.47 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 124.459 1.104 . . . . 0.0 111.258 -171.286 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -96.0 -11.2 26.86 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -175.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -164.32 173.17 40.27 Favored Glycine 0 N--CA 1.424 -2.138 1 N-CA-C 98.494 -5.842 . . . . 0.0 98.494 177.112 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -157.35 175.35 14.11 Favored 'General case' 0 N--CA 1.428 -1.558 1 N-CA-C 95.061 -5.903 . . . . 0.0 95.061 177.032 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.0 m -88.26 153.68 21.02 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.5 -31.42 69.66 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.093 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.3 p -87.26 9.5 20.07 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.749 1.22 . . . . 0.0 111.086 173.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.68 -78.96 0.49 Allowed Glycine 0 C--N 1.351 1.37 0 O-C-N 120.866 -1.147 . . . . 0.0 110.495 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.44 146.7 32.63 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 117.431 0.615 . . . . 0.0 111.368 -161.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.6 t -125.78 131.51 52.47 Favored 'General case' 0 N--CA 1.429 -1.499 1 N-CA-C 97.741 -4.911 . . . . 0.0 97.741 173.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -149.16 51.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.137 0 N-CA-C 101.407 -3.553 . . . . 0.0 101.407 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.01 -60.73 1.64 Allowed Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.235 -2.746 . . . . 0.0 106.235 -176.777 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.4 m -100.28 161.34 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.007 -2.219 . . . . 0.0 105.007 167.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 54.1 m -80.65 136.74 36.26 Favored 'General case' 0 CA--C 1.49 -1.357 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 174.112 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.01 -165.29 2.13 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -176.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -101.8 -172.85 2.22 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 103.643 -2.725 . . . . 0.0 103.643 170.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 9.2 tp -153.79 164.04 39.01 Favored 'General case' 0 N--CA 1.422 -1.839 1 N-CA-C 96.139 -5.504 . . . . 0.0 96.139 175.897 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.91 0 O-C-N 124.073 0.858 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 . . . . . 0 N--CA 1.493 1.682 1 N-CA-C 98.807 -4.516 . . . . 0.0 98.807 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -93.34 -162.96 0.99 Allowed 'General case' 0 N--CA 1.44 -0.966 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 154.84 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.5 p -153.91 -179.21 7.64 Favored 'General case' 0 N--CA 1.426 -1.638 1 N-CA-C 97.086 -5.153 . . . . 0.0 97.086 170.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.1 mt -107.59 148.43 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.322 0 N-CA-C 102.083 -3.303 . . . . 0.0 102.083 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -86.0 142.06 29.04 Favored 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 126.061 1.745 . . . . 0.0 108.343 -162.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 70.92 14.38 6.91 Favored 'General case' 0 C--N 1.358 0.958 0 C-N-CA 126.382 1.873 . . . . 0.0 112.079 -174.586 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.4 167.01 22.16 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 169.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.19 142.44 32.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -175.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.76 173.29 6.83 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p 168.79 -145.98 0.0 OUTLIER 'General case' 0 N--CA 1.431 -1.39 1 N-CA-C 93.375 -6.528 . . . . 0.0 93.375 -173.313 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.6 mt -121.04 100.94 45.38 Favored Pre-proline 0 C--N 1.353 0.741 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 165.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -140.76 28.96 0.0 OUTLIER 'Trans proline' 0 CA--C 1.507 -0.87 0 CA-C-N 123.23 2.189 . . . . 0.0 108.099 -167.095 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 pt -126.03 -55.73 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.242 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -124.19 -162.59 1.08 Allowed 'General case' 0 N--CA 1.432 -1.345 1 N-CA-C 98.54 -4.615 . . . . 0.0 98.54 161.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.46 34.62 1.43 Allowed 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 173.702 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -151.47 165.77 33.16 Favored 'General case' 0 N--CA 1.424 -1.756 1 N-CA-C 95.887 -5.597 . . . . 0.0 95.887 160.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.7 163.57 34.8 Favored Glycine 0 N--CA 1.421 -2.345 1 N-CA-C 97.283 -6.327 . . . . 0.0 97.283 179.257 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 93.6 mt -150.47 160.45 43.76 Favored 'General case' 0 CA--C 1.484 -1.595 1 N-CA-C 97.513 -4.995 . . . . 0.0 97.513 177.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 91.5 m -90.63 150.21 21.79 Favored 'General case' 0 CA--C 1.492 -1.269 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 174.585 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.25 -29.5 69.15 Favored 'General case' 0 C--N 1.352 0.71 0 CA-C-N 118.713 0.688 . . . . 0.0 111.414 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -90.03 -3.05 58.19 Favored 'General case' 0 N--CA 1.438 -1.071 0 O-C-N 121.292 -0.88 . . . . 0.0 109.841 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 115.48 -79.28 0.28 Allowed Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 109.829 -1.309 . . . . 0.0 109.829 170.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.19 151.4 24.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 O-C-N 122.596 -0.356 . . . . 0.0 110.585 -163.172 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -123.82 131.2 53.54 Favored 'General case' 0 CA--C 1.489 -1.39 1 N-CA-C 98.553 -4.61 . . . . 0.0 98.553 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.67 39.03 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 103.33 -2.841 . . . . 0.0 103.33 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.61 -55.68 1.03 Allowed Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.251 -2.74 . . . . 0.0 106.251 -176.636 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.5 m -98.21 164.3 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 163.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 63.7 m -81.69 139.55 34.85 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 171.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.35 -152.93 0.46 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 -177.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -175.1 -171.87 0.55 Allowed 'General case' 0 N--CA 1.424 -1.742 1 N-CA-C 97.337 -5.06 . . . . 0.0 97.337 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -86.28 68.97 10.41 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.362 1.112 0 CA-C-N 116.348 -0.387 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 102.68 -3.081 . . . . 0.0 102.68 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 45.7 m-20 -103.94 -114.77 0.22 Allowed 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 103.177 -2.897 . . . . 0.0 103.177 170.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p -132.17 168.23 18.38 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 167.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.1 mt -97.97 149.49 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 175.693 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.06 144.55 34.5 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 125.132 1.373 . . . . 0.0 108.496 -163.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.263 97.2 m-85 67.78 24.36 8.27 Favored 'General case' 0 CA--C 1.503 -0.857 0 C-N-CA 127.035 2.134 . . . . 0.0 112.057 -171.603 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.64 170.8 28.47 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 105.414 -3.074 . . . . 0.0 105.414 164.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -88.23 140.36 29.56 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 -176.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.9 p -141.94 -179.28 6.12 Favored 'General case' 0 CA--C 1.498 -1.027 0 CA-C-O 122.275 1.036 . . . . 0.0 109.142 -174.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 p -158.85 -166.78 1.95 Allowed 'General case' 0 N--CA 1.428 -1.543 1 N-CA-C 95.126 -5.879 . . . . 0.0 95.126 167.632 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.4 mp -116.65 139.03 25.04 Favored Pre-proline 0 N--CA 1.434 -1.24 1 N-CA-C 97.313 -5.069 . . . . 0.0 97.313 169.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -82.71 27.82 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.759 0 CA-C-N 123.656 2.341 . . . . 0.0 110.997 -173.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 28.7 mm 72.85 -58.86 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 128.13 2.572 . . . . 0.0 110.162 175.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -89.65 101.98 14.66 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 102.403 -3.184 . . . . 0.0 102.403 168.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -72.39 100.15 2.61 Favored 'General case' 0 CA--C 1.5 -0.947 0 C-N-CA 123.994 0.917 . . . . 0.0 109.046 -165.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -133.29 7.58 3.93 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 -176.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -157.23 150.84 22.09 Favored Glycine 0 CA--C 1.478 -2.239 1 N-CA-C 96.233 -6.747 . . . . 0.0 96.233 176.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.0 mt -164.29 179.59 6.72 Favored 'General case' 0 N--CA 1.426 -1.629 1 N-CA-C 96.11 -5.515 . . . . 0.0 96.11 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.9 m -87.72 151.8 22.63 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -72.64 -28.5 62.78 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.598 -0.689 . . . . 0.0 109.957 -178.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.5 p -90.66 11.63 21.53 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 124.36 1.064 . . . . 0.0 110.404 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.65 -77.72 0.93 Allowed Glycine 0 CA--C 1.491 -1.465 0 O-C-N 121.065 -1.022 . . . . 0.0 110.989 171.455 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.63 142.0 31.12 Favored 'General case' 0 CA--C 1.497 -1.092 0 CA-C-N 117.948 0.874 . . . . 0.0 109.999 -159.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 t -118.44 130.26 55.86 Favored 'General case' 0 CA--C 1.485 -1.544 1 N-CA-C 99.796 -4.15 . . . . 0.0 99.796 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -142.46 42.91 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.34 -60.41 1.31 Allowed Glycine 0 C--N 1.352 1.455 0 N-CA-C 106.232 -2.747 . . . . 0.0 106.232 -176.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.82 157.6 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 164.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 m -79.4 133.25 36.56 Favored 'General case' 0 CA--C 1.486 -1.504 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 174.359 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.55 -164.44 1.41 Allowed 'General case' 0 N--CA 1.428 -1.547 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 -176.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.5 p30 -134.74 168.0 19.83 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 100.752 -3.795 . . . . 0.0 100.752 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.1 mt -154.5 174.21 15.22 Favored 'General case' 0 N--CA 1.424 -1.736 1 N-CA-C 94.837 -5.986 . . . . 0.0 94.837 169.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.044 0 O-C-N 124.04 0.838 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 . . . . . 0 N--CA 1.5 2.074 0 N-CA-C 102.894 -3.002 . . . . 0.0 102.894 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -150.83 163.91 37.51 Favored 'General case' 0 CA--C 1.488 -1.407 0 N-CA-C 101.901 -3.37 . . . . 0.0 101.901 -166.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 6.2 p -103.57 166.19 10.58 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 102.223 -3.251 . . . . 0.0 102.223 166.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 35.5 mt -94.54 141.64 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -70.19 139.59 52.37 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 127.334 2.254 . . . . 0.0 110.579 -163.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 65.5 24.83 11.85 Favored 'General case' 0 C--N 1.355 0.841 0 C-N-CA 126.689 1.996 . . . . 0.0 113.049 -171.711 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.2 166.46 21.05 Favored Glycine 0 CA--C 1.493 -1.324 0 N-CA-C 105.056 -3.218 . . . . 0.0 105.056 164.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -66.6 148.2 52.23 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 125.399 1.48 . . . . 0.0 107.167 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.4 p -143.83 178.72 7.63 Favored 'General case' 0 CA--C 1.483 -1.612 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 178.058 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -168.83 -169.9 1.08 Allowed 'General case' 0 N--CA 1.415 -2.224 1 N-CA-C 95.356 -5.794 . . . . 0.0 95.356 -170.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -108.42 -56.08 0.05 OUTLIER Pre-proline 0 N--CA 1.442 -0.844 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -71.46 148.19 53.76 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 CA-C-N 124.541 2.657 . . . . 0.0 110.165 166.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -142.75 -90.16 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 101.636 -3.468 . . . . 0.0 101.636 169.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.1 mt -85.06 -57.79 2.95 Favored 'General case' 0 CA--C 1.494 -1.173 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.3 mmtm -119.73 -69.44 0.85 Allowed 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 104.232 -2.507 . . . . 0.0 104.232 177.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.52 173.9 15.11 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 96.619 -5.326 . . . . 0.0 96.619 175.198 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -164.61 179.66 39.21 Favored Glycine 0 N--CA 1.419 -2.445 1 N-CA-C 98.456 -5.857 . . . . 0.0 98.456 177.759 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 15.4 tp -160.9 175.47 12.49 Favored 'General case' 0 N--CA 1.423 -1.803 1 N-CA-C 95.913 -5.588 . . . . 0.0 95.913 173.153 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 94.0 m -90.25 153.66 20.31 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -172.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 33.7 m -71.58 -30.4 65.79 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -175.752 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.09 -1.9 58.02 Favored 'General case' 0 N--CA 1.439 -0.991 0 C-N-CA 124.83 1.252 . . . . 0.0 110.245 177.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.86 -70.26 0.21 Allowed Glycine 0 CA--C 1.49 -1.503 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 172.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.61 145.68 27.9 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -161.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.2 t -132.22 133.03 43.68 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 100.726 -3.805 . . . . 0.0 100.726 -177.665 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.68 -125.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.885 1 N-CA-C 98.563 -4.606 . . . . 0.0 98.563 161.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.58 -9.17 86.25 Favored Glycine 0 C--N 1.349 1.276 0 O-C-N 118.316 -2.74 . . . . 0.0 110.801 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 m -148.12 161.58 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.755 1 N-CA-C 99.482 -4.266 . . . . 0.0 99.482 -172.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 97.8 m -78.7 136.57 37.47 Favored 'General case' 0 CA--C 1.489 -1.376 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.944 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 -165.46 1.5 Allowed 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -159.87 175.11 13.46 Favored 'General case' 0 N--CA 1.421 -1.9 1 N-CA-C 99.108 -4.404 . . . . 0.0 99.108 -174.319 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 16.3 mt -149.49 173.79 13.21 Favored 'General case' 0 N--CA 1.429 -1.518 1 N-CA-C 94.478 -6.119 . . . . 0.0 94.478 168.358 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.896 0 O-C-N 124.087 0.867 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.6 m-20 -90.6 -133.53 0.11 Allowed 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p -123.02 168.98 11.66 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 100.513 -3.884 . . . . 0.0 100.513 163.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.5 mt -100.68 154.47 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 173.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -79.89 142.08 35.51 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 125.294 1.437 . . . . 0.0 108.53 -161.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 62.54 42.3 8.76 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 126.148 1.779 . . . . 0.0 111.091 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.57 173.28 16.44 Favored Glycine 0 C--N 1.35 1.334 1 N-CA-C 102.348 -4.301 . . . . 0.0 102.348 162.84 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -89.86 145.86 24.85 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -175.064 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.8 p -135.9 -170.44 2.63 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 -177.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.9 p -169.48 -168.12 0.77 Allowed 'General case' 0 N--CA 1.421 -1.909 1 N-CA-C 97.63 -4.952 . . . . 0.0 97.63 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -116.31 118.34 37.73 Favored Pre-proline 0 N--CA 1.435 -1.208 1 N-CA-C 99.227 -4.36 . . . . 0.0 99.227 172.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -74.41 -57.16 0.06 OUTLIER 'Trans proline' 0 CA--C 1.507 -0.835 0 CA-C-N 123.039 2.121 . . . . 0.0 113.263 -172.438 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.1 tp -151.06 -50.67 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.495 -1.169 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 -176.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 80.3 mt -125.58 -163.1 1.17 Allowed 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 102.293 -3.225 . . . . 0.0 102.293 170.036 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -87.44 65.4 8.63 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 106.392 -1.707 . . . . 0.0 106.392 171.335 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -100.94 12.48 37.58 Favored 'General case' 0 CA--C 1.507 -0.673 0 C-N-CA 124.186 0.994 . . . . 0.0 109.728 -173.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -166.75 164.26 37.63 Favored Glycine 0 N--CA 1.429 -1.827 1 N-CA-C 96.364 -6.694 . . . . 0.0 96.364 174.282 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 17.0 tp -163.39 178.68 7.9 Favored 'General case' 0 N--CA 1.428 -1.569 1 N-CA-C 96.791 -5.262 . . . . 0.0 96.791 177.767 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 77.7 m -89.71 148.11 23.46 Favored 'General case' 0 CA--C 1.488 -1.404 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.29 -28.56 66.39 Favored 'General case' 0 C--N 1.35 0.617 0 CA-C-O 121.12 0.486 . . . . 0.0 110.183 -176.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 7.2 p -90.31 11.17 22.16 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 124.622 1.169 . . . . 0.0 110.833 175.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.69 -68.75 0.88 Allowed Glycine 0 CA--C 1.492 -1.359 0 O-C-N 120.672 -1.268 . . . . 0.0 111.704 165.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.78 142.66 28.8 Favored 'General case' 0 CA--C 1.496 -1.099 0 O-C-N 121.272 -1.134 . . . . 0.0 109.698 -164.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.3 t -132.93 127.48 34.38 Favored 'General case' 0 CA--C 1.486 -1.487 1 N-CA-C 99.653 -4.202 . . . . 0.0 99.653 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.44 62.8 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.161 0 N-CA-C 101.712 -3.44 . . . . 0.0 101.712 172.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.18 -63.41 2.76 Favored Glycine 0 C--N 1.351 1.414 0 N-CA-C 106.993 -2.443 . . . . 0.0 106.993 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.0 m -91.65 155.33 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.21 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 168.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.2 m -80.24 122.67 27.16 Favored 'General case' 0 CA--C 1.487 -1.445 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 166.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.55 -147.56 0.37 Allowed 'General case' 0 N--CA 1.432 -1.365 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -146.91 164.92 31.36 Favored 'General case' 0 N--CA 1.42 -1.965 1 N-CA-C 95.58 -5.711 . . . . 0.0 95.58 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.1 tp -123.56 116.88 23.87 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 101.385 -3.561 . . . . 0.0 101.385 -176.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.036 0 O-C-N 123.256 0.348 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 . . . . . 0 N--CA 1.495 1.801 0 N-CA-C 102.113 -3.292 . . . . 0.0 102.113 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.2 m-20 -157.36 177.48 11.39 Favored 'General case' 0 N--CA 1.428 -1.526 1 N-CA-C 97.184 -5.117 . . . . 0.0 97.184 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.2 p -147.39 166.81 26.05 Favored 'General case' 0 N--CA 1.427 -1.621 1 N-CA-C 96.47 -5.381 . . . . 0.0 96.47 167.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mt -89.43 140.6 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 -177.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 74.6 tttt -85.46 148.28 26.06 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -158.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.306 68.3 m-85 58.75 31.37 21.12 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 127.694 2.397 . . . . 0.0 113.213 -170.322 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.36 168.65 16.66 Favored Glycine 0 N--CA 1.437 -1.298 0 N-CA-C 103.345 -3.902 . . . . 0.0 103.345 158.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -87.86 143.89 26.88 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.002 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.4 p -117.17 -118.35 0.32 Allowed 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 102.488 -3.153 . . . . 0.0 102.488 174.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 86.5 p -154.13 -136.85 0.06 Allowed 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 102.65 -3.092 . . . . 0.0 102.65 170.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 78.5 mt -148.94 155.01 40.57 Favored Pre-proline 0 N--CA 1.425 -1.719 1 N-CA-C 99.658 -4.201 . . . . 0.0 99.658 -176.455 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -74.85 5.3 3.99 Favored 'Trans proline' 0 CA--C 1.508 -0.804 0 C-N-CA 123.896 3.064 . . . . 0.0 112.649 -175.64 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 17.5 tt -94.71 -12.14 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 174.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.95 -72.08 0.74 Allowed 'General case' 0 CA--C 1.489 -1.401 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 -176.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 18.3 mtmm -124.15 -96.95 0.45 Allowed 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 101.545 -3.502 . . . . 0.0 101.545 171.503 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 177.66 -165.2 0.04 OUTLIER 'General case' 0 N--CA 1.431 -1.381 1 N-CA-C 96.52 -5.363 . . . . 0.0 96.52 179.172 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -170.35 144.67 8.57 Favored Glycine 0 CA--C 1.477 -2.282 1 N-CA-C 102.417 -4.273 . . . . 0.0 102.417 169.196 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.6 mp -117.48 101.93 8.79 Favored 'General case' 0 CA--C 1.488 -1.433 0 N-CA-C 103.193 -2.892 . . . . 0.0 103.193 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 88.1 m -90.7 149.06 22.21 Favored 'General case' 0 CA--C 1.489 -1.386 0 C-N-CA 124.396 1.079 . . . . 0.0 108.42 -175.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 38.9 m -66.9 -36.11 81.53 Favored 'General case' 0 C--N 1.351 0.637 0 CA-C-O 121.026 0.441 . . . . 0.0 111.516 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.6 p -90.34 15.04 11.27 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 123.846 0.858 . . . . 0.0 111.114 177.308 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.47 -67.7 0.69 Allowed Glycine 0 CA--C 1.489 -1.545 0 O-C-N 121.128 -0.983 . . . . 0.0 110.722 167.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.03 133.07 35.26 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 121.639 -0.918 . . . . 0.0 110.252 -166.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 12.5 t -123.61 122.48 38.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 100.487 -3.894 . . . . 0.0 100.487 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -151.21 65.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 103.228 -2.879 . . . . 0.0 103.228 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.25 -62.84 3.78 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 107.069 -2.412 . . . . 0.0 107.069 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -99.65 159.44 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 104.756 -2.312 . . . . 0.0 104.756 171.725 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 66.1 m -83.42 128.43 34.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 170.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.45 -152.36 0.41 Allowed 'General case' 0 N--CA 1.432 -1.333 0 N-CA-C 104.502 -2.406 . . . . 0.0 104.502 -174.08 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -143.16 173.03 11.94 Favored 'General case' 0 N--CA 1.424 -1.743 1 N-CA-C 97.371 -5.048 . . . . 0.0 97.371 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.6 mt -149.52 166.25 29.75 Favored 'General case' 0 N--CA 1.419 -1.985 1 N-CA-C 93.939 -6.319 . . . . 0.0 93.939 174.254 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 0.769 0 O-C-N 124.115 0.885 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.4 t70 . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 104.979 -2.23 . . . . 0.0 104.979 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -102.69 -106.17 0.27 Allowed 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 103.681 -2.711 . . . . 0.0 103.681 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p -97.47 160.02 14.57 Favored 'General case' 0 CA--C 1.495 -1.138 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 167.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.3 mt -95.52 146.37 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 -175.396 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 ttpp -70.05 142.21 52.74 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 127.074 2.149 . . . . 0.0 110.197 -167.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 62.52 28.02 16.53 Favored 'General case' 0 C--N 1.355 0.816 0 C-N-CA 126.186 1.794 . . . . 0.0 113.046 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.16 167.18 23.66 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 103.784 -3.726 . . . . 0.0 103.784 160.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -82.66 141.44 32.48 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 176.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p -108.39 -177.84 3.43 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 122.403 1.097 . . . . 0.0 109.933 -169.429 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.9 p -174.49 -156.55 0.07 Allowed 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 95.168 -5.864 . . . . 0.0 95.168 -171.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -149.1 -174.23 0.4 Allowed Pre-proline 0 N--CA 1.435 -1.221 1 N-CA-C 98.763 -4.532 . . . . 0.0 98.763 -169.33 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -59.48 149.99 78.41 Favored 'Trans proline' 0 CA--C 1.507 -0.87 0 C-N-CA 123.652 2.902 . . . . 0.0 112.049 166.332 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 4.6 tp -164.6 -51.42 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 100.937 -3.727 . . . . 0.0 100.937 -176.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 66.6 mt -115.0 -158.28 0.66 Allowed 'General case' 0 N--CA 1.434 -1.23 1 N-CA-C 99.238 -4.356 . . . . 0.0 99.238 159.403 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -68.02 120.09 13.7 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 174.043 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -176.26 -171.97 0.45 Allowed 'General case' 0 N--CA 1.425 -1.682 1 N-CA-C 96.538 -5.356 . . . . 0.0 96.538 -168.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -174.16 -163.28 27.29 Favored Glycine 0 CA--C 1.474 -2.507 1 N-CA-C 100.697 -4.961 . . . . 0.0 100.697 -167.817 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -88.96 -161.79 0.8 Allowed 'General case' 0 N--CA 1.435 -1.217 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 178.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 75.2 m -90.0 155.58 18.99 Favored 'General case' 0 N--CA 1.428 -1.561 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 55.8 m -70.16 -31.93 69.66 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -173.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.41 9.79 27.68 Favored 'General case' 0 N--CA 1.442 -0.834 0 C-N-CA 124.268 1.027 . . . . 0.0 110.43 175.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.27 -72.82 0.38 Allowed Glycine 0 CA--C 1.489 -1.554 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 170.754 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.79 151.95 25.9 Favored 'General case' 0 CA--C 1.498 -1.021 0 O-C-N 122.192 -0.593 . . . . 0.0 111.286 -162.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 1.9 t -138.23 133.61 33.41 Favored 'General case' 0 CA--C 1.485 -1.528 1 N-CA-C 97.315 -5.069 . . . . 0.0 97.315 -175.151 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -158.19 55.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 102.975 -2.972 . . . . 0.0 102.975 175.438 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.67 -64.23 2.16 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 106.113 -2.795 . . . . 0.0 106.113 -176.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.3 m -92.43 159.85 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 168.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.6 m -79.92 139.54 37.05 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 168.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.62 -149.39 0.28 Allowed 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 104.38 -2.452 . . . . 0.0 104.38 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -142.22 167.46 22.06 Favored 'General case' 0 N--CA 1.425 -1.695 1 N-CA-C 96.513 -5.366 . . . . 0.0 96.513 173.188 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 71.8 mt -153.46 167.88 27.98 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 94.927 -5.953 . . . . 0.0 94.927 176.308 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.885 0 O-C-N 124.114 0.884 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 11.5 p-10 . . . . . 0 N--CA 1.496 1.837 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -145.39 156.02 43.52 Favored 'General case' 0 N--CA 1.429 -1.51 1 N-CA-C 95.339 -5.8 . . . . 0.0 95.339 172.572 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 2.0 p -165.83 169.17 15.25 Favored 'General case' 0 N--CA 1.425 -1.7 1 N-CA-C 99.738 -4.171 . . . . 0.0 99.738 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -93.37 144.4 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.158 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 -177.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -68.97 145.76 53.33 Favored 'General case' 0 N--CA 1.437 -1.097 0 C-N-CA 127.853 2.461 . . . . 0.0 108.604 -170.582 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 68.0 28.96 6.63 Favored 'General case' 0 CA--C 1.503 -0.848 0 C-N-CA 125.58 1.552 . . . . 0.0 112.56 -174.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.67 166.49 13.67 Favored Glycine 0 C--N 1.349 1.296 0 N-CA-C 104.293 -3.523 . . . . 0.0 104.293 163.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -81.35 134.37 35.56 Favored 'General case' 0 CA--C 1.503 -0.834 0 CA-C-N 118.253 1.026 . . . . 0.0 108.251 -175.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.5 p -106.82 78.98 1.29 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-O 122.518 1.151 . . . . 0.0 108.44 -179.434 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -146.68 167.45 23.77 Favored 'General case' 0 N--CA 1.423 -1.801 1 N-CA-C 98.088 -4.782 . . . . 0.0 98.088 170.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 61.1 mt -154.1 -175.96 0.55 Allowed Pre-proline 0 N--CA 1.432 -1.356 1 N-CA-C 95.797 -5.631 . . . . 0.0 95.797 175.791 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_exo -58.46 110.93 0.73 Allowed 'Trans proline' 0 N--CA 1.456 -0.68 0 CA-C-N 123.917 2.435 . . . . 0.0 109.422 165.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 9.0 tp -83.54 96.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 CA-C-O 123.265 1.507 . . . . 0.0 110.038 -147.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 45.5 mt -158.69 -54.91 0.07 Allowed 'General case' 0 CA--C 1.482 -1.654 1 N-CA-C 97.247 -5.094 . . . . 0.0 97.247 178.055 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -88.66 159.27 17.92 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.825 -2.658 . . . . 0.0 103.825 163.587 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 42.7 t-20 -149.47 173.78 13.21 Favored 'General case' 0 N--CA 1.431 -1.405 1 N-CA-C 96.258 -5.46 . . . . 0.0 96.258 166.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -102.67 -162.42 26.02 Favored Glycine 0 CA--C 1.494 -1.255 0 N-CA-C 105.65 -2.98 . . . . 0.0 105.65 177.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -128.33 156.08 43.64 Favored 'General case' 0 CA--C 1.485 -1.545 1 N-CA-C 98.839 -4.504 . . . . 0.0 98.839 175.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.1 m -90.74 142.47 27.72 Favored 'General case' 0 CA--C 1.489 -1.372 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.4 m -66.77 -36.11 81.65 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 121.182 0.515 . . . . 0.0 110.749 -175.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 p -90.38 10.21 25.93 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.53 0.732 . . . . 0.0 111.518 178.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.21 -47.92 1.07 Allowed Glycine 0 C--N 1.35 1.327 0 O-C-N 121.24 -0.912 . . . . 0.0 112.954 163.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.82 143.16 33.51 Favored 'General case' 0 CA--C 1.489 -1.371 0 CA-C-N 119.042 1.421 . . . . 0.0 107.524 -167.844 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 11.9 t -123.86 136.48 54.39 Favored 'General case' 0 CA--C 1.484 -1.584 1 N-CA-C 98.463 -4.643 . . . . 0.0 98.463 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.6 43.57 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 103.111 -2.922 . . . . 0.0 103.111 176.041 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.49 -56.05 1.43 Allowed Glycine 0 C--N 1.354 1.529 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 m -99.51 160.44 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 164.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 89.9 m -80.12 148.06 31.13 Favored 'General case' 0 CA--C 1.488 -1.411 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 172.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.62 -146.62 0.2 Allowed 'General case' 0 N--CA 1.431 -1.388 0 N-CA-C 102.62 -3.104 . . . . 0.0 102.62 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.97 -178.22 6.16 Favored 'General case' 0 N--CA 1.427 -1.594 1 N-CA-C 96.372 -5.418 . . . . 0.0 96.372 175.06 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.88 155.23 50.63 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 94.364 -6.161 . . . . 0.0 94.364 169.627 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.812 0 O-C-N 124.469 1.105 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.501 2.079 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -97.65 -68.91 0.78 Allowed 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 174.162 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 19.9 p -140.37 170.79 15.16 Favored 'General case' 0 N--CA 1.422 -1.85 1 N-CA-C 95.539 -5.726 . . . . 0.0 95.539 161.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.5 mt -100.21 143.96 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 104.622 -2.362 . . . . 0.0 104.622 176.122 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -75.74 145.94 40.45 Favored 'General case' 0 N--CA 1.439 -0.989 0 C-N-CA 126.678 1.991 . . . . 0.0 108.22 -164.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 31.6 m-85 71.06 16.23 6.43 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 126.272 1.829 . . . . 0.0 111.992 -171.686 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.37 165.25 28.7 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 169.748 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -88.33 138.67 31.23 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.1 p -135.09 156.86 48.29 Favored 'General case' 0 CA--C 1.49 -1.358 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -170.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 167.57 -174.48 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.545 1 N-CA-C 97.248 -5.093 . . . . 0.0 97.248 163.254 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.8 tp -150.02 144.82 18.0 Favored Pre-proline 0 N--CA 1.425 -1.69 1 N-CA-C 94.428 -6.138 . . . . 0.0 94.428 163.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -69.37 -28.28 27.3 Favored 'Trans proline' 0 CA--C 1.506 -0.891 0 CA-C-N 126.947 3.517 . . . . 0.0 113.702 -165.855 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.4 tt -86.18 -32.06 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -174.198 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 83.0 mt -102.89 -16.39 15.89 Favored 'General case' 0 CA--C 1.5 -0.981 0 O-C-N 121.485 -0.759 . . . . 0.0 110.676 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp 68.17 8.58 6.65 Favored 'General case' 0 C--N 1.355 0.805 0 C-N-CA 126.616 1.966 . . . . 0.0 111.783 -179.082 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -149.32 153.34 37.32 Favored 'General case' 0 CA--C 1.478 -1.793 1 N-CA-C 97.839 -4.874 . . . . 0.0 97.839 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -148.8 154.71 25.99 Favored Glycine 0 N--CA 1.424 -2.102 1 N-CA-C 96.113 -6.795 . . . . 0.0 96.113 171.584 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.8 mt -74.54 119.49 18.8 Favored 'General case' 0 CA--C 1.493 -1.22 0 CA-C-N 118.172 0.986 . . . . 0.0 110.409 -164.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.1 m -90.24 148.34 22.97 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.406 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -74.03 -15.19 61.09 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 122.316 -0.24 . . . . 0.0 110.911 178.098 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.4 p -86.35 -25.33 25.43 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 176.319 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.06 -75.01 0.36 Allowed Glycine 0 CA--C 1.485 -1.81 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -176.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.13 34.79 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 122.189 -0.595 . . . . 0.0 110.202 -168.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.1 t -119.02 130.41 55.64 Favored 'General case' 0 CA--C 1.481 -1.69 1 N-CA-C 96.186 -5.487 . . . . 0.0 96.186 173.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.5 p -146.88 44.78 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.96 -60.63 1.99 Allowed Glycine 0 C--N 1.353 1.488 0 N-CA-C 106.639 -2.584 . . . . 0.0 106.639 -176.004 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.57 164.17 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.135 0 N-CA-C 104.511 -2.403 . . . . 0.0 104.511 164.463 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 83.3 m -80.85 134.54 35.78 Favored 'General case' 0 CA--C 1.488 -1.435 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.37 -163.42 1.6 Allowed 'General case' 0 CA--C 1.485 -1.54 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 -174.972 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -162.32 172.27 15.93 Favored 'General case' 0 N--CA 1.423 -1.81 1 N-CA-C 95.284 -5.821 . . . . 0.0 95.284 173.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.9 mp -142.73 146.86 34.76 Favored 'General case' 0 N--CA 1.426 -1.637 1 N-CA-C 94.497 -6.112 . . . . 0.0 94.497 170.247 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.883 0 O-C-N 124.704 1.252 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 . . . . . 0 N--CA 1.499 2.007 0 N-CA-C 104.721 -2.325 . . . . 0.0 104.721 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 49.4 t0 -162.57 -178.92 6.53 Favored 'General case' 0 N--CA 1.428 -1.536 1 N-CA-C 95.727 -5.657 . . . . 0.0 95.727 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.6 p -150.92 173.74 13.92 Favored 'General case' 0 N--CA 1.424 -1.728 1 N-CA-C 99.091 -4.411 . . . . 0.0 99.091 173.47 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.1 mt -97.56 148.59 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 103.212 -2.884 . . . . 0.0 103.212 171.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp -77.26 139.4 39.83 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 125.508 1.523 . . . . 0.0 109.092 -162.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 68.65 29.09 5.52 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 126.307 1.843 . . . . 0.0 110.795 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.61 170.51 18.31 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 103.556 -3.818 . . . . 0.0 103.556 161.345 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -82.26 156.21 24.46 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -176.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p -155.48 -170.6 3.5 Favored 'General case' 0 CA--C 1.489 -1.393 1 N-CA-C 98.723 -4.547 . . . . 0.0 98.723 170.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -161.23 175.83 11.9 Favored 'General case' 0 N--CA 1.425 -1.702 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 -169.831 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.73 163.72 21.65 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -172.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -73.65 41.25 0.6 Allowed 'Trans proline' 0 CA--C 1.518 -0.298 0 C-N-CA 124.308 3.339 . . . . 0.0 113.095 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 6.7 tp -105.95 -17.02 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 164.517 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 77.9 mt -127.38 -137.38 0.25 Allowed 'General case' 0 CA--C 1.484 -1.561 0 N-CA-C 101.605 -3.48 . . . . 0.0 101.605 175.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -87.14 152.56 22.23 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -150.72 -171.99 4.07 Favored 'General case' 0 N--CA 1.425 -1.692 1 N-CA-C 99.484 -4.265 . . . . 0.0 99.484 167.51 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.69 -175.49 44.94 Favored Glycine 0 N--CA 1.414 -2.787 1 N-CA-C 95.828 -6.909 . . . . 0.0 95.828 176.295 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.2 tp -94.04 141.42 28.55 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 103.267 -2.864 . . . . 0.0 103.267 178.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.0 m -90.5 151.26 21.44 Favored 'General case' 0 CA--C 1.49 -1.365 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -67.92 -28.38 67.44 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 119.687 1.13 . . . . 0.0 110.229 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.9 p -90.28 10.42 24.85 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 125.336 1.454 . . . . 0.0 110.407 174.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.25 -69.28 1.83 Allowed Glycine 0 CA--C 1.491 -1.408 0 O-C-N 120.941 -1.1 . . . . 0.0 111.152 168.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.77 141.9 35.86 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 -162.054 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.1 t -137.07 145.78 44.37 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 97.811 -4.885 . . . . 0.0 97.811 -175.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.5 p -160.69 -140.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.427 -1.609 1 N-CA-C 92.667 -6.79 . . . . 0.0 92.667 175.836 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.7 -4.44 61.64 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 122.92 2.6 . . . . 0.0 113.019 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 m -143.72 163.53 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 100.436 -3.913 . . . . 0.0 100.436 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.69 133.46 33.68 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 105.965 -1.865 . . . . 0.0 105.965 168.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.22 -154.93 0.54 Allowed 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 -179.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.22 40.26 Favored 'General case' 0 N--CA 1.427 -1.621 1 N-CA-C 96.281 -5.451 . . . . 0.0 96.281 174.332 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.4 mt -152.83 168.03 27.08 Favored 'General case' 0 N--CA 1.424 -1.74 1 N-CA-C 94.663 -6.051 . . . . 0.0 94.663 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.892 0 O-C-N 124.093 0.871 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.497 1.92 0 N-CA-C 104.236 -2.505 . . . . 0.0 104.236 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -155.07 165.7 35.91 Favored 'General case' 0 N--CA 1.427 -1.58 1 N-CA-C 96.284 -5.45 . . . . 0.0 96.284 179.069 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 9.7 p -171.32 -175.72 1.72 Allowed 'General case' 0 N--CA 1.423 -1.82 1 N-CA-C 96.661 -5.311 . . . . 0.0 96.661 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.19 150.64 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.582 0 N-CA-C 104.081 -2.562 . . . . 0.0 104.081 169.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -75.9 137.9 40.69 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.6 2.36 . . . . 0.0 108.504 -166.551 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 67.49 29.57 7.19 Favored 'General case' 0 C--N 1.357 0.897 0 C-N-CA 125.861 1.665 . . . . 0.0 110.898 -172.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.27 168.81 12.68 Favored Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 103.368 -3.893 . . . . 0.0 103.368 165.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -87.53 147.96 25.11 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.0 157.83 22.9 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.2 p -175.02 -158.63 0.07 Allowed 'General case' 0 N--CA 1.429 -1.512 1 N-CA-C 95.346 -5.798 . . . . 0.0 95.346 -175.995 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 87.4 mt -102.4 104.49 37.94 Favored Pre-proline 0 N--CA 1.441 -0.92 0 N-CA-C 100.632 -3.84 . . . . 0.0 100.632 164.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -82.97 -28.01 1.75 Allowed 'Trans proline' 0 CA--C 1.499 -1.243 0 CA-C-N 122.794 2.034 . . . . 0.0 109.848 -158.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 16.8 tt 171.09 -39.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.497 -1.08 0 N-CA-C 101.585 -3.487 . . . . 0.0 101.585 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 65.5 mt -75.42 152.03 38.04 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 106.429 -1.693 . . . . 0.0 106.429 169.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtpt -95.97 54.99 1.53 Allowed 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -161.693 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -169.07 -179.24 3.53 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 178.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -139.1 43.13 1.19 Allowed Glycine 0 CA--C 1.483 -1.929 0 N-CA-C 104.083 -3.607 . . . . 0.0 104.083 176.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 38.6 tp -79.74 119.21 22.34 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -171.146 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.5 m -90.42 150.89 21.65 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 177.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.03 -28.31 65.37 Favored 'General case' 0 C--N 1.353 0.737 0 CA-C-N 118.779 0.718 . . . . 0.0 111.144 -177.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.0 p -90.01 3.89 51.82 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 124.618 1.167 . . . . 0.0 109.301 176.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.94 -75.23 0.24 Allowed Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 169.584 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.66 144.67 29.25 Favored 'General case' 0 CA--C 1.496 -1.104 0 CA-C-O 120.859 0.362 . . . . 0.0 111.254 -160.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.9 t -123.07 130.39 52.72 Favored 'General case' 0 N--CA 1.428 -1.53 1 N-CA-C 99.449 -4.278 . . . . 0.0 99.449 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.5 p -150.61 56.54 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.08 0 N-CA-C 102.548 -3.13 . . . . 0.0 102.548 170.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.84 -67.03 1.87 Allowed Glycine 0 CA--C 1.491 -1.41 0 N-CA-C 106.133 -2.787 . . . . 0.0 106.133 -177.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.5 m -87.5 157.5 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.099 0 N-CA-C 105.313 -2.106 . . . . 0.0 105.313 167.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 m -84.02 127.15 33.68 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 167.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.79 -141.63 0.13 Allowed 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 102.676 -3.083 . . . . 0.0 102.676 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -150.73 162.58 40.43 Favored 'General case' 0 N--CA 1.425 -1.701 1 N-CA-C 96.589 -5.337 . . . . 0.0 96.589 171.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.8 mt -153.73 170.95 19.68 Favored 'General case' 0 N--CA 1.428 -1.575 1 N-CA-C 94.891 -5.966 . . . . 0.0 94.891 171.715 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.919 0 O-C-N 124.262 0.976 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 . . . . . 0 N--CA 1.496 1.835 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 67.71 -148.49 0.15 Allowed 'General case' 0 C--N 1.358 0.971 0 C-N-CA 125.61 1.564 . . . . 0.0 109.08 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p -140.18 159.94 41.07 Favored 'General case' 0 N--CA 1.427 -1.598 1 N-CA-C 97.476 -5.009 . . . . 0.0 97.476 165.639 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.3 mt -109.02 154.65 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 -175.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -87.58 143.19 27.32 Favored 'General case' 0 N--CA 1.437 -1.097 0 C-N-CA 128.229 2.611 . . . . 0.0 107.44 -157.197 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 79.81 2.91 2.11 Favored 'General case' 0 C--N 1.355 0.846 0 C-N-CA 127.453 2.301 . . . . 0.0 112.34 -173.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.36 165.09 28.61 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.65 -2.58 . . . . 0.0 106.65 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -76.44 144.35 39.98 Favored 'General case' 0 CA--C 1.497 -1.06 0 CA-C-N 118.135 0.967 . . . . 0.0 108.813 -175.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.6 p -138.63 167.16 22.55 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 177.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.16 -105.82 0.07 Allowed 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 179.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.4 mt -153.46 154.11 30.09 Favored Pre-proline 0 N--CA 1.432 -1.361 1 N-CA-C 96.643 -5.317 . . . . 0.0 96.643 166.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.07 134.14 15.76 Favored 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 122.422 2.081 . . . . 0.0 108.975 176.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 70.1 mt -140.21 -68.48 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 102.389 -3.189 . . . . 0.0 102.389 177.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 93.7 mt -111.98 -171.03 1.77 Allowed 'General case' 0 N--CA 1.437 -1.113 1 N-CA-C 99.492 -4.262 . . . . 0.0 99.492 164.703 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.3 mmmp? -81.19 66.49 6.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 122.344 1.069 . . . . 0.0 110.537 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -78.27 -60.85 2.21 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 170.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -153.26 160.66 29.29 Favored Glycine 0 N--CA 1.424 -2.14 1 N-CA-C 99.239 -5.544 . . . . 0.0 99.239 171.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.9 tp -149.07 154.05 38.72 Favored 'General case' 0 N--CA 1.429 -1.476 1 N-CA-C 93.839 -6.356 . . . . 0.0 93.839 169.058 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.5 m -91.6 146.04 24.11 Favored 'General case' 0 CA--C 1.484 -1.561 0 CA-C-N 119.318 0.963 . . . . 0.0 109.437 -177.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.7 m -69.98 -27.26 64.57 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.757 0.313 . . . . 0.0 110.505 -176.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.52 4.66 50.52 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 123.997 0.919 . . . . 0.0 111.221 173.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.85 -74.89 0.27 Allowed Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 172.113 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.58 153.07 25.67 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 118.146 0.973 . . . . 0.0 110.191 -163.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.7 t -142.42 152.02 42.38 Favored 'General case' 0 N--CA 1.429 -1.496 1 N-CA-C 98.166 -4.753 . . . . 0.0 98.166 -171.759 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.8 p -160.31 -142.92 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.146 1 N-CA-C 92.693 -6.78 . . . . 0.0 92.693 176.421 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.57 -15.11 65.81 Favored Glycine 0 C--N 1.35 1.308 0 CA-C-N 124.126 3.148 . . . . 0.0 113.008 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 m -138.14 163.75 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.691 0 N-CA-C 100.927 -3.731 . . . . 0.0 100.927 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.7 m -79.96 136.44 36.62 Favored 'General case' 0 CA--C 1.484 -1.589 0 C-N-CA 124.871 1.268 . . . . 0.0 108.172 176.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.23 -155.17 0.58 Allowed 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 -174.36 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -146.8 156.14 42.9 Favored 'General case' 0 N--CA 1.423 -1.815 1 N-CA-C 95.416 -5.772 . . . . 0.0 95.416 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.1 mt -153.59 165.46 35.83 Favored 'General case' 0 N--CA 1.425 -1.721 1 N-CA-C 94.406 -6.146 . . . . 0.0 94.406 178.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.889 0 O-C-N 124.299 0.999 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -113.82 -74.67 0.61 Allowed 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 -179.141 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.3 p -123.14 159.13 29.2 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 165.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -100.29 141.2 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 N-CA-C 104.447 -2.427 . . . . 0.0 104.447 -174.076 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -66.6 143.71 56.85 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 126.271 1.828 . . . . 0.0 110.589 -166.868 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 56.46 33.88 23.29 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 126.288 1.835 . . . . 0.0 112.665 -172.386 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.59 165.9 18.1 Favored Glycine 0 CA--C 1.487 -1.67 1 N-CA-C 102.481 -4.248 . . . . 0.0 102.481 161.026 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -71.87 152.13 42.84 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -177.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.9 p -151.67 -176.45 5.62 Favored 'General case' 0 N--CA 1.432 -1.372 1 N-CA-C 98.664 -4.569 . . . . 0.0 98.664 169.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 p 141.2 -139.3 0.0 OUTLIER 'General case' 0 CA--C 1.497 -1.092 1 N-CA-C 93.398 -6.519 . . . . 0.0 93.398 -169.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.0 mt -120.42 81.95 31.51 Favored Pre-proline 0 N--CA 1.441 -0.876 0 CA-C-N 119.676 1.126 . . . . 0.0 109.298 177.182 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -85.9 -4.75 8.89 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.122 1.881 . . . . 0.0 110.788 166.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.26 17.9 mt 75.03 -64.9 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 C-N-CA 127.414 2.286 . . . . 0.0 110.023 175.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -72.19 -39.44 68.62 Favored 'General case' 0 CA--C 1.499 -1.0 0 CA-C-O 122.243 1.021 . . . . 0.0 108.818 -170.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -98.34 21.8 10.53 Favored 'General case' 0 N--CA 1.434 -1.243 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.779 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -86.23 174.34 9.16 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 171.554 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.28 -159.83 32.76 Favored Glycine 0 N--CA 1.417 -2.575 1 N-CA-C 94.89 -7.284 . . . . 0.0 94.89 -173.301 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.3 mt -100.08 174.85 5.97 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 102.236 -3.246 . . . . 0.0 102.236 163.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 57.1 m -88.33 148.66 24.17 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 m -72.81 -16.89 61.61 Favored 'General case' 0 C--N 1.352 0.693 0 CA-C-O 120.675 0.274 . . . . 0.0 110.63 -172.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -88.43 -17.24 30.87 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 125.688 1.595 . . . . 0.0 110.158 176.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.1 -78.58 0.29 Allowed Glycine 0 N--CA 1.436 -1.309 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 -175.27 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.87 150.41 29.1 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.83 -0.806 . . . . 0.0 111.418 -166.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.6 t -131.11 137.14 48.94 Favored 'General case' 0 N--CA 1.425 -1.719 1 N-CA-C 97.868 -4.864 . . . . 0.0 97.868 -177.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.19 -129.87 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.189 1 N-CA-C 98.027 -4.805 . . . . 0.0 98.027 164.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.16 -5.01 87.1 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 117.705 -3.122 . . . . 0.0 110.713 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.1 m -145.78 164.42 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.728 1 N-CA-C 99.14 -4.393 . . . . 0.0 99.14 -177.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.9 m -79.07 137.64 37.61 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 169.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.11 -151.23 0.37 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 -174.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -143.65 161.63 38.04 Favored 'General case' 0 N--CA 1.426 -1.647 1 N-CA-C 98.007 -4.812 . . . . 0.0 98.007 175.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.3 mt -150.43 163.96 37.07 Favored 'General case' 0 N--CA 1.423 -1.814 1 N-CA-C 94.276 -6.194 . . . . 0.0 94.276 167.212 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.936 0 O-C-N 124.248 0.967 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.2 p . . . . . 0 N--CA 1.428 -1.549 1 N-CA-C 97.849 -4.871 . . . . 0.0 97.849 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.5 mt -92.09 148.22 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 104.862 -2.274 . . . . 0.0 104.862 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.6 tttt . . . . . 0 N--CA 1.437 -1.092 0 C-N-CA 127.127 2.171 . . . . 0.0 107.747 -168.095 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 . . . . . 0 N--CA 1.444 -0.773 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.26 173.98 25.74 Favored Glycine 0 C--N 1.354 1.568 0 N-CA-C 105.802 -2.919 . . . . 0.0 105.802 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -85.08 131.78 34.41 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-N 118.372 1.086 . . . . 0.0 108.907 -174.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p . . . . . 0 CA--C 1.493 -1.226 0 C-N-CA 123.783 0.833 . . . . 0.0 108.925 -178.353 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 CA--C 1.498 -1.036 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.95 -33.23 75.13 Favored 'General case' 0 C--N 1.354 0.772 0 CA-C-O 121.134 0.493 . . . . 0.0 110.491 176.164 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -90.18 9.69 27.47 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 121.696 -0.628 . . . . 0.0 110.124 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.83 -69.34 1.18 Allowed Glycine 0 CA--C 1.492 -1.348 0 O-C-N 121.142 -0.974 . . . . 0.0 112.995 165.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.87 153.56 20.55 Favored 'General case' 0 CA--C 1.494 -1.187 0 CA-C-N 118.202 1.001 . . . . 0.0 108.768 -160.206 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 50.6 t -130.83 133.91 46.36 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 102.428 -3.175 . . . . 0.0 102.428 -176.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.5 p -137.26 37.27 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 102.671 -3.085 . . . . 0.0 102.671 175.259 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.04 -55.36 0.97 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 106.072 -2.811 . . . . 0.0 106.072 -176.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 m -94.85 156.53 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 165.06 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 57.0 m -73.62 129.7 38.5 Favored 'General case' 0 CA--C 1.486 -1.495 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.48 -156.8 0.7 Allowed 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 . . . . . 0 N--CA 1.418 -2.031 1 N-CA-C 98.569 -4.604 . . . . 0.0 98.569 -170.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.43 -1.474 1 N-CA-C 98.933 -4.469 . . . . 0.0 98.933 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.6 mt -93.58 136.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 176.574 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.5 ttpp . . . . . 0 N--CA 1.435 -1.186 0 C-N-CA 127.847 2.459 . . . . 0.0 108.584 -166.287 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 . . . . . 0 N--CA 1.441 -0.918 0 CA-C-O 120.824 0.345 . . . . 0.0 111.26 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.86 160.22 13.44 Favored Glycine 0 CA--C 1.491 -1.448 1 N-CA-C 102.548 -4.221 . . . . 0.0 102.548 167.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -74.34 149.91 40.38 Favored 'General case' 0 CA--C 1.503 -0.833 0 CA-C-N 118.094 0.947 . . . . 0.0 111.636 -165.301 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 30.1 p . . . . . 0 N--CA 1.436 -1.131 1 N-CA-C 98.884 -4.488 . . . . 0.0 98.884 170.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.7 m . . . . . 0 CA--C 1.485 -1.544 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.3 m -63.19 -37.56 87.71 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 121.327 0.584 . . . . 0.0 111.052 -171.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.8 p -90.52 7.07 40.86 Favored 'General case' 0 N--CA 1.443 -0.821 0 C-N-CA 124.695 1.198 . . . . 0.0 111.741 178.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.21 -69.91 0.27 Allowed Glycine 0 C--N 1.35 1.334 0 O-C-N 121.171 -0.956 . . . . 0.0 111.505 170.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.3 145.16 31.03 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-N 118.227 1.013 . . . . 0.0 110.986 -167.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.3 t -128.31 129.66 46.64 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 101.339 -3.578 . . . . 0.0 101.339 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.409 HG22 ' H ' ' A' ' 27' ' ' GLY . 5.8 p -133.24 -138.6 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -0.982 1 N-CA-C 97.837 -4.875 . . . . 0.0 97.837 165.235 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -70.99 -4.68 56.17 Favored Glycine 0 C--N 1.348 1.236 0 O-C-N 118.657 -2.527 . . . . 0.0 112.322 -179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.45 164.09 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.954 1 N-CA-C 98.794 -4.521 . . . . 0.0 98.794 174.855 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 73.3 m -77.57 141.03 39.77 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 167.746 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.5 -146.1 0.19 Allowed 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 104.165 -2.531 . . . . 0.0 104.165 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.425 -1.706 1 N-CA-C 96.989 -5.189 . . . . 0.0 96.989 173.033 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.0 p . . . . . 0 CA--C 1.491 -1.314 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -92.97 140.63 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 101.543 -3.502 . . . . 0.0 101.543 172.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.7 tttm . . . . . 0 N--CA 1.44 -0.959 0 CA-C-O 117.382 -1.294 . . . . 0.0 108.276 -162.738 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 . . . . . 0 CA--C 1.507 -0.676 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.91 168.39 26.1 Favored Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 105.889 -2.884 . . . . 0.0 105.889 172.258 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -85.46 146.4 26.97 Favored 'General case' 0 CA--C 1.504 -0.805 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -177.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.7 p . . . . . 0 N--CA 1.434 -1.261 0 N-CA-C 103.432 -2.803 . . . . 0.0 103.432 -177.309 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.3 m . . . . . 0 CA--C 1.5 -0.96 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -62.13 -42.65 99.45 Favored 'General case' 0 C--N 1.358 0.938 0 CA-C-N 118.805 0.73 . . . . 0.0 110.024 -177.753 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.4 p -87.53 17.63 4.45 Favored 'General case' 0 N--CA 1.441 -0.916 0 C-N-CA 123.716 0.806 . . . . 0.0 111.314 177.388 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.99 -71.49 0.89 Allowed Glycine 0 CA--C 1.49 -1.494 0 O-C-N 120.552 -1.342 . . . . 0.0 111.595 164.838 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.18 144.73 25.6 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 121.755 -0.85 . . . . 0.0 111.09 -163.36 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.9 t -111.38 133.43 53.7 Favored 'General case' 0 N--CA 1.432 -1.348 0 N-CA-C 101.212 -3.625 . . . . 0.0 101.212 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.77 41.47 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.173 0 N-CA-C 102.86 -3.015 . . . . 0.0 102.86 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.31 -61.19 1.06 Allowed Glycine 0 C--N 1.352 1.431 0 N-CA-C 105.434 -3.066 . . . . 0.0 105.434 -174.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.1 m -95.07 160.6 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 166.018 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 67.1 m -78.86 135.4 37.02 Favored 'General case' 0 CA--C 1.495 -1.17 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 172.64 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.89 -140.7 0.11 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 103.436 -2.802 . . . . 0.0 103.436 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 . . . . . 0 N--CA 1.423 -1.821 1 N-CA-C 96.893 -5.225 . . . . 0.0 96.893 174.594 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.435 -1.224 0 N-CA-C 103.396 -2.816 . . . . 0.0 103.396 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ILE . . . . . 0.426 ' HB ' ' SG ' ' A' ' 20' ' ' CYS . 57.0 mt -89.45 150.69 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 102.835 -3.024 . . . . 0.0 102.835 165.095 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.1 tttm . . . . . 0 N--CA 1.439 -1.006 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 -164.31 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.257 86.9 m-85 . . . . . 0 CA--C 1.503 -0.84 0 CA-C-O 121.301 0.572 . . . . 0.0 110.499 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.9 163.0 19.32 Favored Glycine 0 CA--C 1.491 -1.449 0 N-CA-C 105.335 -3.106 . . . . 0.0 105.335 166.145 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -79.92 145.58 32.58 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.433 -1.294 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 -170.671 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 4' ' ' ILE . 84.8 m . . . . . 0 CA--C 1.484 -1.585 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.0 m -64.6 -36.78 85.34 Favored 'General case' 0 C--N 1.351 0.645 0 CA-C-O 121.242 0.544 . . . . 0.0 110.183 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.6 p -87.69 1.15 54.54 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.17 0.988 . . . . 0.0 110.316 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.9 -79.67 1.5 Allowed Glycine 0 N--CA 1.437 -1.249 0 O-C-N 121.421 -0.799 . . . . 0.0 111.939 173.322 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.57 123.31 28.54 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 113.421 0.897 . . . . 0.0 113.421 -149.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -96.64 127.09 42.3 Favored 'General case' 0 CA--C 1.5 -0.954 0 C-N-CA 125.435 1.494 . . . . 0.0 107.309 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.79 42.22 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.061 -2.941 . . . . 0.0 103.061 175.515 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.88 -56.12 1.14 Allowed Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 106.118 -2.793 . . . . 0.0 106.118 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.7 m -103.91 156.78 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 103.019 -2.956 . . . . 0.0 103.019 163.912 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -89.58 143.89 26.45 Favored 'General case' 0 CA--C 1.482 -1.67 0 CA-C-O 121.172 0.511 . . . . 0.0 109.905 179.323 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.26 -146.75 0.19 Allowed 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 102.421 -3.177 . . . . 0.0 102.421 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.431 -1.406 1 N-CA-C 95.876 -5.601 . . . . 0.0 95.876 166.329 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.428 -1.559 1 N-CA-C 99.276 -4.342 . . . . 0.0 99.276 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.1 mt -88.66 145.98 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 -172.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.5 tttt . . . . . 0 N--CA 1.437 -1.08 0 C-N-CA 126.766 2.026 . . . . 0.0 109.762 -162.179 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.269 96.3 m-85 . . . . . 0 CA--C 1.504 -0.81 0 CA-C-O 120.911 0.386 . . . . 0.0 111.847 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.81 171.05 27.01 Favored Glycine 0 C--N 1.352 1.446 0 N-CA-C 104.473 -3.451 . . . . 0.0 104.473 163.097 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -90.13 159.36 16.82 Favored 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 175.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.433 -1.323 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 -174.228 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 93.1 m . . . . . 0 CA--C 1.485 -1.542 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 59.2 m -66.87 -36.35 82.11 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.905 0.383 . . . . 0.0 110.929 -173.237 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.6 p -90.15 9.65 27.53 Favored 'General case' 0 N--CA 1.438 -1.058 0 C-N-CA 123.925 0.89 . . . . 0.0 111.158 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.48 -74.84 0.21 Allowed Glycine 0 C--N 1.353 1.478 0 O-C-N 121.294 -0.879 . . . . 0.0 111.439 168.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.02 141.1 30.54 Favored 'General case' 0 CA--C 1.494 -1.205 0 O-C-N 121.753 -0.851 . . . . 0.0 109.555 -162.584 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 25.8 t -119.81 126.62 51.43 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 98.492 -4.633 . . . . 0.0 98.492 171.653 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.3 p -146.47 48.29 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 101.924 -3.361 . . . . 0.0 101.924 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.69 -62.67 2.65 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.151 -2.779 . . . . 0.0 106.151 -174.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.9 m -89.25 158.36 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 167.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.0 m -82.1 128.96 34.65 Favored 'General case' 0 CA--C 1.49 -1.347 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 168.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.78 -142.77 0.2 Allowed 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 -178.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.422 -1.843 1 N-CA-C 97.734 -4.913 . . . . 0.0 97.734 -176.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.6 p . . . . . 0 CA--C 1.492 -1.264 0 N-CA-C 102.888 -3.004 . . . . 0.0 102.888 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 38.0 mt -111.75 149.63 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 101.791 -3.411 . . . . 0.0 101.791 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 tptp . . . . . 0 N--CA 1.441 -0.897 0 C-N-CA 125.002 1.321 . . . . 0.0 108.184 -164.946 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.258 75.0 m-85 . . . . . 0 CA--C 1.505 -0.766 0 CA-C-O 120.679 0.276 . . . . 0.0 111.605 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.97 169.41 29.56 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 105.544 -3.023 . . . . 0.0 105.544 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -85.23 154.17 22.13 Favored 'General case' 0 CA--C 1.5 -0.962 0 N-CA-C 106.804 -1.554 . . . . 0.0 106.804 178.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 CA--C 1.492 -1.281 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -173.539 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.0 m . . . . . 0 CA--C 1.496 -1.1 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.5 -31.42 69.66 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.093 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.3 p -87.26 9.5 20.07 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.749 1.22 . . . . 0.0 111.086 173.508 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.68 -78.96 0.49 Allowed Glycine 0 C--N 1.351 1.37 0 O-C-N 120.866 -1.147 . . . . 0.0 110.495 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.44 146.7 32.63 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 117.431 0.615 . . . . 0.0 111.368 -161.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.6 t -125.78 131.51 52.47 Favored 'General case' 0 N--CA 1.429 -1.499 1 N-CA-C 97.741 -4.911 . . . . 0.0 97.741 173.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -149.16 51.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.137 0 N-CA-C 101.407 -3.553 . . . . 0.0 101.407 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.01 -60.73 1.64 Allowed Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.235 -2.746 . . . . 0.0 106.235 -176.777 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.4 m -100.28 161.34 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.007 -2.219 . . . . 0.0 105.007 167.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 54.1 m -80.65 136.74 36.26 Favored 'General case' 0 CA--C 1.49 -1.357 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 174.112 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.01 -165.29 2.13 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -176.317 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.436 -1.128 0 N-CA-C 103.643 -2.725 . . . . 0.0 103.643 170.424 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.426 -1.638 1 N-CA-C 97.086 -5.153 . . . . 0.0 97.086 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.1 mt -107.59 148.43 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.322 0 N-CA-C 102.083 -3.303 . . . . 0.0 102.083 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.2 tptt . . . . . 0 N--CA 1.439 -1.008 0 C-N-CA 126.061 1.745 . . . . 0.0 108.343 -162.48 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 . . . . . 0 CA--C 1.507 -0.708 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.4 167.01 22.16 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 169.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.19 142.44 32.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -175.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p . . . . . 0 CA--C 1.501 -0.918 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 178.967 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 91.5 m . . . . . 0 CA--C 1.492 -1.269 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.25 -29.5 69.15 Favored 'General case' 0 C--N 1.352 0.71 0 CA-C-N 118.713 0.688 . . . . 0.0 111.414 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -90.03 -3.05 58.19 Favored 'General case' 0 N--CA 1.438 -1.071 0 O-C-N 121.292 -0.88 . . . . 0.0 109.841 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 115.48 -79.28 0.28 Allowed Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 109.829 -1.309 . . . . 0.0 109.829 170.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.19 151.4 24.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 O-C-N 122.596 -0.356 . . . . 0.0 110.585 -163.172 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -123.82 131.2 53.54 Favored 'General case' 0 CA--C 1.489 -1.39 1 N-CA-C 98.553 -4.61 . . . . 0.0 98.553 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.67 39.03 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 103.33 -2.841 . . . . 0.0 103.33 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.61 -55.68 1.03 Allowed Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.251 -2.74 . . . . 0.0 106.251 -176.636 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.5 m -98.21 164.3 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 163.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 63.7 m -81.69 139.55 34.85 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 171.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.35 -152.93 0.46 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 -177.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 N--CA 1.424 -1.742 1 N-CA-C 97.337 -5.06 . . . . 0.0 97.337 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p . . . . . 0 CA--C 1.484 -1.574 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.1 mt -97.97 149.49 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 175.693 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.354 0.771 0 C-N-CA 125.132 1.373 . . . . 0.0 108.496 -163.921 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.263 97.2 m-85 . . . . . 0 CA--C 1.503 -0.857 0 CA-C-O 121.108 0.48 . . . . 0.0 112.057 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.64 170.8 28.47 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 105.414 -3.074 . . . . 0.0 105.414 164.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -88.23 140.36 29.56 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 -176.235 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.9 p . . . . . 0 CA--C 1.498 -1.027 0 CA-C-O 122.275 1.036 . . . . 0.0 109.142 -174.044 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -72.64 -28.5 62.78 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.598 -0.689 . . . . 0.0 109.957 -178.111 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.5 p -90.66 11.63 21.53 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 124.36 1.064 . . . . 0.0 110.404 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.65 -77.72 0.93 Allowed Glycine 0 CA--C 1.491 -1.465 0 O-C-N 121.065 -1.022 . . . . 0.0 110.989 171.455 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.63 142.0 31.12 Favored 'General case' 0 CA--C 1.497 -1.092 0 CA-C-N 117.948 0.874 . . . . 0.0 109.999 -159.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 t -118.44 130.26 55.86 Favored 'General case' 0 CA--C 1.485 -1.544 1 N-CA-C 99.796 -4.15 . . . . 0.0 99.796 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -142.46 42.91 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.34 -60.41 1.31 Allowed Glycine 0 C--N 1.352 1.455 0 N-CA-C 106.232 -2.747 . . . . 0.0 106.232 -176.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.82 157.6 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 164.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 m -79.4 133.25 36.56 Favored 'General case' 0 CA--C 1.486 -1.504 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 174.359 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.55 -164.44 1.41 Allowed 'General case' 0 N--CA 1.428 -1.547 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 -176.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.5 p30 . . . . . 0 N--CA 1.423 -1.794 0 N-CA-C 100.752 -3.795 . . . . 0.0 100.752 179.147 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 6.2 p . . . . . 0 CA--C 1.499 -1.016 0 N-CA-C 102.223 -3.251 . . . . 0.0 102.223 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 35.5 mt -94.54 141.64 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt . . . . . 0 N--CA 1.442 -0.872 0 C-N-CA 127.334 2.254 . . . . 0.0 110.579 -163.005 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.443 -0.823 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.2 166.46 21.05 Favored Glycine 0 CA--C 1.493 -1.324 0 N-CA-C 105.056 -3.218 . . . . 0.0 105.056 164.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -66.6 148.2 52.23 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 125.399 1.48 . . . . 0.0 107.167 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.4 p . . . . . 0 CA--C 1.483 -1.612 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 178.058 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 94.0 m . . . . . 0 CA--C 1.489 -1.393 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 33.7 m -71.58 -30.4 65.79 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -175.752 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.09 -1.9 58.02 Favored 'General case' 0 N--CA 1.439 -0.991 0 C-N-CA 124.83 1.252 . . . . 0.0 110.245 177.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.86 -70.26 0.21 Allowed Glycine 0 CA--C 1.49 -1.503 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 172.0 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.61 145.68 27.9 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -161.539 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.2 t -132.22 133.03 43.68 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 100.726 -3.805 . . . . 0.0 100.726 -177.665 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.68 -125.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.885 1 N-CA-C 98.563 -4.606 . . . . 0.0 98.563 161.65 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.58 -9.17 86.25 Favored Glycine 0 C--N 1.349 1.276 0 O-C-N 118.316 -2.74 . . . . 0.0 110.801 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 m -148.12 161.58 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.755 1 N-CA-C 99.482 -4.266 . . . . 0.0 99.482 -172.462 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 97.8 m -78.7 136.57 37.47 Favored 'General case' 0 CA--C 1.489 -1.376 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.944 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 -165.46 1.5 Allowed 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 . . . . . 0 N--CA 1.421 -1.9 1 N-CA-C 99.108 -4.404 . . . . 0.0 99.108 -174.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 CA--C 1.488 -1.429 0 N-CA-C 100.513 -3.884 . . . . 0.0 100.513 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.5 mt -100.68 154.47 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 173.107 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? . . . . . 0 N--CA 1.44 -0.966 0 C-N-CA 125.294 1.437 . . . . 0.0 108.53 -161.577 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 CA--C 1.502 -0.896 0 CA-C-O 122.044 0.926 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.57 173.28 16.44 Favored Glycine 0 C--N 1.35 1.334 1 N-CA-C 102.348 -4.301 . . . . 0.0 102.348 162.84 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -89.86 145.86 24.85 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -175.064 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.8 p . . . . . 0 N--CA 1.433 -1.279 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 -177.501 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 CA--C 1.488 -1.404 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.29 -28.56 66.39 Favored 'General case' 0 C--N 1.35 0.617 0 CA-C-O 121.12 0.486 . . . . 0.0 110.183 -176.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 7.2 p -90.31 11.17 22.16 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 124.622 1.169 . . . . 0.0 110.833 175.106 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.69 -68.75 0.88 Allowed Glycine 0 CA--C 1.492 -1.359 0 O-C-N 120.672 -1.268 . . . . 0.0 111.704 165.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.78 142.66 28.8 Favored 'General case' 0 CA--C 1.496 -1.099 0 O-C-N 121.272 -1.134 . . . . 0.0 109.698 -164.249 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.3 t -132.93 127.48 34.38 Favored 'General case' 0 CA--C 1.486 -1.487 1 N-CA-C 99.653 -4.202 . . . . 0.0 99.653 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.44 62.8 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.161 0 N-CA-C 101.712 -3.44 . . . . 0.0 101.712 172.441 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.18 -63.41 2.76 Favored Glycine 0 C--N 1.351 1.414 0 N-CA-C 106.993 -2.443 . . . . 0.0 106.993 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.0 m -91.65 155.33 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.21 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 168.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.2 m -80.24 122.67 27.16 Favored 'General case' 0 CA--C 1.487 -1.445 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 166.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.55 -147.56 0.37 Allowed 'General case' 0 N--CA 1.432 -1.365 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 . . . . . 0 N--CA 1.42 -1.965 1 N-CA-C 95.58 -5.711 . . . . 0.0 95.58 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.427 -1.621 1 N-CA-C 96.47 -5.381 . . . . 0.0 96.47 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mt -89.43 140.6 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 -177.361 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 74.6 tttt . . . . . 0 N--CA 1.441 -0.877 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -158.558 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.306 68.3 m-85 . . . . . 0 N--CA 1.443 -0.806 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.36 168.65 16.66 Favored Glycine 0 N--CA 1.437 -1.298 0 N-CA-C 103.345 -3.902 . . . . 0.0 103.345 158.833 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -87.86 143.89 26.88 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.002 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.433 -1.308 0 N-CA-C 102.488 -3.153 . . . . 0.0 102.488 174.35 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 88.1 m . . . . . 0 CA--C 1.489 -1.386 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 38.9 m -66.9 -36.11 81.53 Favored 'General case' 0 C--N 1.351 0.637 0 CA-C-O 121.026 0.441 . . . . 0.0 111.516 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.6 p -90.34 15.04 11.27 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 123.846 0.858 . . . . 0.0 111.114 177.308 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.47 -67.7 0.69 Allowed Glycine 0 CA--C 1.489 -1.545 0 O-C-N 121.128 -0.983 . . . . 0.0 110.722 167.777 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.03 133.07 35.26 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 121.639 -0.918 . . . . 0.0 110.252 -166.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 12.5 t -123.61 122.48 38.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 100.487 -3.894 . . . . 0.0 100.487 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -151.21 65.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 103.228 -2.879 . . . . 0.0 103.228 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.25 -62.84 3.78 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 107.069 -2.412 . . . . 0.0 107.069 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -99.65 159.44 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 104.756 -2.312 . . . . 0.0 104.756 171.725 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 66.1 m -83.42 128.43 34.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 170.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.45 -152.36 0.41 Allowed 'General case' 0 N--CA 1.432 -1.333 0 N-CA-C 104.502 -2.406 . . . . 0.0 104.502 -174.08 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.424 -1.743 1 N-CA-C 97.371 -5.048 . . . . 0.0 97.371 173.071 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p . . . . . 0 CA--C 1.495 -1.138 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.3 mt -95.52 146.37 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 -175.396 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 ttpp . . . . . 0 N--CA 1.443 -0.807 0 C-N-CA 127.074 2.149 . . . . 0.0 110.197 -167.279 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 . . . . . 0 N--CA 1.444 -0.727 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.16 167.18 23.66 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 103.784 -3.726 . . . . 0.0 103.784 160.721 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -82.66 141.44 32.48 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 176.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p . . . . . 0 N--CA 1.435 -1.205 0 CA-C-O 122.403 1.097 . . . . 0.0 109.933 -169.429 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 N--CA 1.428 -1.561 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 55.8 m -70.16 -31.93 69.66 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -173.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.41 9.79 27.68 Favored 'General case' 0 N--CA 1.442 -0.834 0 C-N-CA 124.268 1.027 . . . . 0.0 110.43 175.817 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.27 -72.82 0.38 Allowed Glycine 0 CA--C 1.489 -1.554 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 170.754 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.79 151.95 25.9 Favored 'General case' 0 CA--C 1.498 -1.021 0 O-C-N 122.192 -0.593 . . . . 0.0 111.286 -162.165 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 1.9 t -138.23 133.61 33.41 Favored 'General case' 0 CA--C 1.485 -1.528 1 N-CA-C 97.315 -5.069 . . . . 0.0 97.315 -175.151 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -158.19 55.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 102.975 -2.972 . . . . 0.0 102.975 175.438 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.67 -64.23 2.16 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 106.113 -2.795 . . . . 0.0 106.113 -176.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.3 m -92.43 159.85 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 168.342 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.6 m -79.92 139.54 37.05 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 168.306 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.62 -149.39 0.28 Allowed 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 104.38 -2.452 . . . . 0.0 104.38 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.425 -1.695 1 N-CA-C 96.513 -5.366 . . . . 0.0 96.513 173.188 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.425 -1.7 1 N-CA-C 99.738 -4.171 . . . . 0.0 99.738 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -93.37 144.4 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.158 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 -177.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.3 tttm . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 127.853 2.461 . . . . 0.0 108.604 -170.582 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 . . . . . 0 CA--C 1.503 -0.848 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.67 166.49 13.67 Favored Glycine 0 C--N 1.349 1.296 0 N-CA-C 104.293 -3.523 . . . . 0.0 104.293 163.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -81.35 134.37 35.56 Favored 'General case' 0 CA--C 1.503 -0.834 0 CA-C-N 118.253 1.026 . . . . 0.0 108.251 -175.55 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.5 p . . . . . 0 CA--C 1.504 -0.816 0 CA-C-O 122.518 1.151 . . . . 0.0 108.44 -179.434 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.1 m . . . . . 0 CA--C 1.489 -1.372 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.4 m -66.77 -36.11 81.65 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 121.182 0.515 . . . . 0.0 110.749 -175.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 p -90.38 10.21 25.93 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.53 0.732 . . . . 0.0 111.518 178.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.21 -47.92 1.07 Allowed Glycine 0 C--N 1.35 1.327 0 O-C-N 121.24 -0.912 . . . . 0.0 112.954 163.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.82 143.16 33.51 Favored 'General case' 0 CA--C 1.489 -1.371 0 CA-C-N 119.042 1.421 . . . . 0.0 107.524 -167.844 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 11.9 t -123.86 136.48 54.39 Favored 'General case' 0 CA--C 1.484 -1.584 1 N-CA-C 98.463 -4.643 . . . . 0.0 98.463 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.6 43.57 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 103.111 -2.922 . . . . 0.0 103.111 176.041 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.49 -56.05 1.43 Allowed Glycine 0 C--N 1.354 1.529 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 m -99.51 160.44 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 164.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 89.9 m -80.12 148.06 31.13 Favored 'General case' 0 CA--C 1.488 -1.411 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 172.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.62 -146.62 0.2 Allowed 'General case' 0 N--CA 1.431 -1.388 0 N-CA-C 102.62 -3.104 . . . . 0.0 102.62 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.427 -1.594 1 N-CA-C 96.372 -5.418 . . . . 0.0 96.372 175.06 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.422 -1.85 1 N-CA-C 95.539 -5.726 . . . . 0.0 95.539 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.5 mt -100.21 143.96 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 104.622 -2.362 . . . . 0.0 104.622 176.122 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt . . . . . 0 N--CA 1.439 -0.989 0 C-N-CA 126.678 1.991 . . . . 0.0 108.22 -164.783 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 31.6 m-85 . . . . . 0 CA--C 1.504 -0.789 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.37 165.25 28.7 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 169.748 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -88.33 138.67 31.23 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.1 p . . . . . 0 CA--C 1.49 -1.358 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -170.92 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 N--CA 1.432 -1.353 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -74.03 -15.19 61.09 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 122.316 -0.24 . . . . 0.0 110.911 178.098 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.4 p -86.35 -25.33 25.43 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 176.319 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.06 -75.01 0.36 Allowed Glycine 0 CA--C 1.485 -1.81 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -176.486 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.13 34.79 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 122.189 -0.595 . . . . 0.0 110.202 -168.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.1 t -119.02 130.41 55.64 Favored 'General case' 0 CA--C 1.481 -1.69 1 N-CA-C 96.186 -5.487 . . . . 0.0 96.186 173.754 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.5 p -146.88 44.78 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.96 -60.63 1.99 Allowed Glycine 0 C--N 1.353 1.488 0 N-CA-C 106.639 -2.584 . . . . 0.0 106.639 -176.004 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.57 164.17 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.135 0 N-CA-C 104.511 -2.403 . . . . 0.0 104.511 164.463 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 83.3 m -80.85 134.54 35.78 Favored 'General case' 0 CA--C 1.488 -1.435 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.37 -163.42 1.6 Allowed 'General case' 0 CA--C 1.485 -1.54 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 -174.972 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.423 -1.81 1 N-CA-C 95.284 -5.821 . . . . 0.0 95.284 173.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.6 p . . . . . 0 N--CA 1.424 -1.728 1 N-CA-C 99.091 -4.411 . . . . 0.0 99.091 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.1 mt -97.56 148.59 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 103.212 -2.884 . . . . 0.0 103.212 171.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp . . . . . 0 N--CA 1.44 -0.943 0 C-N-CA 125.508 1.523 . . . . 0.0 109.092 -162.644 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 . . . . . 0 CA--C 1.5 -0.962 0 CA-C-O 121.679 0.752 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.61 170.51 18.31 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 103.556 -3.818 . . . . 0.0 103.556 161.345 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -82.26 156.21 24.46 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -176.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p . . . . . 0 CA--C 1.489 -1.393 1 N-CA-C 98.723 -4.547 . . . . 0.0 98.723 170.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.0 m . . . . . 0 CA--C 1.49 -1.365 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -67.92 -28.38 67.44 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 119.687 1.13 . . . . 0.0 110.229 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.9 p -90.28 10.42 24.85 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 125.336 1.454 . . . . 0.0 110.407 174.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.25 -69.28 1.83 Allowed Glycine 0 CA--C 1.491 -1.408 0 O-C-N 120.941 -1.1 . . . . 0.0 111.152 168.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.77 141.9 35.86 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 -162.054 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.1 t -137.07 145.78 44.37 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 97.811 -4.885 . . . . 0.0 97.811 -175.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.5 p -160.69 -140.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.427 -1.609 1 N-CA-C 92.667 -6.79 . . . . 0.0 92.667 175.836 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.7 -4.44 61.64 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 122.92 2.6 . . . . 0.0 113.019 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 m -143.72 163.53 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 100.436 -3.913 . . . . 0.0 100.436 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.69 133.46 33.68 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 105.965 -1.865 . . . . 0.0 105.965 168.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.22 -154.93 0.54 Allowed 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 -179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.427 -1.621 1 N-CA-C 96.281 -5.451 . . . . 0.0 96.281 174.332 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.423 -1.82 1 N-CA-C 96.661 -5.311 . . . . 0.0 96.661 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.19 150.64 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.582 0 N-CA-C 104.081 -2.562 . . . . 0.0 104.081 169.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.1 tptt . . . . . 0 N--CA 1.436 -1.157 0 C-N-CA 127.6 2.36 . . . . 0.0 108.504 -166.551 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 . . . . . 0 CA--C 1.506 -0.737 0 CA-C-O 121.13 0.49 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.27 168.81 12.68 Favored Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 103.368 -3.893 . . . . 0.0 103.368 165.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -87.53 147.96 25.11 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 CA--C 1.497 -1.082 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 -178.572 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.5 m . . . . . 0 CA--C 1.493 -1.234 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.03 -28.31 65.37 Favored 'General case' 0 C--N 1.353 0.737 0 CA-C-N 118.779 0.718 . . . . 0.0 111.144 -177.185 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.0 p -90.01 3.89 51.82 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 124.618 1.167 . . . . 0.0 109.301 176.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.94 -75.23 0.24 Allowed Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 169.584 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.66 144.67 29.25 Favored 'General case' 0 CA--C 1.496 -1.104 0 CA-C-O 120.859 0.362 . . . . 0.0 111.254 -160.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.9 t -123.07 130.39 52.72 Favored 'General case' 0 N--CA 1.428 -1.53 1 N-CA-C 99.449 -4.278 . . . . 0.0 99.449 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.5 p -150.61 56.54 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.08 0 N-CA-C 102.548 -3.13 . . . . 0.0 102.548 170.985 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.84 -67.03 1.87 Allowed Glycine 0 CA--C 1.491 -1.41 0 N-CA-C 106.133 -2.787 . . . . 0.0 106.133 -177.668 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.5 m -87.5 157.5 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.099 0 N-CA-C 105.313 -2.106 . . . . 0.0 105.313 167.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 m -84.02 127.15 33.68 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 167.335 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.79 -141.63 0.13 Allowed 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 102.676 -3.083 . . . . 0.0 102.676 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.425 -1.701 1 N-CA-C 96.589 -5.337 . . . . 0.0 96.589 171.252 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p . . . . . 0 N--CA 1.427 -1.598 1 N-CA-C 97.476 -5.009 . . . . 0.0 97.476 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.3 mt -109.02 154.65 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 -175.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 128.229 2.611 . . . . 0.0 107.44 -157.197 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 . . . . . 0 N--CA 1.446 -0.663 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.36 165.09 28.61 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.65 -2.58 . . . . 0.0 106.65 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -76.44 144.35 39.98 Favored 'General case' 0 CA--C 1.497 -1.06 0 CA-C-N 118.135 0.967 . . . . 0.0 108.813 -175.606 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.6 p . . . . . 0 CA--C 1.482 -1.65 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 177.82 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.5 m . . . . . 0 CA--C 1.484 -1.561 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.7 m -69.98 -27.26 64.57 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.757 0.313 . . . . 0.0 110.505 -176.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.52 4.66 50.52 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 123.997 0.919 . . . . 0.0 111.221 173.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.85 -74.89 0.27 Allowed Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 172.113 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.58 153.07 25.67 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 118.146 0.973 . . . . 0.0 110.191 -163.525 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.7 t -142.42 152.02 42.38 Favored 'General case' 0 N--CA 1.429 -1.496 1 N-CA-C 98.166 -4.753 . . . . 0.0 98.166 -171.759 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.8 p -160.31 -142.92 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.146 1 N-CA-C 92.693 -6.78 . . . . 0.0 92.693 176.421 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.57 -15.11 65.81 Favored Glycine 0 C--N 1.35 1.308 0 CA-C-N 124.126 3.148 . . . . 0.0 113.008 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 m -138.14 163.75 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.691 0 N-CA-C 100.927 -3.731 . . . . 0.0 100.927 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.7 m -79.96 136.44 36.62 Favored 'General case' 0 CA--C 1.484 -1.589 0 C-N-CA 124.871 1.268 . . . . 0.0 108.172 176.321 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.23 -155.17 0.58 Allowed 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 -174.36 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 . . . . . 0 N--CA 1.423 -1.815 1 N-CA-C 95.416 -5.772 . . . . 0.0 95.416 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.3 p . . . . . 0 N--CA 1.433 -1.305 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -100.29 141.2 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 N-CA-C 104.447 -2.427 . . . . 0.0 104.447 -174.076 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp . . . . . 0 N--CA 1.446 -0.653 0 C-N-CA 126.271 1.828 . . . . 0.0 110.589 -166.868 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 . . . . . 0 CA--C 1.5 -0.974 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.59 165.9 18.1 Favored Glycine 0 CA--C 1.487 -1.67 1 N-CA-C 102.481 -4.248 . . . . 0.0 102.481 161.026 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -71.87 152.13 42.84 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -177.744 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.9 p . . . . . 0 N--CA 1.432 -1.372 1 N-CA-C 98.664 -4.569 . . . . 0.0 98.664 169.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 57.1 m . . . . . 0 CA--C 1.483 -1.609 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 m -72.81 -16.89 61.61 Favored 'General case' 0 C--N 1.352 0.693 0 CA-C-O 120.675 0.274 . . . . 0.0 110.63 -172.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -88.43 -17.24 30.87 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 125.688 1.595 . . . . 0.0 110.158 176.324 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.1 -78.58 0.29 Allowed Glycine 0 N--CA 1.436 -1.309 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 -175.27 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.87 150.41 29.1 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.83 -0.806 . . . . 0.0 111.418 -166.093 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.6 t -131.11 137.14 48.94 Favored 'General case' 0 N--CA 1.425 -1.719 1 N-CA-C 97.868 -4.864 . . . . 0.0 97.868 -177.812 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.19 -129.87 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.189 1 N-CA-C 98.027 -4.805 . . . . 0.0 98.027 164.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.16 -5.01 87.1 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 117.705 -3.122 . . . . 0.0 110.713 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.1 m -145.78 164.42 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.728 1 N-CA-C 99.14 -4.393 . . . . 0.0 99.14 -177.088 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.9 m -79.07 137.64 37.61 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 169.788 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.11 -151.23 0.37 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 -174.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.647 1 N-CA-C 98.007 -4.812 . . . . 0.0 98.007 175.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 102.207 -3.257 . . . . 0.0 102.207 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 1.4 p30 178.85 -170.98 0.12 Allowed 'General case' 0 N--CA 1.429 -1.476 1 N-CA-C 96.198 -5.482 . . . . 0.0 96.198 -169.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.2 p -148.97 173.5 13.28 Favored 'General case' 0 N--CA 1.428 -1.549 1 N-CA-C 97.849 -4.871 . . . . 0.0 97.849 168.306 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.5 mt -92.09 148.22 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 104.862 -2.274 . . . . 0.0 104.862 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.6 tttt -74.63 141.59 44.63 Favored 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 127.127 2.171 . . . . 0.0 107.747 -168.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 72.07 20.45 4.3 Favored 'General case' 0 C--N 1.354 0.798 0 C-N-CA 126.394 1.878 . . . . 0.0 111.869 -173.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.26 173.98 25.74 Favored Glycine 0 C--N 1.354 1.568 0 N-CA-C 105.802 -2.919 . . . . 0.0 105.802 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -85.08 131.78 34.41 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-N 118.372 1.086 . . . . 0.0 108.907 -174.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p -125.6 9.37 7.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 C-N-CA 123.783 0.833 . . . . 0.0 108.925 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 12.8 p -77.35 68.49 3.47 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 69.3 mt -98.2 122.05 55.29 Favored Pre-proline 0 N--CA 1.433 -1.323 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 -178.167 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.63 68.78 8.19 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.845 2.364 . . . . 0.0 108.43 174.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.2 141.93 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.764 1 N-CA-C 94.287 -6.19 . . . . 0.0 94.287 176.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.5 mt -92.27 136.3 33.3 Favored 'General case' 0 CA--C 1.489 -1.388 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 -174.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.3 mtmm 66.09 59.15 0.7 Allowed 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 125.799 1.64 . . . . 0.0 108.335 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -159.32 -172.86 3.91 Favored 'General case' 0 N--CA 1.42 -1.945 1 N-CA-C 97.203 -5.11 . . . . 0.0 97.203 -178.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.75 37.2 8.74 Favored Glycine 0 C--N 1.346 1.118 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -170.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 54.1 mt -89.2 91.16 8.67 Favored 'General case' 0 CA--C 1.502 -0.871 0 C-N-CA 123.786 0.834 . . . . 0.0 110.272 -166.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.0 m -83.75 144.09 29.56 Favored 'General case' 0 CA--C 1.498 -1.036 0 C-N-CA 123.671 0.788 . . . . 0.0 109.922 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.95 -33.23 75.13 Favored 'General case' 0 C--N 1.354 0.772 0 CA-C-O 121.134 0.493 . . . . 0.0 110.491 176.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -90.18 9.69 27.47 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 121.696 -0.628 . . . . 0.0 110.124 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.83 -69.34 1.18 Allowed Glycine 0 CA--C 1.492 -1.348 0 O-C-N 121.142 -0.974 . . . . 0.0 112.995 165.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.87 153.56 20.55 Favored 'General case' 0 CA--C 1.494 -1.187 0 CA-C-N 118.202 1.001 . . . . 0.0 108.768 -160.206 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 50.6 t -130.83 133.91 46.36 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 102.428 -3.175 . . . . 0.0 102.428 -176.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.5 p -137.26 37.27 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 102.671 -3.085 . . . . 0.0 102.671 175.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.04 -55.36 0.97 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 106.072 -2.811 . . . . 0.0 106.072 -176.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 m -94.85 156.53 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 165.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 57.0 m -73.62 129.7 38.5 Favored 'General case' 0 CA--C 1.486 -1.495 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.48 -156.8 0.7 Allowed 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -153.69 169.63 22.85 Favored 'General case' 0 N--CA 1.418 -2.031 1 N-CA-C 98.569 -4.604 . . . . 0.0 98.569 -170.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.8 tp -161.03 166.28 28.46 Favored 'General case' 0 N--CA 1.419 -1.981 1 N-CA-C 94.272 -6.196 . . . . 0.0 94.272 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.851 0 O-C-N 123.842 0.714 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 . . . . . 0 N--CA 1.493 1.69 0 N-CA-C 100.54 -3.874 . . . . 0.0 100.54 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -66.63 -26.77 67.24 Favored 'General case' 0 C--N 1.352 0.717 0 C-N-CA 124.163 0.985 . . . . 0.0 110.225 175.354 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.9 p -140.83 170.43 15.77 Favored 'General case' 0 N--CA 1.43 -1.474 1 N-CA-C 98.933 -4.469 . . . . 0.0 98.933 163.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.6 mt -93.58 136.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 176.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.5 ttpp -69.7 146.22 51.72 Favored 'General case' 0 N--CA 1.435 -1.186 0 C-N-CA 127.847 2.459 . . . . 0.0 108.584 -166.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 69.24 29.54 4.56 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 125.951 1.7 . . . . 0.0 111.26 -177.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.86 160.22 13.44 Favored Glycine 0 CA--C 1.491 -1.448 1 N-CA-C 102.548 -4.221 . . . . 0.0 102.548 167.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -74.34 149.91 40.38 Favored 'General case' 0 CA--C 1.503 -0.833 0 CA-C-N 118.094 0.947 . . . . 0.0 111.636 -165.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 30.1 p -160.06 -173.47 4.08 Favored 'General case' 0 N--CA 1.436 -1.131 1 N-CA-C 98.884 -4.488 . . . . 0.0 98.884 170.468 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.3 p -121.32 -80.11 0.62 Allowed 'General case' 0 CA--C 1.507 -0.709 0 CA-C-N 119.652 1.114 . . . . 0.0 109.179 -174.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 66.7 mt -150.19 163.14 25.51 Favored Pre-proline 0 N--CA 1.431 -1.423 1 N-CA-C 98.093 -4.78 . . . . 0.0 98.093 172.117 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -64.43 112.26 1.88 Allowed 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.715 2.277 . . . . 0.0 112.207 176.923 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 20.3 tt -161.66 161.54 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.424 -1.742 1 N-CA-C 96.836 -5.246 . . . . 0.0 96.836 176.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.9 mt 52.63 -121.37 1.85 Allowed 'General case' 0 C--N 1.354 0.798 0 C-N-CA 125.838 1.655 . . . . 0.0 108.842 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 46.6 mmtm -137.19 45.63 2.21 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . 0.259 0.1 OUTLIER -90.73 -35.69 14.74 Favored 'General case' 0 C--N 1.362 1.142 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 175.304 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -81.94 60.64 4.76 Favored Glycine 0 C--N 1.354 1.581 0 O-C-N 120.901 -1.124 . . . . 0.0 110.597 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 89.7 mt -118.66 72.65 0.89 Allowed 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 101.175 -3.639 . . . . 0.0 101.175 168.189 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 138.22 31.7 Favored 'General case' 0 CA--C 1.485 -1.544 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.3 m -63.19 -37.56 87.71 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 121.327 0.584 . . . . 0.0 111.052 -171.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.8 p -90.52 7.07 40.86 Favored 'General case' 0 N--CA 1.443 -0.821 0 C-N-CA 124.695 1.198 . . . . 0.0 111.741 178.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.21 -69.91 0.27 Allowed Glycine 0 C--N 1.35 1.334 0 O-C-N 121.171 -0.956 . . . . 0.0 111.505 170.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.3 145.16 31.03 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-N 118.227 1.013 . . . . 0.0 110.986 -167.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.3 t -128.31 129.66 46.64 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 101.339 -3.578 . . . . 0.0 101.339 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.409 HG22 ' H ' ' A' ' 27' ' ' GLY . 5.8 p -133.24 -138.6 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -0.982 1 N-CA-C 97.837 -4.875 . . . . 0.0 97.837 165.235 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -70.99 -4.68 56.17 Favored Glycine 0 C--N 1.348 1.236 0 O-C-N 118.657 -2.527 . . . . 0.0 112.322 -179.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.45 164.09 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.954 1 N-CA-C 98.794 -4.521 . . . . 0.0 98.794 174.855 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 73.3 m -77.57 141.03 39.77 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 167.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.5 -146.1 0.19 Allowed 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 104.165 -2.531 . . . . 0.0 104.165 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -142.02 164.47 30.08 Favored 'General case' 0 N--CA 1.425 -1.706 1 N-CA-C 96.989 -5.189 . . . . 0.0 96.989 173.033 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.1 mt -150.07 166.13 30.67 Favored 'General case' 0 N--CA 1.425 -1.689 1 N-CA-C 94.611 -6.07 . . . . 0.0 94.611 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.912 0 O-C-N 124.36 1.037 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 . . . . . 0 CA--C 1.487 -1.472 1 N-CA-C 100.146 -4.02 . . . . 0.0 100.146 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -88.65 -147.78 0.16 Allowed 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 170.251 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.0 p -111.71 172.55 6.83 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 -179.448 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -92.97 140.63 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 101.543 -3.502 . . . . 0.0 101.543 172.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -75.39 139.17 42.19 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 117.382 -1.294 . . . . 0.0 108.276 -162.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 75.56 11.72 3.23 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 126.204 1.801 . . . . 0.0 111.637 -171.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.91 168.39 26.1 Favored Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 105.889 -2.884 . . . . 0.0 105.889 172.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -85.46 146.4 26.97 Favored 'General case' 0 CA--C 1.504 -0.805 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -177.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.7 p -145.41 -179.22 6.51 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 103.432 -2.803 . . . . 0.0 103.432 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 154.89 -89.06 0.0 OUTLIER 'General case' 0 CA--C 1.495 -1.151 1 N-CA-C 97.91 -4.848 . . . . 0.0 97.91 177.451 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mp -88.91 152.24 48.29 Favored Pre-proline 0 CA--C 1.498 -1.039 0 N-CA-C 102.511 -3.144 . . . . 0.0 102.511 161.498 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -73.36 148.24 43.01 Favored 'Trans proline' 0 CA--C 1.5 -1.203 0 CA-C-N 121.556 1.591 . . . . 0.0 109.191 -173.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 45.8 mm -62.6 -41.77 93.4 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 C-N-CA 123.953 0.901 . . . . 0.0 108.703 -175.847 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.6 mt -109.63 59.54 0.6 Allowed 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.1 mttp 73.68 -58.24 0.6 Allowed 'General case' 0 C--N 1.357 0.899 0 C-N-CA 126.103 1.761 . . . . 0.0 114.602 160.396 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -137.77 120.19 15.94 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 -175.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.89 179.79 46.82 Favored Glycine 0 CA--C 1.479 -2.193 1 N-CA-C 99.098 -5.601 . . . . 0.0 99.098 178.416 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.1 tp -150.58 165.27 33.82 Favored 'General case' 0 N--CA 1.427 -1.616 1 N-CA-C 95.687 -5.672 . . . . 0.0 95.687 175.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.3 m -72.67 142.48 48.26 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -62.13 -42.65 99.45 Favored 'General case' 0 C--N 1.358 0.938 0 CA-C-N 118.805 0.73 . . . . 0.0 110.024 -177.753 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.4 p -87.53 17.63 4.45 Favored 'General case' 0 N--CA 1.441 -0.916 0 C-N-CA 123.716 0.806 . . . . 0.0 111.314 177.388 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.99 -71.49 0.89 Allowed Glycine 0 CA--C 1.49 -1.494 0 O-C-N 120.552 -1.342 . . . . 0.0 111.595 164.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.18 144.73 25.6 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 121.755 -0.85 . . . . 0.0 111.09 -163.36 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.9 t -111.38 133.43 53.7 Favored 'General case' 0 N--CA 1.432 -1.348 0 N-CA-C 101.212 -3.625 . . . . 0.0 101.212 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.77 41.47 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.173 0 N-CA-C 102.86 -3.015 . . . . 0.0 102.86 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.31 -61.19 1.06 Allowed Glycine 0 C--N 1.352 1.431 0 N-CA-C 105.434 -3.066 . . . . 0.0 105.434 -174.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.1 m -95.07 160.6 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 166.018 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 67.1 m -78.86 135.4 37.02 Favored 'General case' 0 CA--C 1.495 -1.17 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 172.64 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.89 -140.7 0.11 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 103.436 -2.802 . . . . 0.0 103.436 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -145.49 170.51 16.25 Favored 'General case' 0 N--CA 1.423 -1.821 1 N-CA-C 96.893 -5.225 . . . . 0.0 96.893 174.594 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.3 mt -138.86 156.19 47.5 Favored 'General case' 0 N--CA 1.423 -1.803 1 N-CA-C 93.963 -6.31 . . . . 0.0 93.963 171.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.886 0 O-C-N 124.355 1.035 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 36.1 t70 . . . . . 0 N--CA 1.487 1.41 1 N-CA-C 98.956 -4.461 . . . . 0.0 98.956 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -71.82 -45.45 61.44 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 168.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 7.5 p -118.75 -169.75 1.78 Allowed 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 103.396 -2.816 . . . . 0.0 103.396 171.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ILE . . . . . 0.426 ' HB ' ' SG ' ' A' ' 20' ' ' CYS . 57.0 mt -89.45 150.69 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 102.835 -3.024 . . . . 0.0 102.835 165.095 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.1 tttm -76.05 139.29 41.34 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 -164.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.257 86.9 m-85 71.61 24.99 3.4 Favored 'General case' 0 CA--C 1.503 -0.84 0 C-N-CA 126.248 1.819 . . . . 0.0 110.499 -173.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.9 163.0 19.32 Favored Glycine 0 CA--C 1.491 -1.449 0 N-CA-C 105.335 -3.106 . . . . 0.0 105.335 166.145 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -79.92 145.58 32.58 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.3 p -142.1 177.68 8.06 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 -170.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 p 172.29 -158.76 0.01 OUTLIER 'General case' 0 N--CA 1.423 -1.784 1 N-CA-C 94.817 -5.994 . . . . 0.0 94.817 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -113.86 96.18 40.33 Favored Pre-proline 0 N--CA 1.441 -0.889 0 N-CA-C 101.25 -3.611 . . . . 0.0 101.25 167.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.29 147.96 29.88 Favored 'Trans proline' 0 CA--C 1.501 -1.132 0 C-N-CA 122.399 2.066 . . . . 0.0 107.63 175.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 25.6 pt -92.02 -38.32 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.839 0 CA-C-N 118.231 0.469 . . . . 0.0 110.903 -171.155 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 72.7 mt -71.47 -37.66 71.33 Favored 'General case' 0 CA--C 1.492 -1.253 0 C-N-CA 124.279 1.031 . . . . 0.0 111.493 -160.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -133.81 143.46 48.38 Favored 'General case' 0 N--CA 1.421 -1.915 1 N-CA-C 94.119 -6.252 . . . . 0.0 94.119 164.536 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -149.52 161.27 42.46 Favored 'General case' 0 N--CA 1.423 -1.798 1 N-CA-C 98.639 -4.578 . . . . 0.0 98.639 -168.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.15 -165.08 30.68 Favored Glycine 0 N--CA 1.425 -2.096 1 N-CA-C 95.279 -7.128 . . . . 0.0 95.279 -168.642 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -129.3 -165.14 1.48 Allowed 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 102.192 -3.262 . . . . 0.0 102.192 173.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 4' ' ' ILE . 84.8 m -87.52 157.94 19.05 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 -177.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.0 m -64.6 -36.78 85.34 Favored 'General case' 0 C--N 1.351 0.645 0 CA-C-O 121.242 0.544 . . . . 0.0 110.183 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.6 p -87.69 1.15 54.54 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.17 0.988 . . . . 0.0 110.316 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.9 -79.67 1.5 Allowed Glycine 0 N--CA 1.437 -1.249 0 O-C-N 121.421 -0.799 . . . . 0.0 111.939 173.322 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.57 123.31 28.54 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 113.421 0.897 . . . . 0.0 113.421 -149.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -96.64 127.09 42.3 Favored 'General case' 0 CA--C 1.5 -0.954 0 C-N-CA 125.435 1.494 . . . . 0.0 107.309 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.79 42.22 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.061 -2.941 . . . . 0.0 103.061 175.515 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.88 -56.12 1.14 Allowed Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 106.118 -2.793 . . . . 0.0 106.118 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.7 m -103.91 156.78 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 103.019 -2.956 . . . . 0.0 103.019 163.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -89.58 143.89 26.45 Favored 'General case' 0 CA--C 1.482 -1.67 0 CA-C-O 121.172 0.511 . . . . 0.0 109.905 179.323 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.26 -146.75 0.19 Allowed 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 102.421 -3.177 . . . . 0.0 102.421 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -130.41 160.28 34.49 Favored 'General case' 0 N--CA 1.431 -1.406 1 N-CA-C 95.876 -5.601 . . . . 0.0 95.876 166.329 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 31.2 tp -160.69 162.73 32.67 Favored 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 95.765 -5.643 . . . . 0.0 95.765 -174.145 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.879 0 O-C-N 124.595 1.185 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.497 1.881 0 N-CA-C 103.438 -2.801 . . . . 0.0 103.438 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -159.01 171.58 19.76 Favored 'General case' 0 N--CA 1.429 -1.479 1 N-CA-C 95.546 -5.724 . . . . 0.0 95.546 176.281 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.3 p -159.44 169.81 23.12 Favored 'General case' 0 N--CA 1.428 -1.559 1 N-CA-C 99.276 -4.342 . . . . 0.0 99.276 -175.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.1 mt -88.66 145.98 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 -172.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -74.84 138.72 42.72 Favored 'General case' 0 N--CA 1.437 -1.08 0 C-N-CA 126.766 2.026 . . . . 0.0 109.762 -162.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.269 96.3 m-85 70.56 19.61 6.12 Favored 'General case' 0 C--N 1.355 0.827 0 C-N-CA 126.678 1.991 . . . . 0.0 111.847 -176.708 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.81 171.05 27.01 Favored Glycine 0 C--N 1.352 1.446 0 N-CA-C 104.473 -3.451 . . . . 0.0 104.473 163.097 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -90.13 159.36 16.82 Favored 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 175.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.2 p -140.5 152.47 45.62 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 -174.228 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.3 p -155.18 168.78 25.92 Favored 'General case' 0 N--CA 1.421 -1.912 1 N-CA-C 96.749 -5.278 . . . . 0.0 96.749 164.462 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.45 HD23 ' HA ' ' A' ' 12' ' ' LEU . 11.2 mt -157.64 172.31 6.31 Favored Pre-proline 0 N--CA 1.425 -1.681 1 N-CA-C 95.834 -5.617 . . . . 0.0 95.834 166.516 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -61.26 132.93 43.74 Favored 'Trans proline' 0 CA--C 1.504 -1.012 0 C-N-CA 123.062 2.508 . . . . 0.0 107.201 164.311 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 40.3 pt -72.52 29.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.351 0.659 0 N-CA-C 115.637 1.718 . . . . 0.0 115.637 -149.445 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.5 mt -89.44 -19.05 25.61 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.654 1.582 . . . . 0.0 107.083 173.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -140.39 156.04 46.54 Favored 'General case' 0 N--CA 1.424 -1.774 1 N-CA-C 96.477 -5.379 . . . . 0.0 96.477 164.566 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 18.8 m-20 -93.33 -22.29 19.05 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 -178.124 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.68 166.68 35.2 Favored Glycine 0 N--CA 1.416 -2.698 1 N-CA-C 98.923 -5.671 . . . . 0.0 98.923 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 tp -118.13 90.85 3.42 Favored 'General case' 0 CA--C 1.488 -1.409 1 N-CA-C 99.534 -4.247 . . . . 0.0 99.534 165.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 93.1 m -90.17 145.39 25.06 Favored 'General case' 0 CA--C 1.485 -1.542 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 59.2 m -66.87 -36.35 82.11 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.905 0.383 . . . . 0.0 110.929 -173.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.6 p -90.15 9.65 27.53 Favored 'General case' 0 N--CA 1.438 -1.058 0 C-N-CA 123.925 0.89 . . . . 0.0 111.158 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.48 -74.84 0.21 Allowed Glycine 0 C--N 1.353 1.478 0 O-C-N 121.294 -0.879 . . . . 0.0 111.439 168.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.02 141.1 30.54 Favored 'General case' 0 CA--C 1.494 -1.205 0 O-C-N 121.753 -0.851 . . . . 0.0 109.555 -162.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 25.8 t -119.81 126.62 51.43 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 98.492 -4.633 . . . . 0.0 98.492 171.653 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.3 p -146.47 48.29 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 101.924 -3.361 . . . . 0.0 101.924 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.69 -62.67 2.65 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.151 -2.779 . . . . 0.0 106.151 -174.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.9 m -89.25 158.36 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 167.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.0 m -82.1 128.96 34.65 Favored 'General case' 0 CA--C 1.49 -1.347 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 168.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.78 -142.77 0.2 Allowed 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 -178.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.62 168.43 24.98 Favored 'General case' 0 N--CA 1.422 -1.843 1 N-CA-C 97.734 -4.913 . . . . 0.0 97.734 -176.993 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -89.49 69.36 7.94 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 -174.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 . . . . . 0 N--CA 1.484 1.266 0 N-CA-C 101.961 -3.348 . . . . 0.0 101.961 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -109.27 -113.38 0.3 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 103.444 -2.799 . . . . 0.0 103.444 179.275 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.6 p -122.03 -179.69 4.23 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 102.888 -3.004 . . . . 0.0 102.888 171.745 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 38.0 mt -111.75 149.63 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 101.791 -3.411 . . . . 0.0 101.791 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -76.43 137.42 39.71 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 125.002 1.321 . . . . 0.0 108.184 -164.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.258 75.0 m-85 74.77 15.72 3.15 Favored 'General case' 0 C--N 1.355 0.839 0 C-N-CA 127.421 2.288 . . . . 0.0 111.605 -174.051 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.97 169.41 29.56 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 105.544 -3.023 . . . . 0.0 105.544 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -85.23 154.17 22.13 Favored 'General case' 0 CA--C 1.5 -0.962 0 N-CA-C 106.804 -1.554 . . . . 0.0 106.804 178.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 p -148.17 -173.5 4.33 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.4 p -149.83 179.54 7.94 Favored 'General case' 0 N--CA 1.423 -1.792 1 N-CA-C 96.562 -5.347 . . . . 0.0 96.562 176.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -113.84 100.98 53.39 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 100.821 -3.77 . . . . 0.0 100.821 175.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -70.83 144.87 49.45 Favored 'Trans proline' 0 N--CA 1.453 -0.91 0 CA-C-N 122.029 1.76 . . . . 0.0 107.998 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.3 tt -77.95 -49.23 22.05 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.948 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 -169.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 73.9 mt -89.64 102.21 14.9 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 100.888 -3.745 . . . . 0.0 100.888 163.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.5 mtpt -59.75 106.36 0.47 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 124.459 1.104 . . . . 0.0 111.258 -171.286 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -96.0 -11.2 26.86 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -175.889 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -164.32 173.17 40.27 Favored Glycine 0 N--CA 1.424 -2.138 1 N-CA-C 98.494 -5.842 . . . . 0.0 98.494 177.112 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -157.35 175.35 14.11 Favored 'General case' 0 N--CA 1.428 -1.558 1 N-CA-C 95.061 -5.903 . . . . 0.0 95.061 177.032 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.0 m -88.26 153.68 21.02 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.5 -31.42 69.66 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.093 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.3 p -87.26 9.5 20.07 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.749 1.22 . . . . 0.0 111.086 173.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.68 -78.96 0.49 Allowed Glycine 0 C--N 1.351 1.37 0 O-C-N 120.866 -1.147 . . . . 0.0 110.495 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.44 146.7 32.63 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 117.431 0.615 . . . . 0.0 111.368 -161.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.6 t -125.78 131.51 52.47 Favored 'General case' 0 N--CA 1.429 -1.499 1 N-CA-C 97.741 -4.911 . . . . 0.0 97.741 173.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -149.16 51.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.137 0 N-CA-C 101.407 -3.553 . . . . 0.0 101.407 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.01 -60.73 1.64 Allowed Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.235 -2.746 . . . . 0.0 106.235 -176.777 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.4 m -100.28 161.34 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.007 -2.219 . . . . 0.0 105.007 167.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 54.1 m -80.65 136.74 36.26 Favored 'General case' 0 CA--C 1.49 -1.357 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 174.112 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.01 -165.29 2.13 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -176.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -101.8 -172.85 2.22 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 103.643 -2.725 . . . . 0.0 103.643 170.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.416 HD12 ' HA ' ' A' ' 32' ' ' LEU . 9.2 tp -153.79 164.04 39.01 Favored 'General case' 0 N--CA 1.422 -1.839 1 N-CA-C 96.139 -5.504 . . . . 0.0 96.139 175.897 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.91 0 O-C-N 124.073 0.858 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 . . . . . 0 N--CA 1.493 1.682 1 N-CA-C 98.807 -4.516 . . . . 0.0 98.807 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -93.34 -162.96 0.99 Allowed 'General case' 0 N--CA 1.44 -0.966 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 154.84 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.5 p -153.91 -179.21 7.64 Favored 'General case' 0 N--CA 1.426 -1.638 1 N-CA-C 97.086 -5.153 . . . . 0.0 97.086 170.367 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.1 mt -107.59 148.43 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.322 0 N-CA-C 102.083 -3.303 . . . . 0.0 102.083 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -86.0 142.06 29.04 Favored 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 126.061 1.745 . . . . 0.0 108.343 -162.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 70.92 14.38 6.91 Favored 'General case' 0 C--N 1.358 0.958 0 C-N-CA 126.382 1.873 . . . . 0.0 112.079 -174.586 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.4 167.01 22.16 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 169.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.19 142.44 32.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -175.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.76 173.29 6.83 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p 168.79 -145.98 0.0 OUTLIER 'General case' 0 N--CA 1.431 -1.39 1 N-CA-C 93.375 -6.528 . . . . 0.0 93.375 -173.313 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.6 mt -121.04 100.94 45.38 Favored Pre-proline 0 C--N 1.353 0.741 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 165.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -140.76 28.96 0.0 OUTLIER 'Trans proline' 0 CA--C 1.507 -0.87 0 CA-C-N 123.23 2.189 . . . . 0.0 108.099 -167.095 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 pt -126.03 -55.73 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.242 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -124.19 -162.59 1.08 Allowed 'General case' 0 N--CA 1.432 -1.345 1 N-CA-C 98.54 -4.615 . . . . 0.0 98.54 161.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.46 34.62 1.43 Allowed 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 173.702 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -151.47 165.77 33.16 Favored 'General case' 0 N--CA 1.424 -1.756 1 N-CA-C 95.887 -5.597 . . . . 0.0 95.887 160.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.7 163.57 34.8 Favored Glycine 0 N--CA 1.421 -2.345 1 N-CA-C 97.283 -6.327 . . . . 0.0 97.283 179.257 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 93.6 mt -150.47 160.45 43.76 Favored 'General case' 0 CA--C 1.484 -1.595 1 N-CA-C 97.513 -4.995 . . . . 0.0 97.513 177.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 91.5 m -90.63 150.21 21.79 Favored 'General case' 0 CA--C 1.492 -1.269 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 174.585 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.25 -29.5 69.15 Favored 'General case' 0 C--N 1.352 0.71 0 CA-C-N 118.713 0.688 . . . . 0.0 111.414 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -90.03 -3.05 58.19 Favored 'General case' 0 N--CA 1.438 -1.071 0 O-C-N 121.292 -0.88 . . . . 0.0 109.841 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 115.48 -79.28 0.28 Allowed Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 109.829 -1.309 . . . . 0.0 109.829 170.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.19 151.4 24.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 O-C-N 122.596 -0.356 . . . . 0.0 110.585 -163.172 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -123.82 131.2 53.54 Favored 'General case' 0 CA--C 1.489 -1.39 1 N-CA-C 98.553 -4.61 . . . . 0.0 98.553 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.67 39.03 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 103.33 -2.841 . . . . 0.0 103.33 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.61 -55.68 1.03 Allowed Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.251 -2.74 . . . . 0.0 106.251 -176.636 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.5 m -98.21 164.3 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 163.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 63.7 m -81.69 139.55 34.85 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 171.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.35 -152.93 0.46 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 -177.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -175.1 -171.87 0.55 Allowed 'General case' 0 N--CA 1.424 -1.742 1 N-CA-C 97.337 -5.06 . . . . 0.0 97.337 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -86.28 68.97 10.41 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.362 1.112 0 CA-C-N 116.348 -0.387 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 102.68 -3.081 . . . . 0.0 102.68 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 45.7 m-20 -103.94 -114.77 0.22 Allowed 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 103.177 -2.897 . . . . 0.0 103.177 170.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p -132.17 168.23 18.38 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 167.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.1 mt -97.97 149.49 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 175.693 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.06 144.55 34.5 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 125.132 1.373 . . . . 0.0 108.496 -163.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.263 97.2 m-85 67.78 24.36 8.27 Favored 'General case' 0 CA--C 1.503 -0.857 0 C-N-CA 127.035 2.134 . . . . 0.0 112.057 -171.603 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.64 170.8 28.47 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 105.414 -3.074 . . . . 0.0 105.414 164.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -88.23 140.36 29.56 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 -176.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.9 p -141.94 -179.28 6.12 Favored 'General case' 0 CA--C 1.498 -1.027 0 CA-C-O 122.275 1.036 . . . . 0.0 109.142 -174.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 p -158.85 -166.78 1.95 Allowed 'General case' 0 N--CA 1.428 -1.543 1 N-CA-C 95.126 -5.879 . . . . 0.0 95.126 167.632 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.4 mp -116.65 139.03 25.04 Favored Pre-proline 0 N--CA 1.434 -1.24 1 N-CA-C 97.313 -5.069 . . . . 0.0 97.313 169.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -82.71 27.82 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.759 0 CA-C-N 123.656 2.341 . . . . 0.0 110.997 -173.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 28.7 mm 72.85 -58.86 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 128.13 2.572 . . . . 0.0 110.162 175.371 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -89.65 101.98 14.66 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 102.403 -3.184 . . . . 0.0 102.403 168.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -72.39 100.15 2.61 Favored 'General case' 0 CA--C 1.5 -0.947 0 C-N-CA 123.994 0.917 . . . . 0.0 109.046 -165.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -133.29 7.58 3.93 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 -176.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -157.23 150.84 22.09 Favored Glycine 0 CA--C 1.478 -2.239 1 N-CA-C 96.233 -6.747 . . . . 0.0 96.233 176.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.0 mt -164.29 179.59 6.72 Favored 'General case' 0 N--CA 1.426 -1.629 1 N-CA-C 96.11 -5.515 . . . . 0.0 96.11 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.9 m -87.72 151.8 22.63 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -72.64 -28.5 62.78 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.598 -0.689 . . . . 0.0 109.957 -178.111 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.5 p -90.66 11.63 21.53 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 124.36 1.064 . . . . 0.0 110.404 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.65 -77.72 0.93 Allowed Glycine 0 CA--C 1.491 -1.465 0 O-C-N 121.065 -1.022 . . . . 0.0 110.989 171.455 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.63 142.0 31.12 Favored 'General case' 0 CA--C 1.497 -1.092 0 CA-C-N 117.948 0.874 . . . . 0.0 109.999 -159.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 t -118.44 130.26 55.86 Favored 'General case' 0 CA--C 1.485 -1.544 1 N-CA-C 99.796 -4.15 . . . . 0.0 99.796 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -142.46 42.91 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.34 -60.41 1.31 Allowed Glycine 0 C--N 1.352 1.455 0 N-CA-C 106.232 -2.747 . . . . 0.0 106.232 -176.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.82 157.6 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 164.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 m -79.4 133.25 36.56 Favored 'General case' 0 CA--C 1.486 -1.504 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 174.359 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.55 -164.44 1.41 Allowed 'General case' 0 N--CA 1.428 -1.547 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 -176.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.5 p30 -134.74 168.0 19.83 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 100.752 -3.795 . . . . 0.0 100.752 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.1 mt -154.5 174.21 15.22 Favored 'General case' 0 N--CA 1.424 -1.736 1 N-CA-C 94.837 -5.986 . . . . 0.0 94.837 169.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.044 0 O-C-N 124.04 0.838 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 . . . . . 0 N--CA 1.5 2.074 0 N-CA-C 102.894 -3.002 . . . . 0.0 102.894 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -150.83 163.91 37.51 Favored 'General case' 0 CA--C 1.488 -1.407 0 N-CA-C 101.901 -3.37 . . . . 0.0 101.901 -166.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 6.2 p -103.57 166.19 10.58 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 102.223 -3.251 . . . . 0.0 102.223 166.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 35.5 mt -94.54 141.64 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -70.19 139.59 52.37 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 127.334 2.254 . . . . 0.0 110.579 -163.005 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 65.5 24.83 11.85 Favored 'General case' 0 C--N 1.355 0.841 0 C-N-CA 126.689 1.996 . . . . 0.0 113.049 -171.711 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.2 166.46 21.05 Favored Glycine 0 CA--C 1.493 -1.324 0 N-CA-C 105.056 -3.218 . . . . 0.0 105.056 164.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -66.6 148.2 52.23 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 125.399 1.48 . . . . 0.0 107.167 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.4 p -143.83 178.72 7.63 Favored 'General case' 0 CA--C 1.483 -1.612 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 178.058 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -168.83 -169.9 1.08 Allowed 'General case' 0 N--CA 1.415 -2.224 1 N-CA-C 95.356 -5.794 . . . . 0.0 95.356 -170.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -108.42 -56.08 0.05 OUTLIER Pre-proline 0 N--CA 1.442 -0.844 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -71.46 148.19 53.76 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 CA-C-N 124.541 2.657 . . . . 0.0 110.165 166.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -142.75 -90.16 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 101.636 -3.468 . . . . 0.0 101.636 169.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.1 mt -85.06 -57.79 2.95 Favored 'General case' 0 CA--C 1.494 -1.173 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.3 mmtm -119.73 -69.44 0.85 Allowed 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 104.232 -2.507 . . . . 0.0 104.232 177.833 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.52 173.9 15.11 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 96.619 -5.326 . . . . 0.0 96.619 175.198 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -164.61 179.66 39.21 Favored Glycine 0 N--CA 1.419 -2.445 1 N-CA-C 98.456 -5.857 . . . . 0.0 98.456 177.759 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 15.4 tp -160.9 175.47 12.49 Favored 'General case' 0 N--CA 1.423 -1.803 1 N-CA-C 95.913 -5.588 . . . . 0.0 95.913 173.153 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 94.0 m -90.25 153.66 20.31 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -172.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 33.7 m -71.58 -30.4 65.79 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -175.752 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.09 -1.9 58.02 Favored 'General case' 0 N--CA 1.439 -0.991 0 C-N-CA 124.83 1.252 . . . . 0.0 110.245 177.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.86 -70.26 0.21 Allowed Glycine 0 CA--C 1.49 -1.503 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 172.0 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.61 145.68 27.9 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -161.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.2 t -132.22 133.03 43.68 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 100.726 -3.805 . . . . 0.0 100.726 -177.665 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.68 -125.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.885 1 N-CA-C 98.563 -4.606 . . . . 0.0 98.563 161.65 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.58 -9.17 86.25 Favored Glycine 0 C--N 1.349 1.276 0 O-C-N 118.316 -2.74 . . . . 0.0 110.801 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 m -148.12 161.58 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.755 1 N-CA-C 99.482 -4.266 . . . . 0.0 99.482 -172.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 97.8 m -78.7 136.57 37.47 Favored 'General case' 0 CA--C 1.489 -1.376 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.944 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 -165.46 1.5 Allowed 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -159.87 175.11 13.46 Favored 'General case' 0 N--CA 1.421 -1.9 1 N-CA-C 99.108 -4.404 . . . . 0.0 99.108 -174.319 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 16.3 mt -149.49 173.79 13.21 Favored 'General case' 0 N--CA 1.429 -1.518 1 N-CA-C 94.478 -6.119 . . . . 0.0 94.478 168.358 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.896 0 O-C-N 124.087 0.867 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.6 m-20 -90.6 -133.53 0.11 Allowed 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p -123.02 168.98 11.66 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 100.513 -3.884 . . . . 0.0 100.513 163.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.5 mt -100.68 154.47 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 173.107 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -79.89 142.08 35.51 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 125.294 1.437 . . . . 0.0 108.53 -161.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 62.54 42.3 8.76 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 126.148 1.779 . . . . 0.0 111.091 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.57 173.28 16.44 Favored Glycine 0 C--N 1.35 1.334 1 N-CA-C 102.348 -4.301 . . . . 0.0 102.348 162.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -89.86 145.86 24.85 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -175.064 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.8 p -135.9 -170.44 2.63 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 -177.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.9 p -169.48 -168.12 0.77 Allowed 'General case' 0 N--CA 1.421 -1.909 1 N-CA-C 97.63 -4.952 . . . . 0.0 97.63 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -116.31 118.34 37.73 Favored Pre-proline 0 N--CA 1.435 -1.208 1 N-CA-C 99.227 -4.36 . . . . 0.0 99.227 172.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -74.41 -57.16 0.06 OUTLIER 'Trans proline' 0 CA--C 1.507 -0.835 0 CA-C-N 123.039 2.121 . . . . 0.0 113.263 -172.438 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.1 tp -151.06 -50.67 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.495 -1.169 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 -176.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 80.3 mt -125.58 -163.1 1.17 Allowed 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 102.293 -3.225 . . . . 0.0 102.293 170.036 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -87.44 65.4 8.63 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 106.392 -1.707 . . . . 0.0 106.392 171.335 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -100.94 12.48 37.58 Favored 'General case' 0 CA--C 1.507 -0.673 0 C-N-CA 124.186 0.994 . . . . 0.0 109.728 -173.483 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -166.75 164.26 37.63 Favored Glycine 0 N--CA 1.429 -1.827 1 N-CA-C 96.364 -6.694 . . . . 0.0 96.364 174.282 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 17.0 tp -163.39 178.68 7.9 Favored 'General case' 0 N--CA 1.428 -1.569 1 N-CA-C 96.791 -5.262 . . . . 0.0 96.791 177.767 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 77.7 m -89.71 148.11 23.46 Favored 'General case' 0 CA--C 1.488 -1.404 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.29 -28.56 66.39 Favored 'General case' 0 C--N 1.35 0.617 0 CA-C-O 121.12 0.486 . . . . 0.0 110.183 -176.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 7.2 p -90.31 11.17 22.16 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 124.622 1.169 . . . . 0.0 110.833 175.106 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.69 -68.75 0.88 Allowed Glycine 0 CA--C 1.492 -1.359 0 O-C-N 120.672 -1.268 . . . . 0.0 111.704 165.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.78 142.66 28.8 Favored 'General case' 0 CA--C 1.496 -1.099 0 O-C-N 121.272 -1.134 . . . . 0.0 109.698 -164.249 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.3 t -132.93 127.48 34.38 Favored 'General case' 0 CA--C 1.486 -1.487 1 N-CA-C 99.653 -4.202 . . . . 0.0 99.653 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.44 62.8 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.161 0 N-CA-C 101.712 -3.44 . . . . 0.0 101.712 172.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.18 -63.41 2.76 Favored Glycine 0 C--N 1.351 1.414 0 N-CA-C 106.993 -2.443 . . . . 0.0 106.993 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.0 m -91.65 155.33 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.21 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 168.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.2 m -80.24 122.67 27.16 Favored 'General case' 0 CA--C 1.487 -1.445 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 166.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.55 -147.56 0.37 Allowed 'General case' 0 N--CA 1.432 -1.365 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -146.91 164.92 31.36 Favored 'General case' 0 N--CA 1.42 -1.965 1 N-CA-C 95.58 -5.711 . . . . 0.0 95.58 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.1 tp -123.56 116.88 23.87 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 101.385 -3.561 . . . . 0.0 101.385 -176.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.036 0 O-C-N 123.256 0.348 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 . . . . . 0 N--CA 1.495 1.801 0 N-CA-C 102.113 -3.292 . . . . 0.0 102.113 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.2 m-20 -157.36 177.48 11.39 Favored 'General case' 0 N--CA 1.428 -1.526 1 N-CA-C 97.184 -5.117 . . . . 0.0 97.184 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.2 p -147.39 166.81 26.05 Favored 'General case' 0 N--CA 1.427 -1.621 1 N-CA-C 96.47 -5.381 . . . . 0.0 96.47 167.659 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mt -89.43 140.6 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 -177.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 74.6 tttt -85.46 148.28 26.06 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -158.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.306 68.3 m-85 58.75 31.37 21.12 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 127.694 2.397 . . . . 0.0 113.213 -170.322 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.36 168.65 16.66 Favored Glycine 0 N--CA 1.437 -1.298 0 N-CA-C 103.345 -3.902 . . . . 0.0 103.345 158.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -87.86 143.89 26.88 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.002 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.4 p -117.17 -118.35 0.32 Allowed 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 102.488 -3.153 . . . . 0.0 102.488 174.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 86.5 p -154.13 -136.85 0.06 Allowed 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 102.65 -3.092 . . . . 0.0 102.65 170.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 78.5 mt -148.94 155.01 40.57 Favored Pre-proline 0 N--CA 1.425 -1.719 1 N-CA-C 99.658 -4.201 . . . . 0.0 99.658 -176.455 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -74.85 5.3 3.99 Favored 'Trans proline' 0 CA--C 1.508 -0.804 0 C-N-CA 123.896 3.064 . . . . 0.0 112.649 -175.64 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 17.5 tt -94.71 -12.14 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 174.567 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.95 -72.08 0.74 Allowed 'General case' 0 CA--C 1.489 -1.401 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 -176.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 18.3 mtmm -124.15 -96.95 0.45 Allowed 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 101.545 -3.502 . . . . 0.0 101.545 171.503 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 177.66 -165.2 0.04 OUTLIER 'General case' 0 N--CA 1.431 -1.381 1 N-CA-C 96.52 -5.363 . . . . 0.0 96.52 179.172 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -170.35 144.67 8.57 Favored Glycine 0 CA--C 1.477 -2.282 1 N-CA-C 102.417 -4.273 . . . . 0.0 102.417 169.196 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.6 mp -117.48 101.93 8.79 Favored 'General case' 0 CA--C 1.488 -1.433 0 N-CA-C 103.193 -2.892 . . . . 0.0 103.193 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 88.1 m -90.7 149.06 22.21 Favored 'General case' 0 CA--C 1.489 -1.386 0 C-N-CA 124.396 1.079 . . . . 0.0 108.42 -175.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 38.9 m -66.9 -36.11 81.53 Favored 'General case' 0 C--N 1.351 0.637 0 CA-C-O 121.026 0.441 . . . . 0.0 111.516 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.6 p -90.34 15.04 11.27 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 123.846 0.858 . . . . 0.0 111.114 177.308 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.47 -67.7 0.69 Allowed Glycine 0 CA--C 1.489 -1.545 0 O-C-N 121.128 -0.983 . . . . 0.0 110.722 167.777 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.03 133.07 35.26 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 121.639 -0.918 . . . . 0.0 110.252 -166.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 12.5 t -123.61 122.48 38.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 100.487 -3.894 . . . . 0.0 100.487 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -151.21 65.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 103.228 -2.879 . . . . 0.0 103.228 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.25 -62.84 3.78 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 107.069 -2.412 . . . . 0.0 107.069 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -99.65 159.44 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 104.756 -2.312 . . . . 0.0 104.756 171.725 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 66.1 m -83.42 128.43 34.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 170.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.45 -152.36 0.41 Allowed 'General case' 0 N--CA 1.432 -1.333 0 N-CA-C 104.502 -2.406 . . . . 0.0 104.502 -174.08 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -143.16 173.03 11.94 Favored 'General case' 0 N--CA 1.424 -1.743 1 N-CA-C 97.371 -5.048 . . . . 0.0 97.371 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.6 mt -149.52 166.25 29.75 Favored 'General case' 0 N--CA 1.419 -1.985 1 N-CA-C 93.939 -6.319 . . . . 0.0 93.939 174.254 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 0.769 0 O-C-N 124.115 0.885 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.4 t70 . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 104.979 -2.23 . . . . 0.0 104.979 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -102.69 -106.17 0.27 Allowed 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 103.681 -2.711 . . . . 0.0 103.681 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p -97.47 160.02 14.57 Favored 'General case' 0 CA--C 1.495 -1.138 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 167.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.3 mt -95.52 146.37 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 -175.396 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 ttpp -70.05 142.21 52.74 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 127.074 2.149 . . . . 0.0 110.197 -167.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 62.52 28.02 16.53 Favored 'General case' 0 C--N 1.355 0.816 0 C-N-CA 126.186 1.794 . . . . 0.0 113.046 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.16 167.18 23.66 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 103.784 -3.726 . . . . 0.0 103.784 160.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -82.66 141.44 32.48 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 176.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p -108.39 -177.84 3.43 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 122.403 1.097 . . . . 0.0 109.933 -169.429 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.9 p -174.49 -156.55 0.07 Allowed 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 95.168 -5.864 . . . . 0.0 95.168 -171.409 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -149.1 -174.23 0.4 Allowed Pre-proline 0 N--CA 1.435 -1.221 1 N-CA-C 98.763 -4.532 . . . . 0.0 98.763 -169.33 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -59.48 149.99 78.41 Favored 'Trans proline' 0 CA--C 1.507 -0.87 0 C-N-CA 123.652 2.902 . . . . 0.0 112.049 166.332 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ILE . . . . . 0.424 HG23 ' H ' ' A' ' 15' ' ' LEU . 4.6 tp -164.6 -51.42 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 100.937 -3.727 . . . . 0.0 100.937 -176.766 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.424 ' H ' HG23 ' A' ' 14' ' ' ILE . 66.6 mt -115.0 -158.28 0.66 Allowed 'General case' 0 N--CA 1.434 -1.23 1 N-CA-C 99.238 -4.356 . . . . 0.0 99.238 159.403 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -68.02 120.09 13.7 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 174.043 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -176.26 -171.97 0.45 Allowed 'General case' 0 N--CA 1.425 -1.682 1 N-CA-C 96.538 -5.356 . . . . 0.0 96.538 -168.22 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -174.16 -163.28 27.29 Favored Glycine 0 CA--C 1.474 -2.507 1 N-CA-C 100.697 -4.961 . . . . 0.0 100.697 -167.817 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -88.96 -161.79 0.8 Allowed 'General case' 0 N--CA 1.435 -1.217 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 178.372 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 75.2 m -90.0 155.58 18.99 Favored 'General case' 0 N--CA 1.428 -1.561 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 55.8 m -70.16 -31.93 69.66 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -173.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.41 9.79 27.68 Favored 'General case' 0 N--CA 1.442 -0.834 0 C-N-CA 124.268 1.027 . . . . 0.0 110.43 175.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.27 -72.82 0.38 Allowed Glycine 0 CA--C 1.489 -1.554 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 170.754 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.79 151.95 25.9 Favored 'General case' 0 CA--C 1.498 -1.021 0 O-C-N 122.192 -0.593 . . . . 0.0 111.286 -162.165 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 1.9 t -138.23 133.61 33.41 Favored 'General case' 0 CA--C 1.485 -1.528 1 N-CA-C 97.315 -5.069 . . . . 0.0 97.315 -175.151 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -158.19 55.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 102.975 -2.972 . . . . 0.0 102.975 175.438 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.67 -64.23 2.16 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 106.113 -2.795 . . . . 0.0 106.113 -176.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.3 m -92.43 159.85 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 168.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.6 m -79.92 139.54 37.05 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 168.306 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.62 -149.39 0.28 Allowed 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 104.38 -2.452 . . . . 0.0 104.38 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -142.22 167.46 22.06 Favored 'General case' 0 N--CA 1.425 -1.695 1 N-CA-C 96.513 -5.366 . . . . 0.0 96.513 173.188 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 71.8 mt -153.46 167.88 27.98 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 94.927 -5.953 . . . . 0.0 94.927 176.308 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.885 0 O-C-N 124.114 0.884 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 11.5 p-10 . . . . . 0 N--CA 1.496 1.837 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -145.39 156.02 43.52 Favored 'General case' 0 N--CA 1.429 -1.51 1 N-CA-C 95.339 -5.8 . . . . 0.0 95.339 172.572 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 2.0 p -165.83 169.17 15.25 Favored 'General case' 0 N--CA 1.425 -1.7 1 N-CA-C 99.738 -4.171 . . . . 0.0 99.738 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -93.37 144.4 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.158 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 -177.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -68.97 145.76 53.33 Favored 'General case' 0 N--CA 1.437 -1.097 0 C-N-CA 127.853 2.461 . . . . 0.0 108.604 -170.582 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 68.0 28.96 6.63 Favored 'General case' 0 CA--C 1.503 -0.848 0 C-N-CA 125.58 1.552 . . . . 0.0 112.56 -174.1 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.67 166.49 13.67 Favored Glycine 0 C--N 1.349 1.296 0 N-CA-C 104.293 -3.523 . . . . 0.0 104.293 163.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -81.35 134.37 35.56 Favored 'General case' 0 CA--C 1.503 -0.834 0 CA-C-N 118.253 1.026 . . . . 0.0 108.251 -175.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.5 p -106.82 78.98 1.29 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-O 122.518 1.151 . . . . 0.0 108.44 -179.434 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -146.68 167.45 23.77 Favored 'General case' 0 N--CA 1.423 -1.801 1 N-CA-C 98.088 -4.782 . . . . 0.0 98.088 170.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 61.1 mt -154.1 -175.96 0.55 Allowed Pre-proline 0 N--CA 1.432 -1.356 1 N-CA-C 95.797 -5.631 . . . . 0.0 95.797 175.791 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_exo -58.46 110.93 0.73 Allowed 'Trans proline' 0 N--CA 1.456 -0.68 0 CA-C-N 123.917 2.435 . . . . 0.0 109.422 165.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 9.0 tp -83.54 96.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 CA-C-O 123.265 1.507 . . . . 0.0 110.038 -147.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 45.5 mt -158.69 -54.91 0.07 Allowed 'General case' 0 CA--C 1.482 -1.654 1 N-CA-C 97.247 -5.094 . . . . 0.0 97.247 178.055 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -88.66 159.27 17.92 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.825 -2.658 . . . . 0.0 103.825 163.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 42.7 t-20 -149.47 173.78 13.21 Favored 'General case' 0 N--CA 1.431 -1.405 1 N-CA-C 96.258 -5.46 . . . . 0.0 96.258 166.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -102.67 -162.42 26.02 Favored Glycine 0 CA--C 1.494 -1.255 0 N-CA-C 105.65 -2.98 . . . . 0.0 105.65 177.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -128.33 156.08 43.64 Favored 'General case' 0 CA--C 1.485 -1.545 1 N-CA-C 98.839 -4.504 . . . . 0.0 98.839 175.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.1 m -90.74 142.47 27.72 Favored 'General case' 0 CA--C 1.489 -1.372 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.4 m -66.77 -36.11 81.65 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 121.182 0.515 . . . . 0.0 110.749 -175.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 p -90.38 10.21 25.93 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.53 0.732 . . . . 0.0 111.518 178.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.21 -47.92 1.07 Allowed Glycine 0 C--N 1.35 1.327 0 O-C-N 121.24 -0.912 . . . . 0.0 112.954 163.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.82 143.16 33.51 Favored 'General case' 0 CA--C 1.489 -1.371 0 CA-C-N 119.042 1.421 . . . . 0.0 107.524 -167.844 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 11.9 t -123.86 136.48 54.39 Favored 'General case' 0 CA--C 1.484 -1.584 1 N-CA-C 98.463 -4.643 . . . . 0.0 98.463 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.6 43.57 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 103.111 -2.922 . . . . 0.0 103.111 176.041 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.49 -56.05 1.43 Allowed Glycine 0 C--N 1.354 1.529 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 m -99.51 160.44 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 164.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 89.9 m -80.12 148.06 31.13 Favored 'General case' 0 CA--C 1.488 -1.411 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 172.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.62 -146.62 0.2 Allowed 'General case' 0 N--CA 1.431 -1.388 0 N-CA-C 102.62 -3.104 . . . . 0.0 102.62 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.97 -178.22 6.16 Favored 'General case' 0 N--CA 1.427 -1.594 1 N-CA-C 96.372 -5.418 . . . . 0.0 96.372 175.06 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.88 155.23 50.63 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 94.364 -6.161 . . . . 0.0 94.364 169.627 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.812 0 O-C-N 124.469 1.105 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.501 2.079 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -97.65 -68.91 0.78 Allowed 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 174.162 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 19.9 p -140.37 170.79 15.16 Favored 'General case' 0 N--CA 1.422 -1.85 1 N-CA-C 95.539 -5.726 . . . . 0.0 95.539 161.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.5 mt -100.21 143.96 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 104.622 -2.362 . . . . 0.0 104.622 176.122 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -75.74 145.94 40.45 Favored 'General case' 0 N--CA 1.439 -0.989 0 C-N-CA 126.678 1.991 . . . . 0.0 108.22 -164.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 31.6 m-85 71.06 16.23 6.43 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 126.272 1.829 . . . . 0.0 111.992 -171.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.37 165.25 28.7 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 169.748 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -88.33 138.67 31.23 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.1 p -135.09 156.86 48.29 Favored 'General case' 0 CA--C 1.49 -1.358 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -170.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 167.57 -174.48 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.545 1 N-CA-C 97.248 -5.093 . . . . 0.0 97.248 163.254 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.8 tp -150.02 144.82 18.0 Favored Pre-proline 0 N--CA 1.425 -1.69 1 N-CA-C 94.428 -6.138 . . . . 0.0 94.428 163.56 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -69.37 -28.28 27.3 Favored 'Trans proline' 0 CA--C 1.506 -0.891 0 CA-C-N 126.947 3.517 . . . . 0.0 113.702 -165.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.4 tt -86.18 -32.06 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -174.198 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 83.0 mt -102.89 -16.39 15.89 Favored 'General case' 0 CA--C 1.5 -0.981 0 O-C-N 121.485 -0.759 . . . . 0.0 110.676 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp 68.17 8.58 6.65 Favored 'General case' 0 C--N 1.355 0.805 0 C-N-CA 126.616 1.966 . . . . 0.0 111.783 -179.082 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -149.32 153.34 37.32 Favored 'General case' 0 CA--C 1.478 -1.793 1 N-CA-C 97.839 -4.874 . . . . 0.0 97.839 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -148.8 154.71 25.99 Favored Glycine 0 N--CA 1.424 -2.102 1 N-CA-C 96.113 -6.795 . . . . 0.0 96.113 171.584 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.8 mt -74.54 119.49 18.8 Favored 'General case' 0 CA--C 1.493 -1.22 0 CA-C-N 118.172 0.986 . . . . 0.0 110.409 -164.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.1 m -90.24 148.34 22.97 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.406 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -74.03 -15.19 61.09 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 122.316 -0.24 . . . . 0.0 110.911 178.098 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.4 p -86.35 -25.33 25.43 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 176.319 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.06 -75.01 0.36 Allowed Glycine 0 CA--C 1.485 -1.81 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -176.486 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.13 34.79 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 122.189 -0.595 . . . . 0.0 110.202 -168.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.1 t -119.02 130.41 55.64 Favored 'General case' 0 CA--C 1.481 -1.69 1 N-CA-C 96.186 -5.487 . . . . 0.0 96.186 173.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.5 p -146.88 44.78 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.96 -60.63 1.99 Allowed Glycine 0 C--N 1.353 1.488 0 N-CA-C 106.639 -2.584 . . . . 0.0 106.639 -176.004 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.57 164.17 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.135 0 N-CA-C 104.511 -2.403 . . . . 0.0 104.511 164.463 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 83.3 m -80.85 134.54 35.78 Favored 'General case' 0 CA--C 1.488 -1.435 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.37 -163.42 1.6 Allowed 'General case' 0 CA--C 1.485 -1.54 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 -174.972 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -162.32 172.27 15.93 Favored 'General case' 0 N--CA 1.423 -1.81 1 N-CA-C 95.284 -5.821 . . . . 0.0 95.284 173.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.9 mp -142.73 146.86 34.76 Favored 'General case' 0 N--CA 1.426 -1.637 1 N-CA-C 94.497 -6.112 . . . . 0.0 94.497 170.247 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.883 0 O-C-N 124.704 1.252 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 . . . . . 0 N--CA 1.499 2.007 0 N-CA-C 104.721 -2.325 . . . . 0.0 104.721 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 49.4 t0 -162.57 -178.92 6.53 Favored 'General case' 0 N--CA 1.428 -1.536 1 N-CA-C 95.727 -5.657 . . . . 0.0 95.727 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.6 p -150.92 173.74 13.92 Favored 'General case' 0 N--CA 1.424 -1.728 1 N-CA-C 99.091 -4.411 . . . . 0.0 99.091 173.47 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.1 mt -97.56 148.59 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 103.212 -2.884 . . . . 0.0 103.212 171.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp -77.26 139.4 39.83 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 125.508 1.523 . . . . 0.0 109.092 -162.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 68.65 29.09 5.52 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 126.307 1.843 . . . . 0.0 110.795 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.61 170.51 18.31 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 103.556 -3.818 . . . . 0.0 103.556 161.345 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -82.26 156.21 24.46 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -176.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p -155.48 -170.6 3.5 Favored 'General case' 0 CA--C 1.489 -1.393 1 N-CA-C 98.723 -4.547 . . . . 0.0 98.723 170.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -161.23 175.83 11.9 Favored 'General case' 0 N--CA 1.425 -1.702 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 -169.831 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.73 163.72 21.65 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -172.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -73.65 41.25 0.6 Allowed 'Trans proline' 0 CA--C 1.518 -0.298 0 C-N-CA 124.308 3.339 . . . . 0.0 113.095 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 6.7 tp -105.95 -17.02 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 164.517 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 77.9 mt -127.38 -137.38 0.25 Allowed 'General case' 0 CA--C 1.484 -1.561 0 N-CA-C 101.605 -3.48 . . . . 0.0 101.605 175.555 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -87.14 152.56 22.23 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -150.72 -171.99 4.07 Favored 'General case' 0 N--CA 1.425 -1.692 1 N-CA-C 99.484 -4.265 . . . . 0.0 99.484 167.51 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.69 -175.49 44.94 Favored Glycine 0 N--CA 1.414 -2.787 1 N-CA-C 95.828 -6.909 . . . . 0.0 95.828 176.295 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.2 tp -94.04 141.42 28.55 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 103.267 -2.864 . . . . 0.0 103.267 178.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.0 m -90.5 151.26 21.44 Favored 'General case' 0 CA--C 1.49 -1.365 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -67.92 -28.38 67.44 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 119.687 1.13 . . . . 0.0 110.229 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.9 p -90.28 10.42 24.85 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 125.336 1.454 . . . . 0.0 110.407 174.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.25 -69.28 1.83 Allowed Glycine 0 CA--C 1.491 -1.408 0 O-C-N 120.941 -1.1 . . . . 0.0 111.152 168.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.77 141.9 35.86 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 -162.054 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.1 t -137.07 145.78 44.37 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 97.811 -4.885 . . . . 0.0 97.811 -175.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.5 p -160.69 -140.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.427 -1.609 1 N-CA-C 92.667 -6.79 . . . . 0.0 92.667 175.836 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.7 -4.44 61.64 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 122.92 2.6 . . . . 0.0 113.019 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 m -143.72 163.53 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 100.436 -3.913 . . . . 0.0 100.436 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.69 133.46 33.68 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 105.965 -1.865 . . . . 0.0 105.965 168.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.22 -154.93 0.54 Allowed 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 -179.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.22 40.26 Favored 'General case' 0 N--CA 1.427 -1.621 1 N-CA-C 96.281 -5.451 . . . . 0.0 96.281 174.332 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.4 mt -152.83 168.03 27.08 Favored 'General case' 0 N--CA 1.424 -1.74 1 N-CA-C 94.663 -6.051 . . . . 0.0 94.663 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.892 0 O-C-N 124.093 0.871 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.497 1.92 0 N-CA-C 104.236 -2.505 . . . . 0.0 104.236 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -155.07 165.7 35.91 Favored 'General case' 0 N--CA 1.427 -1.58 1 N-CA-C 96.284 -5.45 . . . . 0.0 96.284 179.069 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 9.7 p -171.32 -175.72 1.72 Allowed 'General case' 0 N--CA 1.423 -1.82 1 N-CA-C 96.661 -5.311 . . . . 0.0 96.661 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.19 150.64 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.582 0 N-CA-C 104.081 -2.562 . . . . 0.0 104.081 169.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -75.9 137.9 40.69 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.6 2.36 . . . . 0.0 108.504 -166.551 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 67.49 29.57 7.19 Favored 'General case' 0 C--N 1.357 0.897 0 C-N-CA 125.861 1.665 . . . . 0.0 110.898 -172.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.27 168.81 12.68 Favored Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 103.368 -3.893 . . . . 0.0 103.368 165.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -87.53 147.96 25.11 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.0 157.83 22.9 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.2 p -175.02 -158.63 0.07 Allowed 'General case' 0 N--CA 1.429 -1.512 1 N-CA-C 95.346 -5.798 . . . . 0.0 95.346 -175.995 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 87.4 mt -102.4 104.49 37.94 Favored Pre-proline 0 N--CA 1.441 -0.92 0 N-CA-C 100.632 -3.84 . . . . 0.0 100.632 164.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -82.97 -28.01 1.75 Allowed 'Trans proline' 0 CA--C 1.499 -1.243 0 CA-C-N 122.794 2.034 . . . . 0.0 109.848 -158.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 16.8 tt 171.09 -39.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.497 -1.08 0 N-CA-C 101.585 -3.487 . . . . 0.0 101.585 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 65.5 mt -75.42 152.03 38.04 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 106.429 -1.693 . . . . 0.0 106.429 169.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtpt -95.97 54.99 1.53 Allowed 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -161.693 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -169.07 -179.24 3.53 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 178.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -139.1 43.13 1.19 Allowed Glycine 0 CA--C 1.483 -1.929 0 N-CA-C 104.083 -3.607 . . . . 0.0 104.083 176.461 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 38.6 tp -79.74 119.21 22.34 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -171.146 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.5 m -90.42 150.89 21.65 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 177.83 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.03 -28.31 65.37 Favored 'General case' 0 C--N 1.353 0.737 0 CA-C-N 118.779 0.718 . . . . 0.0 111.144 -177.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.0 p -90.01 3.89 51.82 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 124.618 1.167 . . . . 0.0 109.301 176.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.94 -75.23 0.24 Allowed Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 169.584 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.66 144.67 29.25 Favored 'General case' 0 CA--C 1.496 -1.104 0 CA-C-O 120.859 0.362 . . . . 0.0 111.254 -160.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.9 t -123.07 130.39 52.72 Favored 'General case' 0 N--CA 1.428 -1.53 1 N-CA-C 99.449 -4.278 . . . . 0.0 99.449 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.5 p -150.61 56.54 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.08 0 N-CA-C 102.548 -3.13 . . . . 0.0 102.548 170.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.84 -67.03 1.87 Allowed Glycine 0 CA--C 1.491 -1.41 0 N-CA-C 106.133 -2.787 . . . . 0.0 106.133 -177.668 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.5 m -87.5 157.5 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.099 0 N-CA-C 105.313 -2.106 . . . . 0.0 105.313 167.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 m -84.02 127.15 33.68 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 167.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.79 -141.63 0.13 Allowed 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 102.676 -3.083 . . . . 0.0 102.676 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -150.73 162.58 40.43 Favored 'General case' 0 N--CA 1.425 -1.701 1 N-CA-C 96.589 -5.337 . . . . 0.0 96.589 171.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.8 mt -153.73 170.95 19.68 Favored 'General case' 0 N--CA 1.428 -1.575 1 N-CA-C 94.891 -5.966 . . . . 0.0 94.891 171.715 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.919 0 O-C-N 124.262 0.976 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 . . . . . 0 N--CA 1.496 1.835 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 67.71 -148.49 0.15 Allowed 'General case' 0 C--N 1.358 0.971 0 C-N-CA 125.61 1.564 . . . . 0.0 109.08 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p -140.18 159.94 41.07 Favored 'General case' 0 N--CA 1.427 -1.598 1 N-CA-C 97.476 -5.009 . . . . 0.0 97.476 165.639 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.3 mt -109.02 154.65 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 -175.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -87.58 143.19 27.32 Favored 'General case' 0 N--CA 1.437 -1.097 0 C-N-CA 128.229 2.611 . . . . 0.0 107.44 -157.197 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 79.81 2.91 2.11 Favored 'General case' 0 C--N 1.355 0.846 0 C-N-CA 127.453 2.301 . . . . 0.0 112.34 -173.799 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.36 165.09 28.61 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.65 -2.58 . . . . 0.0 106.65 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -76.44 144.35 39.98 Favored 'General case' 0 CA--C 1.497 -1.06 0 CA-C-N 118.135 0.967 . . . . 0.0 108.813 -175.606 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.6 p -138.63 167.16 22.55 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 177.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.16 -105.82 0.07 Allowed 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 179.12 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.4 mt -153.46 154.11 30.09 Favored Pre-proline 0 N--CA 1.432 -1.361 1 N-CA-C 96.643 -5.317 . . . . 0.0 96.643 166.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.07 134.14 15.76 Favored 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 122.422 2.081 . . . . 0.0 108.975 176.14 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 70.1 mt -140.21 -68.48 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 102.389 -3.189 . . . . 0.0 102.389 177.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 93.7 mt -111.98 -171.03 1.77 Allowed 'General case' 0 N--CA 1.437 -1.113 1 N-CA-C 99.492 -4.262 . . . . 0.0 99.492 164.703 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.3 mmmp? -81.19 66.49 6.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 122.344 1.069 . . . . 0.0 110.537 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -78.27 -60.85 2.21 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 170.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -153.26 160.66 29.29 Favored Glycine 0 N--CA 1.424 -2.14 1 N-CA-C 99.239 -5.544 . . . . 0.0 99.239 171.44 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.9 tp -149.07 154.05 38.72 Favored 'General case' 0 N--CA 1.429 -1.476 1 N-CA-C 93.839 -6.356 . . . . 0.0 93.839 169.058 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.5 m -91.6 146.04 24.11 Favored 'General case' 0 CA--C 1.484 -1.561 0 CA-C-N 119.318 0.963 . . . . 0.0 109.437 -177.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.7 m -69.98 -27.26 64.57 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.757 0.313 . . . . 0.0 110.505 -176.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.52 4.66 50.52 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 123.997 0.919 . . . . 0.0 111.221 173.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.85 -74.89 0.27 Allowed Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 172.113 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.58 153.07 25.67 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 118.146 0.973 . . . . 0.0 110.191 -163.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.7 t -142.42 152.02 42.38 Favored 'General case' 0 N--CA 1.429 -1.496 1 N-CA-C 98.166 -4.753 . . . . 0.0 98.166 -171.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.8 p -160.31 -142.92 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.146 1 N-CA-C 92.693 -6.78 . . . . 0.0 92.693 176.421 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.57 -15.11 65.81 Favored Glycine 0 C--N 1.35 1.308 0 CA-C-N 124.126 3.148 . . . . 0.0 113.008 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 m -138.14 163.75 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.691 0 N-CA-C 100.927 -3.731 . . . . 0.0 100.927 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.7 m -79.96 136.44 36.62 Favored 'General case' 0 CA--C 1.484 -1.589 0 C-N-CA 124.871 1.268 . . . . 0.0 108.172 176.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.23 -155.17 0.58 Allowed 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 -174.36 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -146.8 156.14 42.9 Favored 'General case' 0 N--CA 1.423 -1.815 1 N-CA-C 95.416 -5.772 . . . . 0.0 95.416 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.1 mt -153.59 165.46 35.83 Favored 'General case' 0 N--CA 1.425 -1.721 1 N-CA-C 94.406 -6.146 . . . . 0.0 94.406 178.283 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.889 0 O-C-N 124.299 0.999 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -113.82 -74.67 0.61 Allowed 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 -179.141 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.3 p -123.14 159.13 29.2 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 165.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -100.29 141.2 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 N-CA-C 104.447 -2.427 . . . . 0.0 104.447 -174.076 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -66.6 143.71 56.85 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 126.271 1.828 . . . . 0.0 110.589 -166.868 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 56.46 33.88 23.29 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 126.288 1.835 . . . . 0.0 112.665 -172.386 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.59 165.9 18.1 Favored Glycine 0 CA--C 1.487 -1.67 1 N-CA-C 102.481 -4.248 . . . . 0.0 102.481 161.026 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -71.87 152.13 42.84 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -177.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.9 p -151.67 -176.45 5.62 Favored 'General case' 0 N--CA 1.432 -1.372 1 N-CA-C 98.664 -4.569 . . . . 0.0 98.664 169.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 p 141.2 -139.3 0.0 OUTLIER 'General case' 0 CA--C 1.497 -1.092 1 N-CA-C 93.398 -6.519 . . . . 0.0 93.398 -169.226 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.0 mt -120.42 81.95 31.51 Favored Pre-proline 0 N--CA 1.441 -0.876 0 CA-C-N 119.676 1.126 . . . . 0.0 109.298 177.182 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -85.9 -4.75 8.89 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.122 1.881 . . . . 0.0 110.788 166.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.26 17.9 mt 75.03 -64.9 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 C-N-CA 127.414 2.286 . . . . 0.0 110.023 175.51 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -72.19 -39.44 68.62 Favored 'General case' 0 CA--C 1.499 -1.0 0 CA-C-O 122.243 1.021 . . . . 0.0 108.818 -170.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -98.34 21.8 10.53 Favored 'General case' 0 N--CA 1.434 -1.243 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.779 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -86.23 174.34 9.16 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 171.554 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.28 -159.83 32.76 Favored Glycine 0 N--CA 1.417 -2.575 1 N-CA-C 94.89 -7.284 . . . . 0.0 94.89 -173.301 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.3 mt -100.08 174.85 5.97 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 102.236 -3.246 . . . . 0.0 102.236 163.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 57.1 m -88.33 148.66 24.17 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.669 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 m -72.81 -16.89 61.61 Favored 'General case' 0 C--N 1.352 0.693 0 CA-C-O 120.675 0.274 . . . . 0.0 110.63 -172.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -88.43 -17.24 30.87 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 125.688 1.595 . . . . 0.0 110.158 176.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.1 -78.58 0.29 Allowed Glycine 0 N--CA 1.436 -1.309 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 -175.27 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.87 150.41 29.1 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.83 -0.806 . . . . 0.0 111.418 -166.093 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.6 t -131.11 137.14 48.94 Favored 'General case' 0 N--CA 1.425 -1.719 1 N-CA-C 97.868 -4.864 . . . . 0.0 97.868 -177.812 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.19 -129.87 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.189 1 N-CA-C 98.027 -4.805 . . . . 0.0 98.027 164.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.16 -5.01 87.1 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 117.705 -3.122 . . . . 0.0 110.713 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.1 m -145.78 164.42 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.728 1 N-CA-C 99.14 -4.393 . . . . 0.0 99.14 -177.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.9 m -79.07 137.64 37.61 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 169.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.11 -151.23 0.37 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 -174.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -143.65 161.63 38.04 Favored 'General case' 0 N--CA 1.426 -1.647 1 N-CA-C 98.007 -4.812 . . . . 0.0 98.007 175.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.3 mt -150.43 163.96 37.07 Favored 'General case' 0 N--CA 1.423 -1.814 1 N-CA-C 94.276 -6.194 . . . . 0.0 94.276 167.212 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.936 0 O-C-N 124.248 0.967 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.2 p . . . . . 0 N--CA 1.428 -1.549 1 N-CA-C 97.849 -4.871 . . . . 0.0 97.849 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.5 mt -92.09 148.22 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 104.862 -2.274 . . . . 0.0 104.862 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.6 tttt . . . . . 0 N--CA 1.437 -1.092 0 C-N-CA 127.127 2.171 . . . . 0.0 107.747 -168.095 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 . . . . . 0 N--CA 1.444 -0.773 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.26 173.98 25.74 Favored Glycine 0 C--N 1.354 1.568 0 N-CA-C 105.802 -2.919 . . . . 0.0 105.802 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -85.08 131.78 34.41 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-N 118.372 1.086 . . . . 0.0 108.907 -174.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p . . . . . 0 CA--C 1.493 -1.226 0 C-N-CA 123.783 0.833 . . . . 0.0 108.925 -178.353 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.0 m . . . . . 0 CA--C 1.498 -1.036 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.95 -33.23 75.13 Favored 'General case' 0 C--N 1.354 0.772 0 CA-C-O 121.134 0.493 . . . . 0.0 110.491 176.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -90.18 9.69 27.47 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 121.696 -0.628 . . . . 0.0 110.124 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.83 -69.34 1.18 Allowed Glycine 0 CA--C 1.492 -1.348 0 O-C-N 121.142 -0.974 . . . . 0.0 112.995 165.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.87 153.56 20.55 Favored 'General case' 0 CA--C 1.494 -1.187 0 CA-C-N 118.202 1.001 . . . . 0.0 108.768 -160.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 50.6 t -130.83 133.91 46.36 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 102.428 -3.175 . . . . 0.0 102.428 -176.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.5 p -137.26 37.27 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 102.671 -3.085 . . . . 0.0 102.671 175.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.04 -55.36 0.97 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 106.072 -2.811 . . . . 0.0 106.072 -176.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 m -94.85 156.53 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 165.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 57.0 m -73.62 129.7 38.5 Favored 'General case' 0 CA--C 1.486 -1.495 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.48 -156.8 0.7 Allowed 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 . . . . . 0 N--CA 1.418 -2.031 1 N-CA-C 98.569 -4.604 . . . . 0.0 98.569 -170.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.43 -1.474 1 N-CA-C 98.933 -4.469 . . . . 0.0 98.933 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.6 mt -93.58 136.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 176.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.5 ttpp . . . . . 0 N--CA 1.435 -1.186 0 C-N-CA 127.847 2.459 . . . . 0.0 108.584 -166.287 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 . . . . . 0 N--CA 1.441 -0.918 0 CA-C-O 120.824 0.345 . . . . 0.0 111.26 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.86 160.22 13.44 Favored Glycine 0 CA--C 1.491 -1.448 1 N-CA-C 102.548 -4.221 . . . . 0.0 102.548 167.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -74.34 149.91 40.38 Favored 'General case' 0 CA--C 1.503 -0.833 0 CA-C-N 118.094 0.947 . . . . 0.0 111.636 -165.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 30.1 p . . . . . 0 N--CA 1.436 -1.131 1 N-CA-C 98.884 -4.488 . . . . 0.0 98.884 170.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.7 m . . . . . 0 CA--C 1.485 -1.544 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.3 m -63.19 -37.56 87.71 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 121.327 0.584 . . . . 0.0 111.052 -171.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.8 p -90.52 7.07 40.86 Favored 'General case' 0 N--CA 1.443 -0.821 0 C-N-CA 124.695 1.198 . . . . 0.0 111.741 178.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.21 -69.91 0.27 Allowed Glycine 0 C--N 1.35 1.334 0 O-C-N 121.171 -0.956 . . . . 0.0 111.505 170.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.3 145.16 31.03 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-N 118.227 1.013 . . . . 0.0 110.986 -167.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.3 t -128.31 129.66 46.64 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 101.339 -3.578 . . . . 0.0 101.339 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.409 HG22 ' H ' ' A' ' 27' ' ' GLY . 5.8 p -133.24 -138.6 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -0.982 1 N-CA-C 97.837 -4.875 . . . . 0.0 97.837 165.235 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -70.99 -4.68 56.17 Favored Glycine 0 C--N 1.348 1.236 0 O-C-N 118.657 -2.527 . . . . 0.0 112.322 -179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.45 164.09 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.954 1 N-CA-C 98.794 -4.521 . . . . 0.0 98.794 174.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 73.3 m -77.57 141.03 39.77 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 167.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.5 -146.1 0.19 Allowed 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 104.165 -2.531 . . . . 0.0 104.165 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.425 -1.706 1 N-CA-C 96.989 -5.189 . . . . 0.0 96.989 173.033 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.0 p . . . . . 0 CA--C 1.491 -1.314 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -92.97 140.63 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 101.543 -3.502 . . . . 0.0 101.543 172.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.7 tttm . . . . . 0 N--CA 1.44 -0.959 0 CA-C-O 117.382 -1.294 . . . . 0.0 108.276 -162.738 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 . . . . . 0 CA--C 1.507 -0.676 0 N-CA-C 111.637 0.236 . . . . 0.0 111.637 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.91 168.39 26.1 Favored Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 105.889 -2.884 . . . . 0.0 105.889 172.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -85.46 146.4 26.97 Favored 'General case' 0 CA--C 1.504 -0.805 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -177.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.7 p . . . . . 0 N--CA 1.434 -1.261 0 N-CA-C 103.432 -2.803 . . . . 0.0 103.432 -177.309 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.3 m . . . . . 0 CA--C 1.5 -0.96 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -62.13 -42.65 99.45 Favored 'General case' 0 C--N 1.358 0.938 0 CA-C-N 118.805 0.73 . . . . 0.0 110.024 -177.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.4 p -87.53 17.63 4.45 Favored 'General case' 0 N--CA 1.441 -0.916 0 C-N-CA 123.716 0.806 . . . . 0.0 111.314 177.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.99 -71.49 0.89 Allowed Glycine 0 CA--C 1.49 -1.494 0 O-C-N 120.552 -1.342 . . . . 0.0 111.595 164.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.18 144.73 25.6 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 121.755 -0.85 . . . . 0.0 111.09 -163.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.9 t -111.38 133.43 53.7 Favored 'General case' 0 N--CA 1.432 -1.348 0 N-CA-C 101.212 -3.625 . . . . 0.0 101.212 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.77 41.47 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.173 0 N-CA-C 102.86 -3.015 . . . . 0.0 102.86 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.31 -61.19 1.06 Allowed Glycine 0 C--N 1.352 1.431 0 N-CA-C 105.434 -3.066 . . . . 0.0 105.434 -174.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.1 m -95.07 160.6 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 166.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 67.1 m -78.86 135.4 37.02 Favored 'General case' 0 CA--C 1.495 -1.17 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 172.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.89 -140.7 0.11 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 103.436 -2.802 . . . . 0.0 103.436 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 . . . . . 0 N--CA 1.423 -1.821 1 N-CA-C 96.893 -5.225 . . . . 0.0 96.893 174.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.435 -1.224 0 N-CA-C 103.396 -2.816 . . . . 0.0 103.396 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . 0.426 ' HB ' ' SG ' ' A' ' 20' ' ' CYS . 57.0 mt -89.45 150.69 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 102.835 -3.024 . . . . 0.0 102.835 165.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.1 tttm . . . . . 0 N--CA 1.439 -1.006 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 -164.31 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.257 86.9 m-85 . . . . . 0 CA--C 1.503 -0.84 0 CA-C-O 121.301 0.572 . . . . 0.0 110.499 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.9 163.0 19.32 Favored Glycine 0 CA--C 1.491 -1.449 0 N-CA-C 105.335 -3.106 . . . . 0.0 105.335 166.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -79.92 145.58 32.58 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.433 -1.294 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 -170.671 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 4' ' ' ILE . 84.8 m . . . . . 0 CA--C 1.484 -1.585 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.0 m -64.6 -36.78 85.34 Favored 'General case' 0 C--N 1.351 0.645 0 CA-C-O 121.242 0.544 . . . . 0.0 110.183 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.6 p -87.69 1.15 54.54 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.17 0.988 . . . . 0.0 110.316 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.9 -79.67 1.5 Allowed Glycine 0 N--CA 1.437 -1.249 0 O-C-N 121.421 -0.799 . . . . 0.0 111.939 173.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.57 123.31 28.54 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 113.421 0.897 . . . . 0.0 113.421 -149.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -96.64 127.09 42.3 Favored 'General case' 0 CA--C 1.5 -0.954 0 C-N-CA 125.435 1.494 . . . . 0.0 107.309 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.79 42.22 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.061 -2.941 . . . . 0.0 103.061 175.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.88 -56.12 1.14 Allowed Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 106.118 -2.793 . . . . 0.0 106.118 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.7 m -103.91 156.78 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 103.019 -2.956 . . . . 0.0 103.019 163.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -89.58 143.89 26.45 Favored 'General case' 0 CA--C 1.482 -1.67 0 CA-C-O 121.172 0.511 . . . . 0.0 109.905 179.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.26 -146.75 0.19 Allowed 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 102.421 -3.177 . . . . 0.0 102.421 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.431 -1.406 1 N-CA-C 95.876 -5.601 . . . . 0.0 95.876 166.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.428 -1.559 1 N-CA-C 99.276 -4.342 . . . . 0.0 99.276 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.1 mt -88.66 145.98 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 -172.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.5 tttt . . . . . 0 N--CA 1.437 -1.08 0 C-N-CA 126.766 2.026 . . . . 0.0 109.762 -162.179 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.269 96.3 m-85 . . . . . 0 CA--C 1.504 -0.81 0 CA-C-O 120.911 0.386 . . . . 0.0 111.847 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.81 171.05 27.01 Favored Glycine 0 C--N 1.352 1.446 0 N-CA-C 104.473 -3.451 . . . . 0.0 104.473 163.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -90.13 159.36 16.82 Favored 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 175.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.433 -1.323 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 -174.228 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 93.1 m . . . . . 0 CA--C 1.485 -1.542 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 59.2 m -66.87 -36.35 82.11 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.905 0.383 . . . . 0.0 110.929 -173.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.6 p -90.15 9.65 27.53 Favored 'General case' 0 N--CA 1.438 -1.058 0 C-N-CA 123.925 0.89 . . . . 0.0 111.158 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.48 -74.84 0.21 Allowed Glycine 0 C--N 1.353 1.478 0 O-C-N 121.294 -0.879 . . . . 0.0 111.439 168.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.02 141.1 30.54 Favored 'General case' 0 CA--C 1.494 -1.205 0 O-C-N 121.753 -0.851 . . . . 0.0 109.555 -162.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 25.8 t -119.81 126.62 51.43 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 98.492 -4.633 . . . . 0.0 98.492 171.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.3 p -146.47 48.29 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 101.924 -3.361 . . . . 0.0 101.924 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.69 -62.67 2.65 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.151 -2.779 . . . . 0.0 106.151 -174.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.9 m -89.25 158.36 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 167.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.0 m -82.1 128.96 34.65 Favored 'General case' 0 CA--C 1.49 -1.347 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 168.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.78 -142.77 0.2 Allowed 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 -178.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.422 -1.843 1 N-CA-C 97.734 -4.913 . . . . 0.0 97.734 -176.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.6 p . . . . . 0 CA--C 1.492 -1.264 0 N-CA-C 102.888 -3.004 . . . . 0.0 102.888 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 38.0 mt -111.75 149.63 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 101.791 -3.411 . . . . 0.0 101.791 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 tptp . . . . . 0 N--CA 1.441 -0.897 0 C-N-CA 125.002 1.321 . . . . 0.0 108.184 -164.946 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.258 75.0 m-85 . . . . . 0 CA--C 1.505 -0.766 0 CA-C-O 120.679 0.276 . . . . 0.0 111.605 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.97 169.41 29.56 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 105.544 -3.023 . . . . 0.0 105.544 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -85.23 154.17 22.13 Favored 'General case' 0 CA--C 1.5 -0.962 0 N-CA-C 106.804 -1.554 . . . . 0.0 106.804 178.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 p . . . . . 0 CA--C 1.492 -1.281 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -173.539 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.0 m . . . . . 0 CA--C 1.496 -1.1 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.5 -31.42 69.66 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.093 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.3 p -87.26 9.5 20.07 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.749 1.22 . . . . 0.0 111.086 173.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.68 -78.96 0.49 Allowed Glycine 0 C--N 1.351 1.37 0 O-C-N 120.866 -1.147 . . . . 0.0 110.495 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.44 146.7 32.63 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 117.431 0.615 . . . . 0.0 111.368 -161.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.6 t -125.78 131.51 52.47 Favored 'General case' 0 N--CA 1.429 -1.499 1 N-CA-C 97.741 -4.911 . . . . 0.0 97.741 173.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -149.16 51.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.137 0 N-CA-C 101.407 -3.553 . . . . 0.0 101.407 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.01 -60.73 1.64 Allowed Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.235 -2.746 . . . . 0.0 106.235 -176.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.4 m -100.28 161.34 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.007 -2.219 . . . . 0.0 105.007 167.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 54.1 m -80.65 136.74 36.26 Favored 'General case' 0 CA--C 1.49 -1.357 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 174.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.01 -165.29 2.13 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -176.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.436 -1.128 0 N-CA-C 103.643 -2.725 . . . . 0.0 103.643 170.424 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.5 p . . . . . 0 N--CA 1.426 -1.638 1 N-CA-C 97.086 -5.153 . . . . 0.0 97.086 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.1 mt -107.59 148.43 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.322 0 N-CA-C 102.083 -3.303 . . . . 0.0 102.083 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.2 tptt . . . . . 0 N--CA 1.439 -1.008 0 C-N-CA 126.061 1.745 . . . . 0.0 108.343 -162.48 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 . . . . . 0 CA--C 1.507 -0.708 0 N-CA-C 112.079 0.4 . . . . 0.0 112.079 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.4 167.01 22.16 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 169.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.19 142.44 32.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -175.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p . . . . . 0 CA--C 1.501 -0.918 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 178.967 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 91.5 m . . . . . 0 CA--C 1.492 -1.269 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.25 -29.5 69.15 Favored 'General case' 0 C--N 1.352 0.71 0 CA-C-N 118.713 0.688 . . . . 0.0 111.414 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -90.03 -3.05 58.19 Favored 'General case' 0 N--CA 1.438 -1.071 0 O-C-N 121.292 -0.88 . . . . 0.0 109.841 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 115.48 -79.28 0.28 Allowed Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 109.829 -1.309 . . . . 0.0 109.829 170.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.19 151.4 24.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 O-C-N 122.596 -0.356 . . . . 0.0 110.585 -163.172 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -123.82 131.2 53.54 Favored 'General case' 0 CA--C 1.489 -1.39 1 N-CA-C 98.553 -4.61 . . . . 0.0 98.553 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.67 39.03 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 103.33 -2.841 . . . . 0.0 103.33 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.61 -55.68 1.03 Allowed Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.251 -2.74 . . . . 0.0 106.251 -176.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.5 m -98.21 164.3 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 163.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 63.7 m -81.69 139.55 34.85 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 171.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.35 -152.93 0.46 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 -177.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 N--CA 1.424 -1.742 1 N-CA-C 97.337 -5.06 . . . . 0.0 97.337 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p . . . . . 0 CA--C 1.484 -1.574 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.1 mt -97.97 149.49 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 175.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.354 0.771 0 C-N-CA 125.132 1.373 . . . . 0.0 108.496 -163.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.263 97.2 m-85 . . . . . 0 CA--C 1.503 -0.857 0 CA-C-O 121.108 0.48 . . . . 0.0 112.057 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.64 170.8 28.47 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 105.414 -3.074 . . . . 0.0 105.414 164.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -88.23 140.36 29.56 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 -176.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.9 p . . . . . 0 CA--C 1.498 -1.027 0 CA-C-O 122.275 1.036 . . . . 0.0 109.142 -174.044 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.9 m . . . . . 0 CA--C 1.498 -1.024 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -72.64 -28.5 62.78 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.598 -0.689 . . . . 0.0 109.957 -178.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.5 p -90.66 11.63 21.53 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 124.36 1.064 . . . . 0.0 110.404 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.65 -77.72 0.93 Allowed Glycine 0 CA--C 1.491 -1.465 0 O-C-N 121.065 -1.022 . . . . 0.0 110.989 171.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.63 142.0 31.12 Favored 'General case' 0 CA--C 1.497 -1.092 0 CA-C-N 117.948 0.874 . . . . 0.0 109.999 -159.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 t -118.44 130.26 55.86 Favored 'General case' 0 CA--C 1.485 -1.544 1 N-CA-C 99.796 -4.15 . . . . 0.0 99.796 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -142.46 42.91 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.34 -60.41 1.31 Allowed Glycine 0 C--N 1.352 1.455 0 N-CA-C 106.232 -2.747 . . . . 0.0 106.232 -176.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.82 157.6 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 164.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 m -79.4 133.25 36.56 Favored 'General case' 0 CA--C 1.486 -1.504 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 174.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.55 -164.44 1.41 Allowed 'General case' 0 N--CA 1.428 -1.547 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 -176.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.5 p30 . . . . . 0 N--CA 1.423 -1.794 0 N-CA-C 100.752 -3.795 . . . . 0.0 100.752 179.147 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 6.2 p . . . . . 0 CA--C 1.499 -1.016 0 N-CA-C 102.223 -3.251 . . . . 0.0 102.223 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 35.5 mt -94.54 141.64 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt . . . . . 0 N--CA 1.442 -0.872 0 C-N-CA 127.334 2.254 . . . . 0.0 110.579 -163.005 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 . . . . . 0 N--CA 1.443 -0.823 0 N-CA-C 113.049 0.759 . . . . 0.0 113.049 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.2 166.46 21.05 Favored Glycine 0 CA--C 1.493 -1.324 0 N-CA-C 105.056 -3.218 . . . . 0.0 105.056 164.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -66.6 148.2 52.23 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 125.399 1.48 . . . . 0.0 107.167 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.4 p . . . . . 0 CA--C 1.483 -1.612 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 178.058 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 94.0 m . . . . . 0 CA--C 1.489 -1.393 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 33.7 m -71.58 -30.4 65.79 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -175.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.09 -1.9 58.02 Favored 'General case' 0 N--CA 1.439 -0.991 0 C-N-CA 124.83 1.252 . . . . 0.0 110.245 177.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.86 -70.26 0.21 Allowed Glycine 0 CA--C 1.49 -1.503 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 172.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.61 145.68 27.9 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -161.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.2 t -132.22 133.03 43.68 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 100.726 -3.805 . . . . 0.0 100.726 -177.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.68 -125.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.885 1 N-CA-C 98.563 -4.606 . . . . 0.0 98.563 161.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.58 -9.17 86.25 Favored Glycine 0 C--N 1.349 1.276 0 O-C-N 118.316 -2.74 . . . . 0.0 110.801 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 m -148.12 161.58 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.755 1 N-CA-C 99.482 -4.266 . . . . 0.0 99.482 -172.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 97.8 m -78.7 136.57 37.47 Favored 'General case' 0 CA--C 1.489 -1.376 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 -165.46 1.5 Allowed 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 . . . . . 0 N--CA 1.421 -1.9 1 N-CA-C 99.108 -4.404 . . . . 0.0 99.108 -174.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p . . . . . 0 CA--C 1.488 -1.429 0 N-CA-C 100.513 -3.884 . . . . 0.0 100.513 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.5 mt -100.68 154.47 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 173.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? . . . . . 0 N--CA 1.44 -0.966 0 C-N-CA 125.294 1.437 . . . . 0.0 108.53 -161.577 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 . . . . . 0 CA--C 1.502 -0.896 0 CA-C-O 122.044 0.926 . . . . 0.0 111.091 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.57 173.28 16.44 Favored Glycine 0 C--N 1.35 1.334 1 N-CA-C 102.348 -4.301 . . . . 0.0 102.348 162.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -89.86 145.86 24.85 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -175.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.8 p . . . . . 0 N--CA 1.433 -1.279 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 -177.501 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 77.7 m . . . . . 0 CA--C 1.488 -1.404 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.29 -28.56 66.39 Favored 'General case' 0 C--N 1.35 0.617 0 CA-C-O 121.12 0.486 . . . . 0.0 110.183 -176.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 7.2 p -90.31 11.17 22.16 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 124.622 1.169 . . . . 0.0 110.833 175.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.69 -68.75 0.88 Allowed Glycine 0 CA--C 1.492 -1.359 0 O-C-N 120.672 -1.268 . . . . 0.0 111.704 165.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.78 142.66 28.8 Favored 'General case' 0 CA--C 1.496 -1.099 0 O-C-N 121.272 -1.134 . . . . 0.0 109.698 -164.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.3 t -132.93 127.48 34.38 Favored 'General case' 0 CA--C 1.486 -1.487 1 N-CA-C 99.653 -4.202 . . . . 0.0 99.653 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.44 62.8 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.161 0 N-CA-C 101.712 -3.44 . . . . 0.0 101.712 172.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.18 -63.41 2.76 Favored Glycine 0 C--N 1.351 1.414 0 N-CA-C 106.993 -2.443 . . . . 0.0 106.993 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.0 m -91.65 155.33 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.21 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 168.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.2 m -80.24 122.67 27.16 Favored 'General case' 0 CA--C 1.487 -1.445 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 166.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.55 -147.56 0.37 Allowed 'General case' 0 N--CA 1.432 -1.365 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 . . . . . 0 N--CA 1.42 -1.965 1 N-CA-C 95.58 -5.711 . . . . 0.0 95.58 -179.606 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.2 p . . . . . 0 N--CA 1.427 -1.621 1 N-CA-C 96.47 -5.381 . . . . 0.0 96.47 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mt -89.43 140.6 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 -177.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 74.6 tttt . . . . . 0 N--CA 1.441 -0.877 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -158.558 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.306 68.3 m-85 . . . . . 0 N--CA 1.443 -0.806 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.36 168.65 16.66 Favored Glycine 0 N--CA 1.437 -1.298 0 N-CA-C 103.345 -3.902 . . . . 0.0 103.345 158.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -87.86 143.89 26.88 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.002 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.4 p . . . . . 0 N--CA 1.433 -1.308 0 N-CA-C 102.488 -3.153 . . . . 0.0 102.488 174.35 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 88.1 m . . . . . 0 CA--C 1.489 -1.386 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 38.9 m -66.9 -36.11 81.53 Favored 'General case' 0 C--N 1.351 0.637 0 CA-C-O 121.026 0.441 . . . . 0.0 111.516 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.6 p -90.34 15.04 11.27 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 123.846 0.858 . . . . 0.0 111.114 177.308 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.47 -67.7 0.69 Allowed Glycine 0 CA--C 1.489 -1.545 0 O-C-N 121.128 -0.983 . . . . 0.0 110.722 167.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.03 133.07 35.26 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 121.639 -0.918 . . . . 0.0 110.252 -166.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 12.5 t -123.61 122.48 38.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 100.487 -3.894 . . . . 0.0 100.487 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -151.21 65.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 103.228 -2.879 . . . . 0.0 103.228 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.25 -62.84 3.78 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 107.069 -2.412 . . . . 0.0 107.069 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -99.65 159.44 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 104.756 -2.312 . . . . 0.0 104.756 171.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 66.1 m -83.42 128.43 34.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 170.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.45 -152.36 0.41 Allowed 'General case' 0 N--CA 1.432 -1.333 0 N-CA-C 104.502 -2.406 . . . . 0.0 104.502 -174.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.424 -1.743 1 N-CA-C 97.371 -5.048 . . . . 0.0 97.371 173.071 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p . . . . . 0 CA--C 1.495 -1.138 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.3 mt -95.52 146.37 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 -175.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 ttpp . . . . . 0 N--CA 1.443 -0.807 0 C-N-CA 127.074 2.149 . . . . 0.0 110.197 -167.279 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 . . . . . 0 N--CA 1.444 -0.727 0 N-CA-C 113.046 0.758 . . . . 0.0 113.046 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.16 167.18 23.66 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 103.784 -3.726 . . . . 0.0 103.784 160.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -82.66 141.44 32.48 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 176.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p . . . . . 0 N--CA 1.435 -1.205 0 CA-C-O 122.403 1.097 . . . . 0.0 109.933 -169.429 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 75.2 m . . . . . 0 N--CA 1.428 -1.561 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 55.8 m -70.16 -31.93 69.66 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -173.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.41 9.79 27.68 Favored 'General case' 0 N--CA 1.442 -0.834 0 C-N-CA 124.268 1.027 . . . . 0.0 110.43 175.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.27 -72.82 0.38 Allowed Glycine 0 CA--C 1.489 -1.554 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 170.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.79 151.95 25.9 Favored 'General case' 0 CA--C 1.498 -1.021 0 O-C-N 122.192 -0.593 . . . . 0.0 111.286 -162.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 1.9 t -138.23 133.61 33.41 Favored 'General case' 0 CA--C 1.485 -1.528 1 N-CA-C 97.315 -5.069 . . . . 0.0 97.315 -175.151 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -158.19 55.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 102.975 -2.972 . . . . 0.0 102.975 175.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.67 -64.23 2.16 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 106.113 -2.795 . . . . 0.0 106.113 -176.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.3 m -92.43 159.85 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 168.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.6 m -79.92 139.54 37.05 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 168.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.62 -149.39 0.28 Allowed 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 104.38 -2.452 . . . . 0.0 104.38 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.425 -1.695 1 N-CA-C 96.513 -5.366 . . . . 0.0 96.513 173.188 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 2.0 p . . . . . 0 N--CA 1.425 -1.7 1 N-CA-C 99.738 -4.171 . . . . 0.0 99.738 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -93.37 144.4 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.158 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 -177.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.3 tttm . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 127.853 2.461 . . . . 0.0 108.604 -170.582 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 . . . . . 0 CA--C 1.503 -0.848 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.67 166.49 13.67 Favored Glycine 0 C--N 1.349 1.296 0 N-CA-C 104.293 -3.523 . . . . 0.0 104.293 163.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -81.35 134.37 35.56 Favored 'General case' 0 CA--C 1.503 -0.834 0 CA-C-N 118.253 1.026 . . . . 0.0 108.251 -175.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.5 p . . . . . 0 CA--C 1.504 -0.816 0 CA-C-O 122.518 1.151 . . . . 0.0 108.44 -179.434 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.1 m . . . . . 0 CA--C 1.489 -1.372 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.4 m -66.77 -36.11 81.65 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 121.182 0.515 . . . . 0.0 110.749 -175.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 p -90.38 10.21 25.93 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.53 0.732 . . . . 0.0 111.518 178.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.21 -47.92 1.07 Allowed Glycine 0 C--N 1.35 1.327 0 O-C-N 121.24 -0.912 . . . . 0.0 112.954 163.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.82 143.16 33.51 Favored 'General case' 0 CA--C 1.489 -1.371 0 CA-C-N 119.042 1.421 . . . . 0.0 107.524 -167.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 11.9 t -123.86 136.48 54.39 Favored 'General case' 0 CA--C 1.484 -1.584 1 N-CA-C 98.463 -4.643 . . . . 0.0 98.463 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.6 43.57 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 103.111 -2.922 . . . . 0.0 103.111 176.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.49 -56.05 1.43 Allowed Glycine 0 C--N 1.354 1.529 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 m -99.51 160.44 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 164.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 89.9 m -80.12 148.06 31.13 Favored 'General case' 0 CA--C 1.488 -1.411 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 172.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.62 -146.62 0.2 Allowed 'General case' 0 N--CA 1.431 -1.388 0 N-CA-C 102.62 -3.104 . . . . 0.0 102.62 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.427 -1.594 1 N-CA-C 96.372 -5.418 . . . . 0.0 96.372 175.06 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 19.9 p . . . . . 0 N--CA 1.422 -1.85 1 N-CA-C 95.539 -5.726 . . . . 0.0 95.539 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.5 mt -100.21 143.96 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 104.622 -2.362 . . . . 0.0 104.622 176.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt . . . . . 0 N--CA 1.439 -0.989 0 C-N-CA 126.678 1.991 . . . . 0.0 108.22 -164.783 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 31.6 m-85 . . . . . 0 CA--C 1.504 -0.789 0 N-CA-C 111.992 0.367 . . . . 0.0 111.992 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.37 165.25 28.7 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 169.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -88.33 138.67 31.23 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.1 p . . . . . 0 CA--C 1.49 -1.358 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -170.92 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.1 m . . . . . 0 N--CA 1.432 -1.353 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -74.03 -15.19 61.09 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 122.316 -0.24 . . . . 0.0 110.911 178.098 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.4 p -86.35 -25.33 25.43 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 176.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.06 -75.01 0.36 Allowed Glycine 0 CA--C 1.485 -1.81 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -176.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.13 34.79 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 122.189 -0.595 . . . . 0.0 110.202 -168.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.1 t -119.02 130.41 55.64 Favored 'General case' 0 CA--C 1.481 -1.69 1 N-CA-C 96.186 -5.487 . . . . 0.0 96.186 173.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.5 p -146.88 44.78 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.96 -60.63 1.99 Allowed Glycine 0 C--N 1.353 1.488 0 N-CA-C 106.639 -2.584 . . . . 0.0 106.639 -176.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.57 164.17 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.135 0 N-CA-C 104.511 -2.403 . . . . 0.0 104.511 164.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 83.3 m -80.85 134.54 35.78 Favored 'General case' 0 CA--C 1.488 -1.435 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.37 -163.42 1.6 Allowed 'General case' 0 CA--C 1.485 -1.54 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 -174.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.423 -1.81 1 N-CA-C 95.284 -5.821 . . . . 0.0 95.284 173.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.6 p . . . . . 0 N--CA 1.424 -1.728 1 N-CA-C 99.091 -4.411 . . . . 0.0 99.091 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.1 mt -97.56 148.59 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 103.212 -2.884 . . . . 0.0 103.212 171.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp . . . . . 0 N--CA 1.44 -0.943 0 C-N-CA 125.508 1.523 . . . . 0.0 109.092 -162.644 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 . . . . . 0 CA--C 1.5 -0.962 0 CA-C-O 121.679 0.752 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.61 170.51 18.31 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 103.556 -3.818 . . . . 0.0 103.556 161.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -82.26 156.21 24.46 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -176.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p . . . . . 0 CA--C 1.489 -1.393 1 N-CA-C 98.723 -4.547 . . . . 0.0 98.723 170.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.0 m . . . . . 0 CA--C 1.49 -1.365 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -67.92 -28.38 67.44 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 119.687 1.13 . . . . 0.0 110.229 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.9 p -90.28 10.42 24.85 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 125.336 1.454 . . . . 0.0 110.407 174.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.25 -69.28 1.83 Allowed Glycine 0 CA--C 1.491 -1.408 0 O-C-N 120.941 -1.1 . . . . 0.0 111.152 168.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.77 141.9 35.86 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 -162.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.1 t -137.07 145.78 44.37 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 97.811 -4.885 . . . . 0.0 97.811 -175.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.5 p -160.69 -140.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.427 -1.609 1 N-CA-C 92.667 -6.79 . . . . 0.0 92.667 175.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.7 -4.44 61.64 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 122.92 2.6 . . . . 0.0 113.019 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 m -143.72 163.53 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 100.436 -3.913 . . . . 0.0 100.436 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.69 133.46 33.68 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 105.965 -1.865 . . . . 0.0 105.965 168.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.22 -154.93 0.54 Allowed 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 -179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.427 -1.621 1 N-CA-C 96.281 -5.451 . . . . 0.0 96.281 174.332 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.423 -1.82 1 N-CA-C 96.661 -5.311 . . . . 0.0 96.661 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.19 150.64 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.582 0 N-CA-C 104.081 -2.562 . . . . 0.0 104.081 169.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.1 tptt . . . . . 0 N--CA 1.436 -1.157 0 C-N-CA 127.6 2.36 . . . . 0.0 108.504 -166.551 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 . . . . . 0 CA--C 1.506 -0.737 0 CA-C-O 121.13 0.49 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.27 168.81 12.68 Favored Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 103.368 -3.893 . . . . 0.0 103.368 165.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -87.53 147.96 25.11 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p . . . . . 0 CA--C 1.497 -1.082 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 -178.572 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.5 m . . . . . 0 CA--C 1.493 -1.234 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.03 -28.31 65.37 Favored 'General case' 0 C--N 1.353 0.737 0 CA-C-N 118.779 0.718 . . . . 0.0 111.144 -177.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.0 p -90.01 3.89 51.82 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 124.618 1.167 . . . . 0.0 109.301 176.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.94 -75.23 0.24 Allowed Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 169.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.66 144.67 29.25 Favored 'General case' 0 CA--C 1.496 -1.104 0 CA-C-O 120.859 0.362 . . . . 0.0 111.254 -160.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.9 t -123.07 130.39 52.72 Favored 'General case' 0 N--CA 1.428 -1.53 1 N-CA-C 99.449 -4.278 . . . . 0.0 99.449 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.5 p -150.61 56.54 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.08 0 N-CA-C 102.548 -3.13 . . . . 0.0 102.548 170.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.84 -67.03 1.87 Allowed Glycine 0 CA--C 1.491 -1.41 0 N-CA-C 106.133 -2.787 . . . . 0.0 106.133 -177.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.5 m -87.5 157.5 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.099 0 N-CA-C 105.313 -2.106 . . . . 0.0 105.313 167.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 m -84.02 127.15 33.68 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 167.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.79 -141.63 0.13 Allowed 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 102.676 -3.083 . . . . 0.0 102.676 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 N--CA 1.425 -1.701 1 N-CA-C 96.589 -5.337 . . . . 0.0 96.589 171.252 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p . . . . . 0 N--CA 1.427 -1.598 1 N-CA-C 97.476 -5.009 . . . . 0.0 97.476 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.3 mt -109.02 154.65 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 -175.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? . . . . . 0 N--CA 1.437 -1.097 0 C-N-CA 128.229 2.611 . . . . 0.0 107.44 -157.197 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 . . . . . 0 N--CA 1.446 -0.663 0 N-CA-C 112.34 0.496 . . . . 0.0 112.34 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.36 165.09 28.61 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.65 -2.58 . . . . 0.0 106.65 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -76.44 144.35 39.98 Favored 'General case' 0 CA--C 1.497 -1.06 0 CA-C-N 118.135 0.967 . . . . 0.0 108.813 -175.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.6 p . . . . . 0 CA--C 1.482 -1.65 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 177.82 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.5 m . . . . . 0 CA--C 1.484 -1.561 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.7 m -69.98 -27.26 64.57 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.757 0.313 . . . . 0.0 110.505 -176.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.52 4.66 50.52 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 123.997 0.919 . . . . 0.0 111.221 173.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.85 -74.89 0.27 Allowed Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 172.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.58 153.07 25.67 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 118.146 0.973 . . . . 0.0 110.191 -163.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.7 t -142.42 152.02 42.38 Favored 'General case' 0 N--CA 1.429 -1.496 1 N-CA-C 98.166 -4.753 . . . . 0.0 98.166 -171.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.8 p -160.31 -142.92 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.146 1 N-CA-C 92.693 -6.78 . . . . 0.0 92.693 176.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.57 -15.11 65.81 Favored Glycine 0 C--N 1.35 1.308 0 CA-C-N 124.126 3.148 . . . . 0.0 113.008 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 m -138.14 163.75 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.691 0 N-CA-C 100.927 -3.731 . . . . 0.0 100.927 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.7 m -79.96 136.44 36.62 Favored 'General case' 0 CA--C 1.484 -1.589 0 C-N-CA 124.871 1.268 . . . . 0.0 108.172 176.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.23 -155.17 0.58 Allowed 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 -174.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 . . . . . 0 N--CA 1.423 -1.815 1 N-CA-C 95.416 -5.772 . . . . 0.0 95.416 176.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.3 p . . . . . 0 N--CA 1.433 -1.305 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -100.29 141.2 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 N-CA-C 104.447 -2.427 . . . . 0.0 104.447 -174.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp . . . . . 0 N--CA 1.446 -0.653 0 C-N-CA 126.271 1.828 . . . . 0.0 110.589 -166.868 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 . . . . . 0 CA--C 1.5 -0.974 0 N-CA-C 112.665 0.617 . . . . 0.0 112.665 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.59 165.9 18.1 Favored Glycine 0 CA--C 1.487 -1.67 1 N-CA-C 102.481 -4.248 . . . . 0.0 102.481 161.026 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -71.87 152.13 42.84 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -177.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.9 p . . . . . 0 N--CA 1.432 -1.372 1 N-CA-C 98.664 -4.569 . . . . 0.0 98.664 169.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 57.1 m . . . . . 0 CA--C 1.483 -1.609 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 m -72.81 -16.89 61.61 Favored 'General case' 0 C--N 1.352 0.693 0 CA-C-O 120.675 0.274 . . . . 0.0 110.63 -172.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -88.43 -17.24 30.87 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 125.688 1.595 . . . . 0.0 110.158 176.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.1 -78.58 0.29 Allowed Glycine 0 N--CA 1.436 -1.309 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 -175.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.87 150.41 29.1 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.83 -0.806 . . . . 0.0 111.418 -166.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.6 t -131.11 137.14 48.94 Favored 'General case' 0 N--CA 1.425 -1.719 1 N-CA-C 97.868 -4.864 . . . . 0.0 97.868 -177.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.19 -129.87 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.189 1 N-CA-C 98.027 -4.805 . . . . 0.0 98.027 164.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.16 -5.01 87.1 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 117.705 -3.122 . . . . 0.0 110.713 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.1 m -145.78 164.42 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.728 1 N-CA-C 99.14 -4.393 . . . . 0.0 99.14 -177.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.9 m -79.07 137.64 37.61 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 169.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.11 -151.23 0.37 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 -174.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 N--CA 1.426 -1.647 1 N-CA-C 98.007 -4.812 . . . . 0.0 98.007 175.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 30.7 t70 . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 102.207 -3.257 . . . . 0.0 102.207 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 1.4 p30 178.85 -170.98 0.12 Allowed 'General case' 0 N--CA 1.429 -1.476 1 N-CA-C 96.198 -5.482 . . . . 0.0 96.198 -169.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.2 p -148.97 173.5 13.28 Favored 'General case' 0 N--CA 1.428 -1.549 1 N-CA-C 97.849 -4.871 . . . . 0.0 97.849 168.306 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 39.5 mt -92.09 148.22 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.308 0 N-CA-C 104.862 -2.274 . . . . 0.0 104.862 174.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 85.6 tttt -74.63 141.59 44.63 Favored 'General case' 0 N--CA 1.437 -1.092 0 C-N-CA 127.127 2.171 . . . . 0.0 107.747 -168.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 11.7 m-85 72.07 20.45 4.3 Favored 'General case' 0 C--N 1.354 0.798 0 C-N-CA 126.394 1.878 . . . . 0.0 111.869 -173.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -100.26 173.98 25.74 Favored Glycine 0 C--N 1.354 1.568 0 N-CA-C 105.802 -2.919 . . . . 0.0 105.802 168.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 44.8 m-85 -85.08 131.78 34.41 Favored 'General case' 0 CA--C 1.504 -0.805 0 CA-C-N 118.372 1.086 . . . . 0.0 108.907 -174.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 4.9 p -125.6 9.37 7.73 Favored 'General case' 0 CA--C 1.493 -1.226 0 C-N-CA 123.783 0.833 . . . . 0.0 108.925 -178.353 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 12.8 p -77.35 68.49 3.47 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 177.521 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 69.3 mt -98.2 122.05 55.29 Favored Pre-proline 0 N--CA 1.433 -1.323 0 N-CA-C 105.25 -2.129 . . . . 0.0 105.25 -178.167 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -79.63 68.78 8.19 Favored 'Trans proline' 0 N--CA 1.452 -0.962 0 C-N-CA 122.845 2.364 . . . . 0.0 108.43 174.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 52.5 mt -137.2 141.93 38.73 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.764 1 N-CA-C 94.287 -6.19 . . . . 0.0 94.287 176.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.5 mt -92.27 136.3 33.3 Favored 'General case' 0 CA--C 1.489 -1.388 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 -174.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 35.3 mtmm 66.09 59.15 0.7 Allowed 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 125.799 1.64 . . . . 0.0 108.335 -176.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 9.0 t-20 -159.32 -172.86 3.91 Favored 'General case' 0 N--CA 1.42 -1.945 1 N-CA-C 97.203 -5.11 . . . . 0.0 97.203 -178.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 86.75 37.2 8.74 Favored Glycine 0 C--N 1.346 1.118 0 N-CA-C 107.202 -2.359 . . . . 0.0 107.202 -170.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 54.1 mt -89.2 91.16 8.67 Favored 'General case' 0 CA--C 1.502 -0.871 0 C-N-CA 123.786 0.834 . . . . 0.0 110.272 -166.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.0 m -83.75 144.09 29.56 Favored 'General case' 0 CA--C 1.498 -1.036 0 C-N-CA 123.671 0.788 . . . . 0.0 109.922 -179.915 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -66.95 -33.23 75.13 Favored 'General case' 0 C--N 1.354 0.772 0 CA-C-O 121.134 0.493 . . . . 0.0 110.491 176.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.8 p -90.18 9.69 27.47 Favored 'General case' 0 N--CA 1.437 -1.122 0 O-C-N 121.696 -0.628 . . . . 0.0 110.124 177.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.83 -69.34 1.18 Allowed Glycine 0 CA--C 1.492 -1.348 0 O-C-N 121.142 -0.974 . . . . 0.0 112.995 165.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -89.87 153.56 20.55 Favored 'General case' 0 CA--C 1.494 -1.187 0 CA-C-N 118.202 1.001 . . . . 0.0 108.768 -160.206 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 50.6 t -130.83 133.91 46.36 Favored 'General case' 0 CA--C 1.492 -1.262 0 N-CA-C 102.428 -3.175 . . . . 0.0 102.428 -176.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 10.5 p -137.26 37.27 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 102.671 -3.085 . . . . 0.0 102.671 175.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 99.04 -55.36 0.97 Allowed Glycine 0 CA--C 1.49 -1.486 0 N-CA-C 106.072 -2.811 . . . . 0.0 106.072 -176.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.3 m -94.85 156.53 3.15 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.097 0 N-CA-C 104.742 -2.318 . . . . 0.0 104.742 165.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 57.0 m -73.62 129.7 38.5 Favored 'General case' 0 CA--C 1.486 -1.495 0 N-CA-C 107.993 -1.114 . . . . 0.0 107.993 176.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -121.48 -156.8 0.7 Allowed 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 104.002 -2.592 . . . . 0.0 104.002 -177.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.0 p-10 -153.69 169.63 22.85 Favored 'General case' 0 N--CA 1.418 -2.031 1 N-CA-C 98.569 -4.604 . . . . 0.0 98.569 -170.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 45.8 tp -161.03 166.28 28.46 Favored 'General case' 0 N--CA 1.419 -1.981 1 N-CA-C 94.272 -6.196 . . . . 0.0 94.272 171.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.851 0 O-C-N 123.842 0.714 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 . . . . . 0 N--CA 1.493 1.69 0 N-CA-C 100.54 -3.874 . . . . 0.0 100.54 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 -66.63 -26.77 67.24 Favored 'General case' 0 C--N 1.352 0.717 0 C-N-CA 124.163 0.985 . . . . 0.0 110.225 175.354 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.9 p -140.83 170.43 15.77 Favored 'General case' 0 N--CA 1.43 -1.474 1 N-CA-C 98.933 -4.469 . . . . 0.0 98.933 163.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 10.6 mt -93.58 136.67 24.62 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.123 0 N-CA-C 104.169 -2.53 . . . . 0.0 104.169 176.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 24.5 ttpp -69.7 146.22 51.72 Favored 'General case' 0 N--CA 1.435 -1.186 0 C-N-CA 127.847 2.459 . . . . 0.0 108.584 -166.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 50.0 m-85 69.24 29.54 4.56 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 125.951 1.7 . . . . 0.0 111.26 -177.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.86 160.22 13.44 Favored Glycine 0 CA--C 1.491 -1.448 1 N-CA-C 102.548 -4.221 . . . . 0.0 102.548 167.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -74.34 149.91 40.38 Favored 'General case' 0 CA--C 1.503 -0.833 0 CA-C-N 118.094 0.947 . . . . 0.0 111.636 -165.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 30.1 p -160.06 -173.47 4.08 Favored 'General case' 0 N--CA 1.436 -1.131 1 N-CA-C 98.884 -4.488 . . . . 0.0 98.884 170.468 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 16.3 p -121.32 -80.11 0.62 Allowed 'General case' 0 CA--C 1.507 -0.709 0 CA-C-N 119.652 1.114 . . . . 0.0 109.179 -174.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 66.7 mt -150.19 163.14 25.51 Favored Pre-proline 0 N--CA 1.431 -1.423 1 N-CA-C 98.093 -4.78 . . . . 0.0 98.093 172.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_exo -64.43 112.26 1.88 Allowed 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 122.715 2.277 . . . . 0.0 112.207 176.923 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 20.3 tt -161.66 161.54 1.27 Allowed 'Isoleucine or valine' 0 N--CA 1.424 -1.742 1 N-CA-C 96.836 -5.246 . . . . 0.0 96.836 176.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.9 mt 52.63 -121.37 1.85 Allowed 'General case' 0 C--N 1.354 0.798 0 C-N-CA 125.838 1.655 . . . . 0.0 108.842 -173.662 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 46.6 mmtm -137.19 45.63 2.21 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 104.581 -2.377 . . . . 0.0 104.581 169.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . 0.259 0.1 OUTLIER -90.73 -35.69 14.74 Favored 'General case' 0 C--N 1.362 1.142 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 175.304 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -81.94 60.64 4.76 Favored Glycine 0 C--N 1.354 1.581 0 O-C-N 120.901 -1.124 . . . . 0.0 110.597 178.255 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 89.7 mt -118.66 72.65 0.89 Allowed 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 101.175 -3.639 . . . . 0.0 101.175 168.189 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 138.22 31.7 Favored 'General case' 0 CA--C 1.485 -1.544 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 30.3 m -63.19 -37.56 87.71 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-O 121.327 0.584 . . . . 0.0 111.052 -171.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.8 p -90.52 7.07 40.86 Favored 'General case' 0 N--CA 1.443 -0.821 0 C-N-CA 124.695 1.198 . . . . 0.0 111.741 178.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.21 -69.91 0.27 Allowed Glycine 0 C--N 1.35 1.334 0 O-C-N 121.171 -0.956 . . . . 0.0 111.505 170.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.3 145.16 31.03 Favored 'General case' 0 CA--C 1.501 -0.928 0 CA-C-N 118.227 1.013 . . . . 0.0 110.986 -167.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 34.3 t -128.31 129.66 46.64 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 101.339 -3.578 . . . . 0.0 101.339 179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.409 HG22 ' H ' ' A' ' 27' ' ' GLY . 5.8 p -133.24 -138.6 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -0.982 1 N-CA-C 97.837 -4.875 . . . . 0.0 97.837 165.235 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.409 ' H ' HG22 ' A' ' 26' ' ' VAL . . . -70.99 -4.68 56.17 Favored Glycine 0 C--N 1.348 1.236 0 O-C-N 118.657 -2.527 . . . . 0.0 112.322 -179.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.3 m -144.45 164.09 13.83 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.954 1 N-CA-C 98.794 -4.521 . . . . 0.0 98.794 174.855 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 73.3 m -77.57 141.03 39.77 Favored 'General case' 0 N--CA 1.437 -1.108 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 167.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -151.5 -146.1 0.19 Allowed 'General case' 0 N--CA 1.435 -1.183 0 N-CA-C 104.165 -2.531 . . . . 0.0 104.165 -175.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -142.02 164.47 30.08 Favored 'General case' 0 N--CA 1.425 -1.706 1 N-CA-C 96.989 -5.189 . . . . 0.0 96.989 173.033 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 77.1 mt -150.07 166.13 30.67 Favored 'General case' 0 N--CA 1.425 -1.689 1 N-CA-C 94.611 -6.07 . . . . 0.0 94.611 174.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.912 0 O-C-N 124.36 1.037 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 71.8 m-20 . . . . . 0 CA--C 1.487 -1.472 1 N-CA-C 100.146 -4.02 . . . . 0.0 100.146 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 16.0 p-10 -88.65 -147.78 0.16 Allowed 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 105.832 -1.914 . . . . 0.0 105.832 170.251 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 30.0 p -111.71 172.55 6.83 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 105.726 -1.953 . . . . 0.0 105.726 -179.448 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 12.2 mt -92.97 140.63 15.97 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.408 0 N-CA-C 101.543 -3.502 . . . . 0.0 101.543 172.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -75.39 139.17 42.19 Favored 'General case' 0 N--CA 1.44 -0.959 0 CA-C-O 117.382 -1.294 . . . . 0.0 108.276 -162.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 45.8 m-85 75.56 11.72 3.23 Favored 'General case' 0 C--N 1.356 0.851 0 C-N-CA 126.204 1.801 . . . . 0.0 111.637 -171.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.91 168.39 26.1 Favored Glycine 0 CA--C 1.492 -1.404 0 N-CA-C 105.889 -2.884 . . . . 0.0 105.889 172.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 58.9 t80 -85.46 146.4 26.97 Favored 'General case' 0 CA--C 1.504 -0.805 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -177.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.7 p -145.41 -179.22 6.51 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 103.432 -2.803 . . . . 0.0 103.432 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER 154.89 -89.06 0.0 OUTLIER 'General case' 0 CA--C 1.495 -1.151 1 N-CA-C 97.91 -4.848 . . . . 0.0 97.91 177.451 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.7 mp -88.91 152.24 48.29 Favored Pre-proline 0 CA--C 1.498 -1.039 0 N-CA-C 102.511 -3.144 . . . . 0.0 102.511 161.498 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_exo -73.36 148.24 43.01 Favored 'Trans proline' 0 CA--C 1.5 -1.203 0 CA-C-N 121.556 1.591 . . . . 0.0 109.191 -173.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 45.8 mm -62.6 -41.77 93.4 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.743 0 C-N-CA 123.953 0.901 . . . . 0.0 108.703 -175.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.6 mt -109.63 59.54 0.6 Allowed 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 107.389 -1.337 . . . . 0.0 107.389 178.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 60.1 mttp 73.68 -58.24 0.6 Allowed 'General case' 0 C--N 1.357 0.899 0 C-N-CA 126.103 1.761 . . . . 0.0 114.602 160.396 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 p30 -137.77 120.19 15.94 Favored 'General case' 0 CA--C 1.495 -1.155 0 N-CA-C 104.132 -2.544 . . . . 0.0 104.132 -175.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -175.89 179.79 46.82 Favored Glycine 0 CA--C 1.479 -2.193 1 N-CA-C 99.098 -5.601 . . . . 0.0 99.098 178.416 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 53.1 tp -150.58 165.27 33.82 Favored 'General case' 0 N--CA 1.427 -1.616 1 N-CA-C 95.687 -5.672 . . . . 0.0 95.687 175.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.3 m -72.67 142.48 48.26 Favored 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -62.13 -42.65 99.45 Favored 'General case' 0 C--N 1.358 0.938 0 CA-C-N 118.805 0.73 . . . . 0.0 110.024 -177.753 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.4 p -87.53 17.63 4.45 Favored 'General case' 0 N--CA 1.441 -0.916 0 C-N-CA 123.716 0.806 . . . . 0.0 111.314 177.388 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 95.99 -71.49 0.89 Allowed Glycine 0 CA--C 1.49 -1.494 0 O-C-N 120.552 -1.342 . . . . 0.0 111.595 164.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -90.18 144.73 25.6 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 121.755 -0.85 . . . . 0.0 111.09 -163.36 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.9 t -111.38 133.43 53.7 Favored 'General case' 0 N--CA 1.432 -1.348 0 N-CA-C 101.212 -3.625 . . . . 0.0 101.212 172.113 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -141.77 41.47 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.173 0 N-CA-C 102.86 -3.015 . . . . 0.0 102.86 178.148 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.31 -61.19 1.06 Allowed Glycine 0 C--N 1.352 1.431 0 N-CA-C 105.434 -3.066 . . . . 0.0 105.434 -174.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 15.1 m -95.07 160.6 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 N-CA-C 104.769 -2.308 . . . . 0.0 104.769 166.018 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 67.1 m -78.86 135.4 37.02 Favored 'General case' 0 CA--C 1.495 -1.17 0 N-CA-C 107.488 -1.301 . . . . 0.0 107.488 172.64 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.89 -140.7 0.11 Allowed 'General case' 0 N--CA 1.432 -1.328 0 N-CA-C 103.436 -2.802 . . . . 0.0 103.436 -178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 5.3 p-10 -145.49 170.51 16.25 Favored 'General case' 0 N--CA 1.423 -1.821 1 N-CA-C 96.893 -5.225 . . . . 0.0 96.893 174.594 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 63.3 mt -138.86 156.19 47.5 Favored 'General case' 0 N--CA 1.423 -1.803 1 N-CA-C 93.963 -6.31 . . . . 0.0 93.963 171.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.886 0 O-C-N 124.355 1.035 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 36.1 t70 . . . . . 0 N--CA 1.487 1.41 1 N-CA-C 98.956 -4.461 . . . . 0.0 98.956 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -71.82 -45.45 61.44 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 168.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 7.5 p -118.75 -169.75 1.78 Allowed 'General case' 0 N--CA 1.435 -1.224 0 N-CA-C 103.396 -2.816 . . . . 0.0 103.396 171.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . 0.426 ' HB ' ' SG ' ' A' ' 20' ' ' CYS . 57.0 mt -89.45 150.69 3.64 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.755 0 N-CA-C 102.835 -3.024 . . . . 0.0 102.835 165.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.1 tttm -76.05 139.29 41.34 Favored 'General case' 0 N--CA 1.439 -1.006 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 -164.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.257 86.9 m-85 71.61 24.99 3.4 Favored 'General case' 0 CA--C 1.503 -0.84 0 C-N-CA 126.248 1.819 . . . . 0.0 110.499 -173.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.9 163.0 19.32 Favored Glycine 0 CA--C 1.491 -1.449 0 N-CA-C 105.335 -3.106 . . . . 0.0 105.335 166.145 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 19.7 t80 -79.92 145.58 32.58 Favored 'General case' 0 CA--C 1.502 -0.879 0 N-CA-C 105.354 -2.091 . . . . 0.0 105.354 178.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 6.3 p -142.1 177.68 8.06 Favored 'General case' 0 N--CA 1.433 -1.294 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 -170.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.9 p 172.29 -158.76 0.01 OUTLIER 'General case' 0 N--CA 1.423 -1.784 1 N-CA-C 94.817 -5.994 . . . . 0.0 94.817 -168.169 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.3 tm? -113.86 96.18 40.33 Favored Pre-proline 0 N--CA 1.441 -0.889 0 N-CA-C 101.25 -3.611 . . . . 0.0 101.25 167.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -76.29 147.96 29.88 Favored 'Trans proline' 0 CA--C 1.501 -1.132 0 C-N-CA 122.399 2.066 . . . . 0.0 107.63 175.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 25.6 pt -92.02 -38.32 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.839 0 CA-C-N 118.231 0.469 . . . . 0.0 110.903 -171.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 72.7 mt -71.47 -37.66 71.33 Favored 'General case' 0 CA--C 1.492 -1.253 0 C-N-CA 124.279 1.031 . . . . 0.0 111.493 -160.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -133.81 143.46 48.38 Favored 'General case' 0 N--CA 1.421 -1.915 1 N-CA-C 94.119 -6.252 . . . . 0.0 94.119 164.536 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 4.2 p30 -149.52 161.27 42.46 Favored 'General case' 0 N--CA 1.423 -1.798 1 N-CA-C 98.639 -4.578 . . . . 0.0 98.639 -168.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 152.15 -165.08 30.68 Favored Glycine 0 N--CA 1.425 -2.096 1 N-CA-C 95.279 -7.128 . . . . 0.0 95.279 -168.642 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -129.3 -165.14 1.48 Allowed 'General case' 0 CA--C 1.496 -1.112 0 N-CA-C 102.192 -3.262 . . . . 0.0 102.192 173.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.426 ' SG ' ' HB ' ' A' ' 4' ' ' ILE . 84.8 m -87.52 157.94 19.05 Favored 'General case' 0 CA--C 1.484 -1.585 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 -177.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 23.0 m -64.6 -36.78 85.34 Favored 'General case' 0 C--N 1.351 0.645 0 CA-C-O 121.242 0.544 . . . . 0.0 110.183 -178.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 25.6 p -87.69 1.15 54.54 Favored 'General case' 0 N--CA 1.441 -0.88 0 C-N-CA 124.17 0.988 . . . . 0.0 110.316 177.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 89.9 -79.67 1.5 Allowed Glycine 0 N--CA 1.437 -1.249 0 O-C-N 121.421 -0.799 . . . . 0.0 111.939 173.322 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -81.57 123.31 28.54 Favored 'General case' 0 CA--C 1.497 -1.072 0 N-CA-C 113.421 0.897 . . . . 0.0 113.421 -149.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 51.0 t -96.64 127.09 42.3 Favored 'General case' 0 CA--C 1.5 -0.954 0 C-N-CA 125.435 1.494 . . . . 0.0 107.309 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -133.79 42.22 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.439 -1.008 0 N-CA-C 103.061 -2.941 . . . . 0.0 103.061 175.515 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 97.88 -56.12 1.14 Allowed Glycine 0 CA--C 1.491 -1.429 0 N-CA-C 106.118 -2.793 . . . . 0.0 106.118 -177.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.7 m -103.91 156.78 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.203 0 N-CA-C 103.019 -2.956 . . . . 0.0 103.019 163.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -89.58 143.89 26.45 Favored 'General case' 0 CA--C 1.482 -1.67 0 CA-C-O 121.172 0.511 . . . . 0.0 109.905 179.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.26 -146.75 0.19 Allowed 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 102.421 -3.177 . . . . 0.0 102.421 179.587 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -130.41 160.28 34.49 Favored 'General case' 0 N--CA 1.431 -1.406 1 N-CA-C 95.876 -5.601 . . . . 0.0 95.876 166.329 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 31.2 tp -160.69 162.73 32.67 Favored 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 95.765 -5.643 . . . . 0.0 95.765 -174.145 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.879 0 O-C-N 124.595 1.185 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 . . . . . 0 N--CA 1.497 1.881 0 N-CA-C 103.438 -2.801 . . . . 0.0 103.438 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -159.01 171.58 19.76 Favored 'General case' 0 N--CA 1.429 -1.479 1 N-CA-C 95.546 -5.724 . . . . 0.0 95.546 176.281 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.3 p -159.44 169.81 23.12 Favored 'General case' 0 N--CA 1.428 -1.559 1 N-CA-C 99.276 -4.342 . . . . 0.0 99.276 -175.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 41.1 mt -88.66 145.98 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 N-CA-C 105.75 -1.944 . . . . 0.0 105.75 -172.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -74.84 138.72 42.72 Favored 'General case' 0 N--CA 1.437 -1.08 0 C-N-CA 126.766 2.026 . . . . 0.0 109.762 -162.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.269 96.3 m-85 70.56 19.61 6.12 Favored 'General case' 0 C--N 1.355 0.827 0 C-N-CA 126.678 1.991 . . . . 0.0 111.847 -176.708 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -96.81 171.05 27.01 Favored Glycine 0 C--N 1.352 1.446 0 N-CA-C 104.473 -3.451 . . . . 0.0 104.473 163.097 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -90.13 159.36 16.82 Favored 'General case' 0 CA--C 1.494 -1.192 0 N-CA-C 106.528 -1.656 . . . . 0.0 106.528 175.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.2 p -140.5 152.47 45.62 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 -174.228 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 14.3 p -155.18 168.78 25.92 Favored 'General case' 0 N--CA 1.421 -1.912 1 N-CA-C 96.749 -5.278 . . . . 0.0 96.749 164.462 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.45 HD23 ' HA ' ' A' ' 12' ' ' LEU . 11.2 mt -157.64 172.31 6.31 Favored Pre-proline 0 N--CA 1.425 -1.681 1 N-CA-C 95.834 -5.617 . . . . 0.0 95.834 166.516 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.3 Cg_exo -61.26 132.93 43.74 Favored 'Trans proline' 0 CA--C 1.504 -1.012 0 C-N-CA 123.062 2.508 . . . . 0.0 107.201 164.311 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 40.3 pt -72.52 29.97 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.351 0.659 0 N-CA-C 115.637 1.718 . . . . 0.0 115.637 -149.445 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.5 mt -89.44 -19.05 25.61 Favored 'General case' 0 N--CA 1.437 -1.103 0 C-N-CA 125.654 1.582 . . . . 0.0 107.083 173.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 40.7 tttm -140.39 156.04 46.54 Favored 'General case' 0 N--CA 1.424 -1.774 1 N-CA-C 96.477 -5.379 . . . . 0.0 96.477 164.566 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -93.33 -22.29 19.05 Favored 'General case' 0 CA--C 1.49 -1.359 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 -178.124 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 178.68 166.68 35.2 Favored Glycine 0 N--CA 1.416 -2.698 1 N-CA-C 98.923 -5.671 . . . . 0.0 98.923 177.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 60.0 tp -118.13 90.85 3.42 Favored 'General case' 0 CA--C 1.488 -1.409 1 N-CA-C 99.534 -4.247 . . . . 0.0 99.534 165.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 93.1 m -90.17 145.39 25.06 Favored 'General case' 0 CA--C 1.485 -1.542 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 -179.553 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 59.2 m -66.87 -36.35 82.11 Favored 'General case' 0 CA--C 1.507 -0.696 0 CA-C-O 120.905 0.383 . . . . 0.0 110.929 -173.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.6 p -90.15 9.65 27.53 Favored 'General case' 0 N--CA 1.438 -1.058 0 C-N-CA 123.925 0.89 . . . . 0.0 111.158 179.257 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 108.48 -74.84 0.21 Allowed Glycine 0 C--N 1.353 1.478 0 O-C-N 121.294 -0.879 . . . . 0.0 111.439 168.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.02 141.1 30.54 Favored 'General case' 0 CA--C 1.494 -1.205 0 O-C-N 121.753 -0.851 . . . . 0.0 109.555 -162.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 25.8 t -119.81 126.62 51.43 Favored 'General case' 0 CA--C 1.487 -1.458 1 N-CA-C 98.492 -4.633 . . . . 0.0 98.492 171.653 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 5.3 p -146.47 48.29 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.128 0 N-CA-C 101.924 -3.361 . . . . 0.0 101.924 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.69 -62.67 2.65 Favored Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.151 -2.779 . . . . 0.0 106.151 -174.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.9 m -89.25 158.36 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 N-CA-C 105.397 -2.075 . . . . 0.0 105.397 167.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 56.0 m -82.1 128.96 34.65 Favored 'General case' 0 CA--C 1.49 -1.347 0 N-CA-C 105.773 -1.936 . . . . 0.0 105.773 168.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -133.78 -142.77 0.2 Allowed 'General case' 0 CA--C 1.491 -1.322 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 -178.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -151.62 168.43 24.98 Favored 'General case' 0 N--CA 1.422 -1.843 1 N-CA-C 97.734 -4.913 . . . . 0.0 97.734 -176.993 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -89.49 69.36 7.94 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 106.322 -1.733 . . . . 0.0 106.322 -174.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.363 1.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 61.2 m-20 . . . . . 0 N--CA 1.484 1.266 0 N-CA-C 101.961 -3.348 . . . . 0.0 101.961 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 49.5 m-20 -109.27 -113.38 0.3 Allowed 'General case' 0 CA--C 1.5 -0.97 0 N-CA-C 103.444 -2.799 . . . . 0.0 103.444 179.275 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 20.6 p -122.03 -179.69 4.23 Favored 'General case' 0 CA--C 1.492 -1.264 0 N-CA-C 102.888 -3.004 . . . . 0.0 102.888 171.745 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 38.0 mt -111.75 149.63 14.35 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.451 0 N-CA-C 101.791 -3.411 . . . . 0.0 101.791 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 tptp -76.43 137.42 39.71 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 125.002 1.321 . . . . 0.0 108.184 -164.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.258 75.0 m-85 74.77 15.72 3.15 Favored 'General case' 0 C--N 1.355 0.839 0 C-N-CA 127.421 2.288 . . . . 0.0 111.605 -174.051 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -93.97 169.41 29.56 Favored Glycine 0 C--N 1.351 1.406 0 N-CA-C 105.544 -3.023 . . . . 0.0 105.544 166.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 6.5 p90 -85.23 154.17 22.13 Favored 'General case' 0 CA--C 1.5 -0.962 0 N-CA-C 106.804 -1.554 . . . . 0.0 106.804 178.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 5.6 p -148.17 -173.5 4.33 Favored 'General case' 0 CA--C 1.492 -1.281 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 -173.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 13.4 p -149.83 179.54 7.94 Favored 'General case' 0 N--CA 1.423 -1.792 1 N-CA-C 96.562 -5.347 . . . . 0.0 96.562 176.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -113.84 100.98 53.39 Favored Pre-proline 0 N--CA 1.432 -1.361 0 N-CA-C 100.821 -3.77 . . . . 0.0 100.821 175.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -70.83 144.87 49.45 Favored 'Trans proline' 0 N--CA 1.453 -0.91 0 CA-C-N 122.029 1.76 . . . . 0.0 107.998 169.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 8.3 tt -77.95 -49.23 22.05 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.948 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 -169.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 73.9 mt -89.64 102.21 14.9 Favored 'General case' 0 CA--C 1.49 -1.327 0 N-CA-C 100.888 -3.745 . . . . 0.0 100.888 163.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 37.5 mtpt -59.75 106.36 0.47 Allowed 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 124.459 1.104 . . . . 0.0 111.258 -171.286 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.2 t-20 -96.0 -11.2 26.86 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -175.889 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -164.32 173.17 40.27 Favored Glycine 0 N--CA 1.424 -2.138 1 N-CA-C 98.494 -5.842 . . . . 0.0 98.494 177.112 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -157.35 175.35 14.11 Favored 'General case' 0 N--CA 1.428 -1.558 1 N-CA-C 95.061 -5.903 . . . . 0.0 95.061 177.032 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 73.0 m -88.26 153.68 21.02 Favored 'General case' 0 CA--C 1.496 -1.1 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 -177.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.5 -31.42 69.66 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.195 -0.941 . . . . 0.0 110.093 -175.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 12.3 p -87.26 9.5 20.07 Favored 'General case' 0 N--CA 1.442 -0.855 0 C-N-CA 124.749 1.22 . . . . 0.0 111.086 173.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 99.68 -78.96 0.49 Allowed Glycine 0 C--N 1.351 1.37 0 O-C-N 120.866 -1.147 . . . . 0.0 110.495 171.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.44 146.7 32.63 Favored 'General case' 0 CA--C 1.496 -1.127 0 CA-C-N 117.431 0.615 . . . . 0.0 111.368 -161.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.6 t -125.78 131.51 52.47 Favored 'General case' 0 N--CA 1.429 -1.499 1 N-CA-C 97.741 -4.911 . . . . 0.0 97.741 173.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.7 p -149.16 51.5 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.137 0 N-CA-C 101.407 -3.553 . . . . 0.0 101.407 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.01 -60.73 1.64 Allowed Glycine 0 C--N 1.351 1.364 0 N-CA-C 106.235 -2.746 . . . . 0.0 106.235 -176.777 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 11.4 m -100.28 161.34 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.196 0 N-CA-C 105.007 -2.219 . . . . 0.0 105.007 167.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 54.1 m -80.65 136.74 36.26 Favored 'General case' 0 CA--C 1.49 -1.357 0 N-CA-C 107.034 -1.469 . . . . 0.0 107.034 174.112 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.01 -165.29 2.13 Favored 'General case' 0 CA--C 1.493 -1.223 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -176.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -101.8 -172.85 2.22 Favored 'General case' 0 N--CA 1.436 -1.128 0 N-CA-C 103.643 -2.725 . . . . 0.0 103.643 170.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.416 HD12 ' HA ' ' A' ' 32' ' ' LEU . 9.2 tp -153.79 164.04 39.01 Favored 'General case' 0 N--CA 1.422 -1.839 1 N-CA-C 96.139 -5.504 . . . . 0.0 96.139 175.897 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.91 0 O-C-N 124.073 0.858 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 51.8 m-20 . . . . . 0 N--CA 1.493 1.682 1 N-CA-C 98.807 -4.516 . . . . 0.0 98.807 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.4 m-20 -93.34 -162.96 0.99 Allowed 'General case' 0 N--CA 1.44 -0.966 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 154.84 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 26.5 p -153.91 -179.21 7.64 Favored 'General case' 0 N--CA 1.426 -1.638 1 N-CA-C 97.086 -5.153 . . . . 0.0 97.086 170.367 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.1 mt -107.59 148.43 11.79 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.322 0 N-CA-C 102.083 -3.303 . . . . 0.0 102.083 173.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 53.2 tptt -86.0 142.06 29.04 Favored 'General case' 0 N--CA 1.439 -1.008 0 C-N-CA 126.061 1.745 . . . . 0.0 108.343 -162.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 52.8 m-85 70.92 14.38 6.91 Favored 'General case' 0 C--N 1.358 0.958 0 C-N-CA 126.382 1.873 . . . . 0.0 112.079 -174.586 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -98.4 167.01 22.16 Favored Glycine 0 C--N 1.351 1.415 0 N-CA-C 105.095 -3.202 . . . . 0.0 105.095 169.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 66.1 m-85 -82.19 142.44 32.18 Favored 'General case' 0 CA--C 1.5 -0.943 0 N-CA-C 107.834 -1.173 . . . . 0.0 107.834 -175.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 3.5 p -117.76 173.29 6.83 Favored 'General case' 0 CA--C 1.501 -0.918 0 N-CA-C 107.071 -1.455 . . . . 0.0 107.071 178.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 4.0 p 168.79 -145.98 0.0 OUTLIER 'General case' 0 N--CA 1.431 -1.39 1 N-CA-C 93.375 -6.528 . . . . 0.0 93.375 -173.313 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 75.6 mt -121.04 100.94 45.38 Favored Pre-proline 0 C--N 1.353 0.741 0 N-CA-C 104.469 -2.419 . . . . 0.0 104.469 165.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_endo -140.76 28.96 0.0 OUTLIER 'Trans proline' 0 CA--C 1.507 -0.87 0 CA-C-N 123.23 2.189 . . . . 0.0 108.099 -167.095 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.2 pt -126.03 -55.73 1.91 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.242 0 N-CA-C 104.702 -2.333 . . . . 0.0 104.702 179.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -124.19 -162.59 1.08 Allowed 'General case' 0 N--CA 1.432 -1.345 1 N-CA-C 98.54 -4.615 . . . . 0.0 98.54 161.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.46 34.62 1.43 Allowed 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 173.702 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 1.1 p30 -151.47 165.77 33.16 Favored 'General case' 0 N--CA 1.424 -1.756 1 N-CA-C 95.887 -5.597 . . . . 0.0 95.887 160.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -173.7 163.57 34.8 Favored Glycine 0 N--CA 1.421 -2.345 1 N-CA-C 97.283 -6.327 . . . . 0.0 97.283 179.257 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 93.6 mt -150.47 160.45 43.76 Favored 'General case' 0 CA--C 1.484 -1.595 1 N-CA-C 97.513 -4.995 . . . . 0.0 97.513 177.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 91.5 m -90.63 150.21 21.79 Favored 'General case' 0 CA--C 1.492 -1.269 0 N-CA-C 106.096 -1.816 . . . . 0.0 106.096 174.585 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -67.25 -29.5 69.15 Favored 'General case' 0 C--N 1.352 0.71 0 CA-C-N 118.713 0.688 . . . . 0.0 111.414 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -90.03 -3.05 58.19 Favored 'General case' 0 N--CA 1.438 -1.071 0 O-C-N 121.292 -0.88 . . . . 0.0 109.841 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 115.48 -79.28 0.28 Allowed Glycine 0 CA--C 1.489 -1.574 0 N-CA-C 109.829 -1.309 . . . . 0.0 109.829 170.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.19 151.4 24.87 Favored 'General case' 0 CA--C 1.498 -1.054 0 O-C-N 122.596 -0.356 . . . . 0.0 110.585 -163.172 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.8 t -123.82 131.2 53.54 Favored 'General case' 0 CA--C 1.489 -1.39 1 N-CA-C 98.553 -4.61 . . . . 0.0 98.553 178.473 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.3 p -142.67 39.03 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.1 0 N-CA-C 103.33 -2.841 . . . . 0.0 103.33 -179.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 98.61 -55.68 1.03 Allowed Glycine 0 C--N 1.351 1.409 0 N-CA-C 106.251 -2.74 . . . . 0.0 106.251 -176.636 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 12.5 m -98.21 164.3 2.41 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.124 0 N-CA-C 104.301 -2.481 . . . . 0.0 104.301 163.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 63.7 m -81.69 139.55 34.85 Favored 'General case' 0 CA--C 1.486 -1.486 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 171.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.35 -152.93 0.46 Allowed 'General case' 0 N--CA 1.434 -1.232 0 N-CA-C 104.881 -2.266 . . . . 0.0 104.881 -177.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -175.1 -171.87 0.55 Allowed 'General case' 0 N--CA 1.424 -1.742 1 N-CA-C 97.337 -5.06 . . . . 0.0 97.337 179.482 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -86.28 68.97 10.41 Favored 'General case' 0 N--CA 1.437 -1.097 0 N-CA-C 106.878 -1.527 . . . . 0.0 106.878 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.362 1.112 0 CA-C-N 116.348 -0.387 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 . . . . . 0 N--CA 1.49 1.565 0 N-CA-C 102.68 -3.081 . . . . 0.0 102.68 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 45.7 m-20 -103.94 -114.77 0.22 Allowed 'General case' 0 CA--C 1.5 -0.96 0 N-CA-C 103.177 -2.897 . . . . 0.0 103.177 170.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 29.9 p -132.17 168.23 18.38 Favored 'General case' 0 CA--C 1.484 -1.574 0 N-CA-C 100.567 -3.864 . . . . 0.0 100.567 167.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 48.1 mt -97.97 149.49 5.17 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 N-CA-C 103.854 -2.647 . . . . 0.0 103.854 175.693 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -79.06 144.55 34.5 Favored 'General case' 0 C--N 1.354 0.771 0 C-N-CA 125.132 1.373 . . . . 0.0 108.496 -163.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.263 97.2 m-85 67.78 24.36 8.27 Favored 'General case' 0 CA--C 1.503 -0.857 0 C-N-CA 127.035 2.134 . . . . 0.0 112.057 -171.603 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -95.64 170.8 28.47 Favored Glycine 0 C--N 1.35 1.361 0 N-CA-C 105.414 -3.074 . . . . 0.0 105.414 164.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -88.23 140.36 29.56 Favored 'General case' 0 N--CA 1.444 -0.769 0 N-CA-C 106.149 -1.797 . . . . 0.0 106.149 -176.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 16.9 p -141.94 -179.28 6.12 Favored 'General case' 0 CA--C 1.498 -1.027 0 CA-C-O 122.275 1.036 . . . . 0.0 109.142 -174.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.9 p -158.85 -166.78 1.95 Allowed 'General case' 0 N--CA 1.428 -1.543 1 N-CA-C 95.126 -5.879 . . . . 0.0 95.126 167.632 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.4 mp -116.65 139.03 25.04 Favored Pre-proline 0 N--CA 1.434 -1.24 1 N-CA-C 97.313 -5.069 . . . . 0.0 97.313 169.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.7 Cg_endo -82.71 27.82 0.59 Allowed 'Trans proline' 0 C--N 1.324 -0.759 0 CA-C-N 123.656 2.341 . . . . 0.0 110.997 -173.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 28.7 mm 72.85 -58.86 0.28 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.911 0 C-N-CA 128.13 2.572 . . . . 0.0 110.162 175.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -89.65 101.98 14.66 Favored 'General case' 0 CA--C 1.494 -1.18 0 N-CA-C 102.403 -3.184 . . . . 0.0 102.403 168.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 8.5 mptt -72.39 100.15 2.61 Favored 'General case' 0 CA--C 1.5 -0.947 0 C-N-CA 123.994 0.917 . . . . 0.0 109.046 -165.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 3.4 p30 -133.29 7.58 3.93 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 -176.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -157.23 150.84 22.09 Favored Glycine 0 CA--C 1.478 -2.239 1 N-CA-C 96.233 -6.747 . . . . 0.0 96.233 176.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 16.0 mt -164.29 179.59 6.72 Favored 'General case' 0 N--CA 1.426 -1.629 1 N-CA-C 96.11 -5.515 . . . . 0.0 96.11 -173.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.9 m -87.72 151.8 22.63 Favored 'General case' 0 CA--C 1.498 -1.024 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 -179.834 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.1 m -72.64 -28.5 62.78 Favored 'General case' 0 C--N 1.354 0.767 0 O-C-N 121.598 -0.689 . . . . 0.0 109.957 -178.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.5 p -90.66 11.63 21.53 Favored 'General case' 0 N--CA 1.435 -1.219 0 C-N-CA 124.36 1.064 . . . . 0.0 110.404 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 94.65 -77.72 0.93 Allowed Glycine 0 CA--C 1.491 -1.465 0 O-C-N 121.065 -1.022 . . . . 0.0 110.989 171.455 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.63 142.0 31.12 Favored 'General case' 0 CA--C 1.497 -1.092 0 CA-C-N 117.948 0.874 . . . . 0.0 109.999 -159.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 37.2 t -118.44 130.26 55.86 Favored 'General case' 0 CA--C 1.485 -1.544 1 N-CA-C 99.796 -4.15 . . . . 0.0 99.796 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.2 p -142.46 42.91 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.117 0 N-CA-C 102.962 -2.977 . . . . 0.0 102.962 178.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.34 -60.41 1.31 Allowed Glycine 0 C--N 1.352 1.455 0 N-CA-C 106.232 -2.747 . . . . 0.0 106.232 -176.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 2.9 m -94.82 157.6 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 104.242 -2.503 . . . . 0.0 104.242 164.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 50.6 m -79.4 133.25 36.56 Favored 'General case' 0 CA--C 1.486 -1.504 0 N-CA-C 106.779 -1.563 . . . . 0.0 106.779 174.359 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.55 -164.44 1.41 Allowed 'General case' 0 N--CA 1.428 -1.547 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 -176.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 10.5 p30 -134.74 168.0 19.83 Favored 'General case' 0 N--CA 1.423 -1.794 0 N-CA-C 100.752 -3.795 . . . . 0.0 100.752 179.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 73.1 mt -154.5 174.21 15.22 Favored 'General case' 0 N--CA 1.424 -1.736 1 N-CA-C 94.837 -5.986 . . . . 0.0 94.837 169.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.044 0 O-C-N 124.04 0.838 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 . . . . . 0 N--CA 1.5 2.074 0 N-CA-C 102.894 -3.002 . . . . 0.0 102.894 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -150.83 163.91 37.51 Favored 'General case' 0 CA--C 1.488 -1.407 0 N-CA-C 101.901 -3.37 . . . . 0.0 101.901 -166.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 6.2 p -103.57 166.19 10.58 Favored 'General case' 0 CA--C 1.499 -1.016 0 N-CA-C 102.223 -3.251 . . . . 0.0 102.223 166.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 35.5 mt -94.54 141.64 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.057 0 N-CA-C 106.216 -1.772 . . . . 0.0 106.216 -175.131 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -70.19 139.59 52.37 Favored 'General case' 0 N--CA 1.442 -0.872 0 C-N-CA 127.334 2.254 . . . . 0.0 110.579 -163.005 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 34.6 m-85 65.5 24.83 11.85 Favored 'General case' 0 C--N 1.355 0.841 0 C-N-CA 126.689 1.996 . . . . 0.0 113.049 -171.711 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -99.2 166.46 21.05 Favored Glycine 0 CA--C 1.493 -1.324 0 N-CA-C 105.056 -3.218 . . . . 0.0 105.056 164.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -66.6 148.2 52.23 Favored 'General case' 0 CA--C 1.502 -0.9 0 C-N-CA 125.399 1.48 . . . . 0.0 107.167 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 27.4 p -143.83 178.72 7.63 Favored 'General case' 0 CA--C 1.483 -1.612 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 178.058 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -168.83 -169.9 1.08 Allowed 'General case' 0 N--CA 1.415 -2.224 1 N-CA-C 95.356 -5.794 . . . . 0.0 95.356 -170.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -108.42 -56.08 0.05 OUTLIER Pre-proline 0 N--CA 1.442 -0.844 0 N-CA-C 106.032 -1.84 . . . . 0.0 106.032 173.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_endo -71.46 148.19 53.76 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 CA-C-N 124.541 2.657 . . . . 0.0 110.165 166.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -142.75 -90.16 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.083 0 N-CA-C 101.636 -3.468 . . . . 0.0 101.636 169.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 75.1 mt -85.06 -57.79 2.95 Favored 'General case' 0 CA--C 1.494 -1.173 0 N-CA-C 106.889 -1.522 . . . . 0.0 106.889 175.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 45.3 mmtm -119.73 -69.44 0.85 Allowed 'General case' 0 N--CA 1.436 -1.142 0 N-CA-C 104.232 -2.507 . . . . 0.0 104.232 177.833 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -153.52 173.9 15.11 Favored 'General case' 0 CA--C 1.484 -1.587 1 N-CA-C 96.619 -5.326 . . . . 0.0 96.619 175.198 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -164.61 179.66 39.21 Favored Glycine 0 N--CA 1.419 -2.445 1 N-CA-C 98.456 -5.857 . . . . 0.0 98.456 177.759 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 15.4 tp -160.9 175.47 12.49 Favored 'General case' 0 N--CA 1.423 -1.803 1 N-CA-C 95.913 -5.588 . . . . 0.0 95.913 173.153 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 94.0 m -90.25 153.66 20.31 Favored 'General case' 0 CA--C 1.489 -1.393 0 N-CA-C 108.975 -0.75 . . . . 0.0 108.975 -172.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 33.7 m -71.58 -30.4 65.79 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -175.752 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 2.8 p -90.09 -1.9 58.02 Favored 'General case' 0 N--CA 1.439 -0.991 0 C-N-CA 124.83 1.252 . . . . 0.0 110.245 177.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 109.86 -70.26 0.21 Allowed Glycine 0 CA--C 1.49 -1.503 0 N-CA-C 110.405 -1.078 . . . . 0.0 110.405 172.0 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -84.61 145.68 27.9 Favored 'General case' 0 CA--C 1.5 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 -161.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 35.2 t -132.22 133.03 43.68 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 100.726 -3.805 . . . . 0.0 100.726 -177.665 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.6 p -127.68 -125.81 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.441 -0.885 1 N-CA-C 98.563 -4.606 . . . . 0.0 98.563 161.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -76.58 -9.17 86.25 Favored Glycine 0 C--N 1.349 1.276 0 O-C-N 118.316 -2.74 . . . . 0.0 110.801 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.5 m -148.12 161.58 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.755 1 N-CA-C 99.482 -4.266 . . . . 0.0 99.482 -172.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 97.8 m -78.7 136.57 37.47 Favored 'General case' 0 CA--C 1.489 -1.376 0 N-CA-C 108.614 -0.884 . . . . 0.0 108.614 176.944 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.28 -165.46 1.5 Allowed 'General case' 0 N--CA 1.435 -1.223 0 N-CA-C 106.249 -1.76 . . . . 0.0 106.249 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -159.87 175.11 13.46 Favored 'General case' 0 N--CA 1.421 -1.9 1 N-CA-C 99.108 -4.404 . . . . 0.0 99.108 -174.319 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 16.3 mt -149.49 173.79 13.21 Favored 'General case' 0 N--CA 1.429 -1.518 1 N-CA-C 94.478 -6.119 . . . . 0.0 94.478 168.358 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.896 0 O-C-N 124.087 0.867 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.9 p30 . . . . . 0 N--CA 1.491 1.592 0 N-CA-C 102.971 -2.974 . . . . 0.0 102.971 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 53.6 m-20 -90.6 -133.53 0.11 Allowed 'General case' 0 N--CA 1.445 -0.72 0 N-CA-C 105.706 -1.961 . . . . 0.0 105.706 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 31.7 p -123.02 168.98 11.66 Favored 'General case' 0 CA--C 1.488 -1.429 0 N-CA-C 100.513 -3.884 . . . . 0.0 100.513 163.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.5 mt -100.68 154.47 4.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.159 0 N-CA-C 103.669 -2.715 . . . . 0.0 103.669 173.107 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 3.2 ttpm? -79.89 142.08 35.51 Favored 'General case' 0 N--CA 1.44 -0.966 0 C-N-CA 125.294 1.437 . . . . 0.0 108.53 -161.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 62.54 42.3 8.76 Favored 'General case' 0 CA--C 1.502 -0.896 0 C-N-CA 126.148 1.779 . . . . 0.0 111.091 -173.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -123.57 173.28 16.44 Favored Glycine 0 C--N 1.35 1.334 1 N-CA-C 102.348 -4.301 . . . . 0.0 102.348 162.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -89.86 145.86 24.85 Favored 'General case' 0 CA--C 1.493 -1.24 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 -175.064 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.8 p -135.9 -170.44 2.63 Favored 'General case' 0 N--CA 1.433 -1.279 0 N-CA-C 105.418 -2.067 . . . . 0.0 105.418 -177.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 20.9 p -169.48 -168.12 0.77 Allowed 'General case' 0 N--CA 1.421 -1.909 1 N-CA-C 97.63 -4.952 . . . . 0.0 97.63 179.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -116.31 118.34 37.73 Favored Pre-proline 0 N--CA 1.435 -1.208 1 N-CA-C 99.227 -4.36 . . . . 0.0 99.227 172.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 80.1 Cg_exo -74.41 -57.16 0.06 OUTLIER 'Trans proline' 0 CA--C 1.507 -0.835 0 CA-C-N 123.039 2.121 . . . . 0.0 113.263 -172.438 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 3.1 tp -151.06 -50.67 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.495 -1.169 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 -176.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 80.3 mt -125.58 -163.1 1.17 Allowed 'General case' 0 N--CA 1.435 -1.177 0 N-CA-C 102.293 -3.225 . . . . 0.0 102.293 170.036 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 54.1 mtmt -87.44 65.4 8.63 Favored 'General case' 0 N--CA 1.44 -0.964 0 N-CA-C 106.392 -1.707 . . . . 0.0 106.392 171.335 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 2.7 p-10 -100.94 12.48 37.58 Favored 'General case' 0 CA--C 1.507 -0.673 0 C-N-CA 124.186 0.994 . . . . 0.0 109.728 -173.483 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -166.75 164.26 37.63 Favored Glycine 0 N--CA 1.429 -1.827 1 N-CA-C 96.364 -6.694 . . . . 0.0 96.364 174.282 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 17.0 tp -163.39 178.68 7.9 Favored 'General case' 0 N--CA 1.428 -1.569 1 N-CA-C 96.791 -5.262 . . . . 0.0 96.791 177.767 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 77.7 m -89.71 148.11 23.46 Favored 'General case' 0 CA--C 1.488 -1.404 0 N-CA-C 107.046 -1.464 . . . . 0.0 107.046 -179.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.3 m -69.29 -28.56 66.39 Favored 'General case' 0 C--N 1.35 0.617 0 CA-C-O 121.12 0.486 . . . . 0.0 110.183 -176.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 7.2 p -90.31 11.17 22.16 Favored 'General case' 0 N--CA 1.439 -0.996 0 C-N-CA 124.622 1.169 . . . . 0.0 110.833 175.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 96.69 -68.75 0.88 Allowed Glycine 0 CA--C 1.492 -1.359 0 O-C-N 120.672 -1.268 . . . . 0.0 111.704 165.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -85.78 142.66 28.8 Favored 'General case' 0 CA--C 1.496 -1.099 0 O-C-N 121.272 -1.134 . . . . 0.0 109.698 -164.249 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 17.3 t -132.93 127.48 34.38 Favored 'General case' 0 CA--C 1.486 -1.487 1 N-CA-C 99.653 -4.202 . . . . 0.0 99.653 178.554 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 2.5 p -152.44 62.8 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.161 0 N-CA-C 101.712 -3.44 . . . . 0.0 101.712 172.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 91.18 -63.41 2.76 Favored Glycine 0 C--N 1.351 1.414 0 N-CA-C 106.993 -2.443 . . . . 0.0 106.993 -177.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 6.0 m -91.65 155.33 3.09 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.21 0 N-CA-C 105.528 -2.027 . . . . 0.0 105.528 168.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 41.2 m -80.24 122.67 27.16 Favored 'General case' 0 CA--C 1.487 -1.445 0 N-CA-C 106.17 -1.789 . . . . 0.0 106.17 166.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -125.55 -147.56 0.37 Allowed 'General case' 0 N--CA 1.432 -1.365 0 N-CA-C 104.177 -2.527 . . . . 0.0 104.177 -177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.4 p-10 -146.91 164.92 31.36 Favored 'General case' 0 N--CA 1.42 -1.965 1 N-CA-C 95.58 -5.711 . . . . 0.0 95.58 -179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 6.1 tp -123.56 116.88 23.87 Favored 'General case' 0 N--CA 1.43 -1.433 0 N-CA-C 101.385 -3.561 . . . . 0.0 101.385 -176.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.36 1.036 0 O-C-N 123.256 0.348 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 44.7 m-20 . . . . . 0 N--CA 1.495 1.801 0 N-CA-C 102.113 -3.292 . . . . 0.0 102.113 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 22.2 m-20 -157.36 177.48 11.39 Favored 'General case' 0 N--CA 1.428 -1.526 1 N-CA-C 97.184 -5.117 . . . . 0.0 97.184 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 1.2 p -147.39 166.81 26.05 Favored 'General case' 0 N--CA 1.427 -1.621 1 N-CA-C 96.47 -5.381 . . . . 0.0 96.47 167.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 33.0 mt -89.43 140.6 15.58 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 104.642 -2.355 . . . . 0.0 104.642 -177.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 74.6 tttt -85.46 148.28 26.06 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 -158.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . 0.306 68.3 m-85 58.75 31.37 21.12 Favored 'General case' 0 N--CA 1.443 -0.806 0 C-N-CA 127.694 2.397 . . . . 0.0 113.213 -170.322 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.36 168.65 16.66 Favored Glycine 0 N--CA 1.437 -1.298 0 N-CA-C 103.345 -3.902 . . . . 0.0 103.345 158.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 m-85 -87.86 143.89 26.88 Favored 'General case' 0 CA--C 1.495 -1.173 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 -179.002 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 7.4 p -117.17 -118.35 0.32 Allowed 'General case' 0 N--CA 1.433 -1.308 0 N-CA-C 102.488 -3.153 . . . . 0.0 102.488 174.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 86.5 p -154.13 -136.85 0.06 Allowed 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 102.65 -3.092 . . . . 0.0 102.65 170.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 78.5 mt -148.94 155.01 40.57 Favored Pre-proline 0 N--CA 1.425 -1.719 1 N-CA-C 99.658 -4.201 . . . . 0.0 99.658 -176.455 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_endo -74.85 5.3 3.99 Favored 'Trans proline' 0 CA--C 1.508 -0.804 0 C-N-CA 123.896 3.064 . . . . 0.0 112.649 -175.64 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 17.5 tt -94.71 -12.14 8.69 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.086 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 174.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 88.6 mt -108.95 -72.08 0.74 Allowed 'General case' 0 CA--C 1.489 -1.401 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 -176.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 18.3 mtmm -124.15 -96.95 0.45 Allowed 'General case' 0 N--CA 1.433 -1.298 0 N-CA-C 101.545 -3.502 . . . . 0.0 101.545 171.503 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 177.66 -165.2 0.04 OUTLIER 'General case' 0 N--CA 1.431 -1.381 1 N-CA-C 96.52 -5.363 . . . . 0.0 96.52 179.172 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -170.35 144.67 8.57 Favored Glycine 0 CA--C 1.477 -2.282 1 N-CA-C 102.417 -4.273 . . . . 0.0 102.417 169.196 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 5.6 mp -117.48 101.93 8.79 Favored 'General case' 0 CA--C 1.488 -1.433 0 N-CA-C 103.193 -2.892 . . . . 0.0 103.193 178.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 88.1 m -90.7 149.06 22.21 Favored 'General case' 0 CA--C 1.489 -1.386 0 C-N-CA 124.396 1.079 . . . . 0.0 108.42 -175.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 38.9 m -66.9 -36.11 81.53 Favored 'General case' 0 C--N 1.351 0.637 0 CA-C-O 121.026 0.441 . . . . 0.0 111.516 -174.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.6 p -90.34 15.04 11.27 Favored 'General case' 0 N--CA 1.444 -0.75 0 C-N-CA 123.846 0.858 . . . . 0.0 111.114 177.308 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 98.47 -67.7 0.69 Allowed Glycine 0 CA--C 1.489 -1.545 0 O-C-N 121.128 -0.983 . . . . 0.0 110.722 167.777 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.03 133.07 35.26 Favored 'General case' 0 CA--C 1.5 -0.946 0 O-C-N 121.639 -0.918 . . . . 0.0 110.252 -166.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 12.5 t -123.61 122.48 38.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 100.487 -3.894 . . . . 0.0 100.487 176.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -151.21 65.45 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 103.228 -2.879 . . . . 0.0 103.228 175.838 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 88.25 -62.84 3.78 Favored Glycine 0 CA--C 1.489 -1.56 0 N-CA-C 107.069 -2.412 . . . . 0.0 107.069 -177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.8 m -99.65 159.44 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.552 0 N-CA-C 104.756 -2.312 . . . . 0.0 104.756 171.725 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 66.1 m -83.42 128.43 34.5 Favored 'General case' 0 CA--C 1.493 -1.243 0 N-CA-C 106.938 -1.504 . . . . 0.0 106.938 170.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -139.45 -152.36 0.41 Allowed 'General case' 0 N--CA 1.432 -1.333 0 N-CA-C 104.502 -2.406 . . . . 0.0 104.502 -174.08 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -143.16 173.03 11.94 Favored 'General case' 0 N--CA 1.424 -1.743 1 N-CA-C 97.371 -5.048 . . . . 0.0 97.371 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 61.6 mt -149.52 166.25 29.75 Favored 'General case' 0 N--CA 1.419 -1.985 1 N-CA-C 93.939 -6.319 . . . . 0.0 93.939 174.254 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 0.769 0 O-C-N 124.115 0.885 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 22.4 t70 . . . . . 0 N--CA 1.489 1.524 0 N-CA-C 104.979 -2.23 . . . . 0.0 104.979 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -102.69 -106.17 0.27 Allowed 'General case' 0 N--CA 1.441 -0.894 0 N-CA-C 103.681 -2.711 . . . . 0.0 103.681 179.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p -97.47 160.02 14.57 Favored 'General case' 0 CA--C 1.495 -1.138 0 N-CA-C 104.215 -2.513 . . . . 0.0 104.215 167.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.3 mt -95.52 146.37 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 N-CA-C 105.786 -1.931 . . . . 0.0 105.786 -175.396 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 ttpp -70.05 142.21 52.74 Favored 'General case' 0 N--CA 1.443 -0.807 0 C-N-CA 127.074 2.149 . . . . 0.0 110.197 -167.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 62.52 28.02 16.53 Favored 'General case' 0 C--N 1.355 0.816 0 C-N-CA 126.186 1.794 . . . . 0.0 113.046 -170.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -97.16 167.18 23.66 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 103.784 -3.726 . . . . 0.0 103.784 160.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 53.4 m-85 -82.66 141.44 32.48 Favored 'General case' 0 CA--C 1.495 -1.149 0 N-CA-C 106.631 -1.618 . . . . 0.0 106.631 176.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p -108.39 -177.84 3.43 Favored 'General case' 0 N--CA 1.435 -1.205 0 CA-C-O 122.403 1.097 . . . . 0.0 109.933 -169.429 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 2.9 p -174.49 -156.55 0.07 Allowed 'General case' 0 N--CA 1.422 -1.826 1 N-CA-C 95.168 -5.864 . . . . 0.0 95.168 -171.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -149.1 -174.23 0.4 Allowed Pre-proline 0 N--CA 1.435 -1.221 1 N-CA-C 98.763 -4.532 . . . . 0.0 98.763 -169.33 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 83.1 Cg_exo -59.48 149.99 78.41 Favored 'Trans proline' 0 CA--C 1.507 -0.87 0 C-N-CA 123.652 2.902 . . . . 0.0 112.049 166.332 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . 0.424 HG23 ' H ' ' A' ' 15' ' ' LEU . 4.6 tp -164.6 -51.42 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.498 -1.032 0 N-CA-C 100.937 -3.727 . . . . 0.0 100.937 -176.766 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.424 ' H ' HG23 ' A' ' 14' ' ' ILE . 66.6 mt -115.0 -158.28 0.66 Allowed 'General case' 0 N--CA 1.434 -1.23 1 N-CA-C 99.238 -4.356 . . . . 0.0 99.238 159.403 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -68.02 120.09 13.7 Favored 'General case' 0 CA--C 1.502 -0.867 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 174.043 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -176.26 -171.97 0.45 Allowed 'General case' 0 N--CA 1.425 -1.682 1 N-CA-C 96.538 -5.356 . . . . 0.0 96.538 -168.22 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -174.16 -163.28 27.29 Favored Glycine 0 CA--C 1.474 -2.507 1 N-CA-C 100.697 -4.961 . . . . 0.0 100.697 -167.817 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -88.96 -161.79 0.8 Allowed 'General case' 0 N--CA 1.435 -1.217 0 N-CA-C 105.513 -2.032 . . . . 0.0 105.513 178.372 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 75.2 m -90.0 155.58 18.99 Favored 'General case' 0 N--CA 1.428 -1.561 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -178.526 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 55.8 m -70.16 -31.93 69.66 Favored 'General case' 0 N--CA 1.445 -0.694 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -173.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.41 9.79 27.68 Favored 'General case' 0 N--CA 1.442 -0.834 0 C-N-CA 124.268 1.027 . . . . 0.0 110.43 175.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 101.27 -72.82 0.38 Allowed Glycine 0 CA--C 1.489 -1.554 0 N-CA-C 110.258 -1.137 . . . . 0.0 110.258 170.754 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.79 151.95 25.9 Favored 'General case' 0 CA--C 1.498 -1.021 0 O-C-N 122.192 -0.593 . . . . 0.0 111.286 -162.165 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 1.9 t -138.23 133.61 33.41 Favored 'General case' 0 CA--C 1.485 -1.528 1 N-CA-C 97.315 -5.069 . . . . 0.0 97.315 -175.151 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.4 p -158.19 55.98 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.438 -1.027 0 N-CA-C 102.975 -2.972 . . . . 0.0 102.975 175.438 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.67 -64.23 2.16 Favored Glycine 0 C--N 1.35 1.356 0 N-CA-C 106.113 -2.795 . . . . 0.0 106.113 -176.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 5.3 m -92.43 159.85 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.135 0 N-CA-C 105.104 -2.184 . . . . 0.0 105.104 168.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 58.6 m -79.92 139.54 37.05 Favored 'General case' 0 CA--C 1.489 -1.403 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 168.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -145.62 -149.39 0.28 Allowed 'General case' 0 CA--C 1.494 -1.186 0 N-CA-C 104.38 -2.452 . . . . 0.0 104.38 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -142.22 167.46 22.06 Favored 'General case' 0 N--CA 1.425 -1.695 1 N-CA-C 96.513 -5.366 . . . . 0.0 96.513 173.188 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 71.8 mt -153.46 167.88 27.98 Favored 'General case' 0 N--CA 1.425 -1.688 1 N-CA-C 94.927 -5.953 . . . . 0.0 94.927 176.308 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.885 0 O-C-N 124.114 0.884 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 11.5 p-10 . . . . . 0 N--CA 1.496 1.837 0 N-CA-C 104.202 -2.518 . . . . 0.0 104.202 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -145.39 156.02 43.52 Favored 'General case' 0 N--CA 1.429 -1.51 1 N-CA-C 95.339 -5.8 . . . . 0.0 95.339 172.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 2.0 p -165.83 169.17 15.25 Favored 'General case' 0 N--CA 1.425 -1.7 1 N-CA-C 99.738 -4.171 . . . . 0.0 99.738 -177.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 22.0 mm -93.37 144.4 9.54 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.158 0 N-CA-C 105.308 -2.108 . . . . 0.0 105.308 -177.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -68.97 145.76 53.33 Favored 'General case' 0 N--CA 1.437 -1.097 0 C-N-CA 127.853 2.461 . . . . 0.0 108.604 -170.582 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 68.0 28.96 6.63 Favored 'General case' 0 CA--C 1.503 -0.848 0 C-N-CA 125.58 1.552 . . . . 0.0 112.56 -174.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -106.67 166.49 13.67 Favored Glycine 0 C--N 1.349 1.296 0 N-CA-C 104.293 -3.523 . . . . 0.0 104.293 163.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 45.7 m-85 -81.35 134.37 35.56 Favored 'General case' 0 CA--C 1.503 -0.834 0 CA-C-N 118.253 1.026 . . . . 0.0 108.251 -175.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.5 p -106.82 78.98 1.29 Allowed 'General case' 0 CA--C 1.504 -0.816 0 CA-C-O 122.518 1.151 . . . . 0.0 108.44 -179.434 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.6 p -146.68 167.45 23.77 Favored 'General case' 0 N--CA 1.423 -1.801 1 N-CA-C 98.088 -4.782 . . . . 0.0 98.088 170.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 61.1 mt -154.1 -175.96 0.55 Allowed Pre-proline 0 N--CA 1.432 -1.356 1 N-CA-C 95.797 -5.631 . . . . 0.0 95.797 175.791 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 62.5 Cg_exo -58.46 110.93 0.73 Allowed 'Trans proline' 0 N--CA 1.456 -0.68 0 CA-C-N 123.917 2.435 . . . . 0.0 109.422 165.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 9.0 tp -83.54 96.03 3.97 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.072 0 CA-C-O 123.265 1.507 . . . . 0.0 110.038 -147.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 45.5 mt -158.69 -54.91 0.07 Allowed 'General case' 0 CA--C 1.482 -1.654 1 N-CA-C 97.247 -5.094 . . . . 0.0 97.247 178.055 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 95.7 mttt -88.66 159.27 17.92 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 103.825 -2.658 . . . . 0.0 103.825 163.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 42.7 t-20 -149.47 173.78 13.21 Favored 'General case' 0 N--CA 1.431 -1.405 1 N-CA-C 96.258 -5.46 . . . . 0.0 96.258 166.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -102.67 -162.42 26.02 Favored Glycine 0 CA--C 1.494 -1.255 0 N-CA-C 105.65 -2.98 . . . . 0.0 105.65 177.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -128.33 156.08 43.64 Favored 'General case' 0 CA--C 1.485 -1.545 1 N-CA-C 98.839 -4.504 . . . . 0.0 98.839 175.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 87.1 m -90.74 142.47 27.72 Favored 'General case' 0 CA--C 1.489 -1.372 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 178.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 57.4 m -66.77 -36.11 81.65 Favored 'General case' 0 C--N 1.353 0.755 0 CA-C-O 121.182 0.515 . . . . 0.0 110.749 -175.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.6 p -90.38 10.21 25.93 Favored 'General case' 0 N--CA 1.441 -0.918 0 C-N-CA 123.53 0.732 . . . . 0.0 111.518 178.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.21 -47.92 1.07 Allowed Glycine 0 C--N 1.35 1.327 0 O-C-N 121.24 -0.912 . . . . 0.0 112.954 163.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -104.82 143.16 33.51 Favored 'General case' 0 CA--C 1.489 -1.371 0 CA-C-N 119.042 1.421 . . . . 0.0 107.524 -167.844 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 11.9 t -123.86 136.48 54.39 Favored 'General case' 0 CA--C 1.484 -1.584 1 N-CA-C 98.463 -4.643 . . . . 0.0 98.463 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.5 p -149.6 43.57 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.164 0 N-CA-C 103.111 -2.922 . . . . 0.0 103.111 176.041 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 96.49 -56.05 1.43 Allowed Glycine 0 C--N 1.354 1.529 0 N-CA-C 106.615 -2.594 . . . . 0.0 106.615 -176.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 8.2 m -99.51 160.44 3.38 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.172 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 164.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 89.9 m -80.12 148.06 31.13 Favored 'General case' 0 CA--C 1.488 -1.411 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 172.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.62 -146.62 0.2 Allowed 'General case' 0 N--CA 1.431 -1.388 0 N-CA-C 102.62 -3.104 . . . . 0.0 102.62 178.722 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -147.97 -178.22 6.16 Favored 'General case' 0 N--CA 1.427 -1.594 1 N-CA-C 96.372 -5.418 . . . . 0.0 96.372 175.06 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 96.0 mt -135.88 155.23 50.63 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 94.364 -6.161 . . . . 0.0 94.364 169.627 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 0.812 0 O-C-N 124.469 1.105 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 41.7 m-20 . . . . . 0 N--CA 1.501 2.079 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -97.65 -68.91 0.78 Allowed 'General case' 0 CA--C 1.493 -1.222 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 174.162 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 19.9 p -140.37 170.79 15.16 Favored 'General case' 0 N--CA 1.422 -1.85 1 N-CA-C 95.539 -5.726 . . . . 0.0 95.539 161.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 36.5 mt -100.21 143.96 13.13 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.457 0 N-CA-C 104.622 -2.362 . . . . 0.0 104.622 176.122 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 39.5 ttpt -75.74 145.94 40.45 Favored 'General case' 0 N--CA 1.439 -0.989 0 C-N-CA 126.678 1.991 . . . . 0.0 108.22 -164.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 31.6 m-85 71.06 16.23 6.43 Favored 'General case' 0 CA--C 1.504 -0.789 0 C-N-CA 126.272 1.829 . . . . 0.0 111.992 -171.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.37 165.25 28.7 Favored Glycine 0 C--N 1.351 1.412 0 N-CA-C 105.696 -2.961 . . . . 0.0 105.696 169.748 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 21.5 t80 -88.33 138.67 31.23 Favored 'General case' 0 CA--C 1.504 -0.82 0 N-CA-C 105.407 -2.072 . . . . 0.0 105.407 -178.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.1 p -135.09 156.86 48.29 Favored 'General case' 0 CA--C 1.49 -1.358 0 N-CA-C 107.415 -1.328 . . . . 0.0 107.415 -170.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 167.57 -174.48 0.02 OUTLIER 'General case' 0 N--CA 1.428 -1.545 1 N-CA-C 97.248 -5.093 . . . . 0.0 97.248 163.254 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 60.8 tp -150.02 144.82 18.0 Favored Pre-proline 0 N--CA 1.425 -1.69 1 N-CA-C 94.428 -6.138 . . . . 0.0 94.428 163.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.6 Cg_exo -69.37 -28.28 27.3 Favored 'Trans proline' 0 CA--C 1.506 -0.891 0 CA-C-N 126.947 3.517 . . . . 0.0 113.702 -165.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 19.4 tt -86.18 -32.06 6.67 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.79 0 N-CA-C 109.816 -0.439 . . . . 0.0 109.816 -174.198 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 83.0 mt -102.89 -16.39 15.89 Favored 'General case' 0 CA--C 1.5 -0.981 0 O-C-N 121.485 -0.759 . . . . 0.0 110.676 -174.313 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp 68.17 8.58 6.65 Favored 'General case' 0 C--N 1.355 0.805 0 C-N-CA 126.616 1.966 . . . . 0.0 111.783 -179.082 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 24.8 m-80 -149.32 153.34 37.32 Favored 'General case' 0 CA--C 1.478 -1.793 1 N-CA-C 97.839 -4.874 . . . . 0.0 97.839 -170.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -148.8 154.71 25.99 Favored Glycine 0 N--CA 1.424 -2.102 1 N-CA-C 96.113 -6.795 . . . . 0.0 96.113 171.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 65.8 mt -74.54 119.49 18.8 Favored 'General case' 0 CA--C 1.493 -1.22 0 CA-C-N 118.172 0.986 . . . . 0.0 110.409 -164.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 86.1 m -90.24 148.34 22.97 Favored 'General case' 0 N--CA 1.432 -1.353 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 177.406 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -74.03 -15.19 61.09 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 122.316 -0.24 . . . . 0.0 110.911 178.098 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 9.4 p -86.35 -25.33 25.43 Favored 'General case' 0 N--CA 1.433 -1.292 0 N-CA-C 108.687 -0.857 . . . . 0.0 108.687 176.319 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 122.06 -75.01 0.36 Allowed Glycine 0 CA--C 1.485 -1.81 0 N-CA-C 107.522 -2.231 . . . . 0.0 107.522 -176.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.13 34.79 Favored 'General case' 0 CA--C 1.494 -1.192 0 O-C-N 122.189 -0.595 . . . . 0.0 110.202 -168.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 15.1 t -119.02 130.41 55.64 Favored 'General case' 0 CA--C 1.481 -1.69 1 N-CA-C 96.186 -5.487 . . . . 0.0 96.186 173.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.5 p -146.88 44.78 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 -178.404 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.96 -60.63 1.99 Allowed Glycine 0 C--N 1.353 1.488 0 N-CA-C 106.639 -2.584 . . . . 0.0 106.639 -176.004 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.2 m -95.57 164.17 2.19 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.135 0 N-CA-C 104.511 -2.403 . . . . 0.0 104.511 164.463 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 83.3 m -80.85 134.54 35.78 Favored 'General case' 0 CA--C 1.488 -1.435 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 170.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -154.37 -163.42 1.6 Allowed 'General case' 0 CA--C 1.485 -1.54 0 N-CA-C 103.717 -2.697 . . . . 0.0 103.717 -174.972 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -162.32 172.27 15.93 Favored 'General case' 0 N--CA 1.423 -1.81 1 N-CA-C 95.284 -5.821 . . . . 0.0 95.284 173.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 5.9 mp -142.73 146.86 34.76 Favored 'General case' 0 N--CA 1.426 -1.637 1 N-CA-C 94.497 -6.112 . . . . 0.0 94.497 170.247 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.883 0 O-C-N 124.704 1.252 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 62.6 m-20 . . . . . 0 N--CA 1.499 2.007 0 N-CA-C 104.721 -2.325 . . . . 0.0 104.721 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 49.4 t0 -162.57 -178.92 6.53 Favored 'General case' 0 N--CA 1.428 -1.536 1 N-CA-C 95.727 -5.657 . . . . 0.0 95.727 174.02 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 27.6 p -150.92 173.74 13.92 Favored 'General case' 0 N--CA 1.424 -1.728 1 N-CA-C 99.091 -4.411 . . . . 0.0 99.091 173.47 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 25.1 mt -97.56 148.59 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.334 0 N-CA-C 103.212 -2.884 . . . . 0.0 103.212 171.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.4 ttpp -77.26 139.4 39.83 Favored 'General case' 0 N--CA 1.44 -0.943 0 C-N-CA 125.508 1.523 . . . . 0.0 109.092 -162.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 77.3 m-85 68.65 29.09 5.52 Favored 'General case' 0 CA--C 1.5 -0.962 0 C-N-CA 126.307 1.843 . . . . 0.0 110.795 -176.145 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -104.61 170.51 18.31 Favored Glycine 0 C--N 1.35 1.316 0 N-CA-C 103.556 -3.818 . . . . 0.0 103.556 161.345 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 89.8 m-85 -82.26 156.21 24.46 Favored 'General case' 0 CA--C 1.499 -1.006 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -176.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 25.7 p -155.48 -170.6 3.5 Favored 'General case' 0 CA--C 1.489 -1.393 1 N-CA-C 98.723 -4.547 . . . . 0.0 98.723 170.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -161.23 175.83 11.9 Favored 'General case' 0 N--CA 1.425 -1.702 1 N-CA-C 99.155 -4.387 . . . . 0.0 99.155 -169.831 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 90.2 mt -94.73 163.72 21.65 Favored Pre-proline 0 N--CA 1.441 -0.924 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -172.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -73.65 41.25 0.6 Allowed 'Trans proline' 0 CA--C 1.518 -0.298 0 C-N-CA 124.308 3.339 . . . . 0.0 113.095 -176.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 6.7 tp -105.95 -17.02 7.85 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.168 0 N-CA-C 104.437 -2.431 . . . . 0.0 104.437 164.517 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 77.9 mt -127.38 -137.38 0.25 Allowed 'General case' 0 CA--C 1.484 -1.561 0 N-CA-C 101.605 -3.48 . . . . 0.0 101.605 175.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 24.6 pttm -87.14 152.56 22.23 Favored 'General case' 0 N--CA 1.431 -1.405 0 N-CA-C 104.218 -2.512 . . . . 0.0 104.218 175.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 16.7 p-10 -150.72 -171.99 4.07 Favored 'General case' 0 N--CA 1.425 -1.692 1 N-CA-C 99.484 -4.265 . . . . 0.0 99.484 167.51 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -177.69 -175.49 44.94 Favored Glycine 0 N--CA 1.414 -2.787 1 N-CA-C 95.828 -6.909 . . . . 0.0 95.828 176.295 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 49.2 tp -94.04 141.42 28.55 Favored 'General case' 0 N--CA 1.432 -1.359 0 N-CA-C 103.267 -2.864 . . . . 0.0 103.267 178.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 72.0 m -90.5 151.26 21.44 Favored 'General case' 0 CA--C 1.49 -1.365 0 N-CA-C 105.03 -2.211 . . . . 0.0 105.03 174.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 2.0 m -67.92 -28.38 67.44 Favored 'General case' 0 C--N 1.349 0.579 0 CA-C-N 119.687 1.13 . . . . 0.0 110.229 -177.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 8.9 p -90.28 10.42 24.85 Favored 'General case' 0 N--CA 1.438 -1.075 0 C-N-CA 125.336 1.454 . . . . 0.0 110.407 174.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 92.25 -69.28 1.83 Allowed Glycine 0 CA--C 1.491 -1.408 0 O-C-N 120.941 -1.1 . . . . 0.0 111.152 168.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -79.77 141.9 35.86 Favored 'General case' 0 CA--C 1.495 -1.154 0 N-CA-C 109.603 -0.518 . . . . 0.0 109.603 -162.054 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 40.1 t -137.07 145.78 44.37 Favored 'General case' 0 N--CA 1.422 -1.837 1 N-CA-C 97.811 -4.885 . . . . 0.0 97.811 -175.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.5 p -160.69 -140.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.427 -1.609 1 N-CA-C 92.667 -6.79 . . . . 0.0 92.667 175.836 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -72.7 -4.44 61.64 Favored Glycine 0 C--N 1.348 1.235 0 CA-C-N 122.92 2.6 . . . . 0.0 113.019 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.6 m -143.72 163.53 15.47 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.668 0 N-CA-C 100.436 -3.913 . . . . 0.0 100.436 179.212 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 59.1 m -86.69 133.46 33.68 Favored 'General case' 0 CA--C 1.485 -1.522 0 N-CA-C 105.965 -1.865 . . . . 0.0 105.965 168.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.22 -154.93 0.54 Allowed 'General case' 0 CA--C 1.486 -1.49 0 N-CA-C 102.874 -3.01 . . . . 0.0 102.874 -179.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.22 40.26 Favored 'General case' 0 N--CA 1.427 -1.621 1 N-CA-C 96.281 -5.451 . . . . 0.0 96.281 174.332 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 79.4 mt -152.83 168.03 27.08 Favored 'General case' 0 N--CA 1.424 -1.74 1 N-CA-C 94.663 -6.051 . . . . 0.0 94.663 178.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.892 0 O-C-N 124.093 0.871 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.497 1.92 0 N-CA-C 104.236 -2.505 . . . . 0.0 104.236 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 41.5 m-20 -155.07 165.7 35.91 Favored 'General case' 0 N--CA 1.427 -1.58 1 N-CA-C 96.284 -5.45 . . . . 0.0 96.284 179.069 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 9.7 p -171.32 -175.72 1.72 Allowed 'General case' 0 N--CA 1.423 -1.82 1 N-CA-C 96.661 -5.311 . . . . 0.0 96.661 175.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 19.9 mt -102.19 150.64 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.582 0 N-CA-C 104.081 -2.562 . . . . 0.0 104.081 169.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.1 tptt -75.9 137.9 40.69 Favored 'General case' 0 N--CA 1.436 -1.157 0 C-N-CA 127.6 2.36 . . . . 0.0 108.504 -166.551 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 67.49 29.57 7.19 Favored 'General case' 0 C--N 1.357 0.897 0 C-N-CA 125.861 1.665 . . . . 0.0 110.898 -172.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -115.27 168.81 12.68 Favored Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 103.368 -3.893 . . . . 0.0 103.368 165.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 1.1 p90 -87.53 147.96 25.11 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 108.037 -1.097 . . . . 0.0 108.037 -178.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 1.8 p -115.0 157.83 22.9 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 105.712 -1.959 . . . . 0.0 105.712 -178.572 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 3.2 p -175.02 -158.63 0.07 Allowed 'General case' 0 N--CA 1.429 -1.512 1 N-CA-C 95.346 -5.798 . . . . 0.0 95.346 -175.995 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 87.4 mt -102.4 104.49 37.94 Favored Pre-proline 0 N--CA 1.441 -0.92 0 N-CA-C 100.632 -3.84 . . . . 0.0 100.632 164.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -82.97 -28.01 1.75 Allowed 'Trans proline' 0 CA--C 1.499 -1.243 0 CA-C-N 122.794 2.034 . . . . 0.0 109.848 -158.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 16.8 tt 171.09 -39.75 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.497 -1.08 0 N-CA-C 101.585 -3.487 . . . . 0.0 101.585 -177.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 65.5 mt -75.42 152.03 38.04 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 106.429 -1.693 . . . . 0.0 106.429 169.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 44.0 mtpt -95.97 54.99 1.53 Allowed 'General case' 0 N--CA 1.436 -1.135 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 -161.693 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 12.1 p30 -169.07 -179.24 3.53 Favored 'General case' 0 CA--C 1.486 -1.483 0 N-CA-C 100.703 -3.814 . . . . 0.0 100.703 178.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -139.1 43.13 1.19 Allowed Glycine 0 CA--C 1.483 -1.929 0 N-CA-C 104.083 -3.607 . . . . 0.0 104.083 176.461 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 38.6 tp -79.74 119.21 22.34 Favored 'General case' 0 CA--C 1.492 -1.256 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 -171.146 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 81.5 m -90.42 150.89 21.65 Favored 'General case' 0 CA--C 1.493 -1.234 0 N-CA-C 106.514 -1.662 . . . . 0.0 106.514 177.83 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 1.2 m -70.03 -28.31 65.37 Favored 'General case' 0 C--N 1.353 0.737 0 CA-C-N 118.779 0.718 . . . . 0.0 111.144 -177.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 4.0 p -90.01 3.89 51.82 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 124.618 1.167 . . . . 0.0 109.301 176.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 104.94 -75.23 0.24 Allowed Glycine 0 CA--C 1.491 -1.451 0 N-CA-C 110.074 -1.21 . . . . 0.0 110.074 169.584 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -83.66 144.67 29.25 Favored 'General case' 0 CA--C 1.496 -1.104 0 CA-C-O 120.859 0.362 . . . . 0.0 111.254 -160.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 5.9 t -123.07 130.39 52.72 Favored 'General case' 0 N--CA 1.428 -1.53 1 N-CA-C 99.449 -4.278 . . . . 0.0 99.449 178.19 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.5 p -150.61 56.54 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.437 -1.08 0 N-CA-C 102.548 -3.13 . . . . 0.0 102.548 170.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.84 -67.03 1.87 Allowed Glycine 0 CA--C 1.491 -1.41 0 N-CA-C 106.133 -2.787 . . . . 0.0 106.133 -177.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.5 m -87.5 157.5 3.17 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.099 0 N-CA-C 105.313 -2.106 . . . . 0.0 105.313 167.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 35.9 m -84.02 127.15 33.68 Favored 'General case' 0 CA--C 1.489 -1.391 0 N-CA-C 106.475 -1.676 . . . . 0.0 106.475 167.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -142.79 -141.63 0.13 Allowed 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 102.676 -3.083 . . . . 0.0 102.676 -177.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 -150.73 162.58 40.43 Favored 'General case' 0 N--CA 1.425 -1.701 1 N-CA-C 96.589 -5.337 . . . . 0.0 96.589 171.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 48.8 mt -153.73 170.95 19.68 Favored 'General case' 0 N--CA 1.428 -1.575 1 N-CA-C 94.891 -5.966 . . . . 0.0 94.891 171.715 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.357 0.919 0 O-C-N 124.262 0.976 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 . . . . . 0 N--CA 1.496 1.835 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 67.71 -148.49 0.15 Allowed 'General case' 0 C--N 1.358 0.971 0 C-N-CA 125.61 1.564 . . . . 0.0 109.08 -178.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 16.3 p -140.18 159.94 41.07 Favored 'General case' 0 N--CA 1.427 -1.598 1 N-CA-C 97.476 -5.009 . . . . 0.0 97.476 165.639 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 53.3 mt -109.02 154.65 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 -175.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 14.8 tppt? -87.58 143.19 27.32 Favored 'General case' 0 N--CA 1.437 -1.097 0 C-N-CA 128.229 2.611 . . . . 0.0 107.44 -157.197 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 85.1 m-85 79.81 2.91 2.11 Favored 'General case' 0 C--N 1.355 0.846 0 C-N-CA 127.453 2.301 . . . . 0.0 112.34 -173.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -92.36 165.09 28.61 Favored Glycine 0 C--N 1.349 1.301 0 N-CA-C 106.65 -2.58 . . . . 0.0 106.65 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 99.7 m-85 -76.44 144.35 39.98 Favored 'General case' 0 CA--C 1.497 -1.06 0 CA-C-N 118.135 0.967 . . . . 0.0 108.813 -175.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 10.6 p -138.63 167.16 22.55 Favored 'General case' 0 CA--C 1.482 -1.65 0 N-CA-C 103.066 -2.939 . . . . 0.0 103.066 177.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -87.16 -105.82 0.07 Allowed 'General case' 0 N--CA 1.429 -1.481 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 179.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 45.4 mt -153.46 154.11 30.09 Favored Pre-proline 0 N--CA 1.432 -1.361 1 N-CA-C 96.643 -5.317 . . . . 0.0 96.643 166.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.07 134.14 15.76 Favored 'Trans proline' 0 N--CA 1.451 -1.011 0 C-N-CA 122.422 2.081 . . . . 0.0 108.975 176.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . . 70.1 mt -140.21 -68.48 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.502 -0.873 0 N-CA-C 102.389 -3.189 . . . . 0.0 102.389 177.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 93.7 mt -111.98 -171.03 1.77 Allowed 'General case' 0 N--CA 1.437 -1.113 1 N-CA-C 99.492 -4.262 . . . . 0.0 99.492 164.703 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 3.3 mmmp? -81.19 66.49 6.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 122.344 1.069 . . . . 0.0 110.537 -177.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 23.1 t-20 -78.27 -60.85 2.21 Favored 'General case' 0 CA--C 1.496 -1.111 0 N-CA-C 104.414 -2.439 . . . . 0.0 104.414 170.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . -153.26 160.66 29.29 Favored Glycine 0 N--CA 1.424 -2.14 1 N-CA-C 99.239 -5.544 . . . . 0.0 99.239 171.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 28.9 tp -149.07 154.05 38.72 Favored 'General case' 0 N--CA 1.429 -1.476 1 N-CA-C 93.839 -6.356 . . . . 0.0 93.839 169.058 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 85.5 m -91.6 146.04 24.11 Favored 'General case' 0 CA--C 1.484 -1.561 0 CA-C-N 119.318 0.963 . . . . 0.0 109.437 -177.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 50.7 m -69.98 -27.26 64.57 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-O 120.757 0.313 . . . . 0.0 110.505 -176.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 3.4 p -90.52 4.66 50.52 Favored 'General case' 0 N--CA 1.445 -0.689 0 C-N-CA 123.997 0.919 . . . . 0.0 111.221 173.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 103.85 -74.89 0.27 Allowed Glycine 0 CA--C 1.49 -1.493 0 N-CA-C 110.371 -1.092 . . . . 0.0 110.371 172.113 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -82.58 153.07 25.67 Favored 'General case' 0 CA--C 1.502 -0.875 0 CA-C-N 118.146 0.973 . . . . 0.0 110.191 -163.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 33.7 t -142.42 152.02 42.38 Favored 'General case' 0 N--CA 1.429 -1.496 1 N-CA-C 98.166 -4.753 . . . . 0.0 98.166 -171.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 4.8 p -160.31 -142.92 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.146 1 N-CA-C 92.693 -6.78 . . . . 0.0 92.693 176.421 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -67.57 -15.11 65.81 Favored Glycine 0 C--N 1.35 1.308 0 CA-C-N 124.126 3.148 . . . . 0.0 113.008 -179.196 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.0 m -138.14 163.75 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.691 0 N-CA-C 100.927 -3.731 . . . . 0.0 100.927 -178.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 48.7 m -79.96 136.44 36.62 Favored 'General case' 0 CA--C 1.484 -1.589 0 C-N-CA 124.871 1.268 . . . . 0.0 108.172 176.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.23 -155.17 0.58 Allowed 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 104.834 -2.284 . . . . 0.0 104.834 -174.36 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -146.8 156.14 42.9 Favored 'General case' 0 N--CA 1.423 -1.815 1 N-CA-C 95.416 -5.772 . . . . 0.0 95.416 176.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 82.1 mt -153.59 165.46 35.83 Favored 'General case' 0 N--CA 1.425 -1.721 1 N-CA-C 94.406 -6.146 . . . . 0.0 94.406 178.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 0.889 0 O-C-N 124.299 0.999 . . . . 0.0 . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 . . . . . 0 N--CA 1.493 1.685 0 N-CA-C 102.447 -3.168 . . . . 0.0 102.447 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -113.82 -74.67 0.61 Allowed 'General case' 0 CA--C 1.494 -1.198 0 N-CA-C 104.456 -2.424 . . . . 0.0 104.456 -179.141 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 28.3 p -123.14 159.13 29.2 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 165.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ILE . . . . . . . . . . . . . 29.0 mt -100.29 141.2 17.68 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.293 0 N-CA-C 104.447 -2.427 . . . . 0.0 104.447 -174.076 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 26.7 ttpp -66.6 143.71 56.85 Favored 'General case' 0 N--CA 1.446 -0.653 0 C-N-CA 126.271 1.828 . . . . 0.0 110.589 -166.868 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' HYP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 90.7 m-85 56.46 33.88 23.29 Favored 'General case' 0 CA--C 1.5 -0.974 0 C-N-CA 126.288 1.835 . . . . 0.0 112.665 -172.386 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . -101.59 165.9 18.1 Favored Glycine 0 CA--C 1.487 -1.67 1 N-CA-C 102.481 -4.248 . . . . 0.0 102.481 161.026 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -71.87 152.13 42.84 Favored 'General case' 0 CA--C 1.501 -0.917 0 N-CA-C 108.571 -0.9 . . . . 0.0 108.571 -177.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 26.9 p -151.67 -176.45 5.62 Favored 'General case' 0 N--CA 1.432 -1.372 1 N-CA-C 98.664 -4.569 . . . . 0.0 98.664 169.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 1.7 p 141.2 -139.3 0.0 OUTLIER 'General case' 0 CA--C 1.497 -1.092 1 N-CA-C 93.398 -6.519 . . . . 0.0 93.398 -169.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 76.0 mt -120.42 81.95 31.51 Favored Pre-proline 0 N--CA 1.441 -0.876 0 CA-C-N 119.676 1.126 . . . . 0.0 109.298 177.182 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -85.9 -4.75 8.89 Favored 'Trans proline' 0 N--CA 1.452 -0.933 0 C-N-CA 122.122 1.881 . . . . 0.0 110.788 166.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ILE . . . . . . . . . . . . 0.26 17.9 mt 75.03 -64.9 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.441 -0.878 0 C-N-CA 127.414 2.286 . . . . 0.0 110.023 175.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 mm? -72.19 -39.44 68.62 Favored 'General case' 0 CA--C 1.499 -1.0 0 CA-C-O 122.243 1.021 . . . . 0.0 108.818 -170.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 85.5 mttt -98.34 21.8 10.53 Favored 'General case' 0 N--CA 1.434 -1.243 0 CA-C-N 114.939 -1.028 . . . . 0.0 108.779 -179.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -86.23 174.34 9.16 Favored 'General case' 0 CA--C 1.497 -1.079 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 171.554 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . 164.28 -159.83 32.76 Favored Glycine 0 N--CA 1.417 -2.575 1 N-CA-C 94.89 -7.284 . . . . 0.0 94.89 -173.301 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LEU . . . . . . . . . . . . . 46.3 mt -100.08 174.85 5.97 Favored 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 102.236 -3.246 . . . . 0.0 102.236 163.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 57.1 m -88.33 148.66 24.17 Favored 'General case' 0 CA--C 1.483 -1.609 0 N-CA-C 105.492 -2.04 . . . . 0.0 105.492 175.669 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' CYS . . . . . . . . . . . . . 27.1 m -72.81 -16.89 61.61 Favored 'General case' 0 C--N 1.352 0.693 0 CA-C-O 120.675 0.274 . . . . 0.0 110.63 -172.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 5.7 p -88.43 -17.24 30.87 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 125.688 1.595 . . . . 0.0 110.158 176.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLY . . . . . . . . . . . . . . . 117.1 -78.58 0.29 Allowed Glycine 0 N--CA 1.436 -1.309 0 N-CA-C 108.479 -1.848 . . . . 0.0 108.479 -175.27 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . . . . . . . . . . . -80.87 150.41 29.1 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.83 -0.806 . . . . 0.0 111.418 -166.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' CYS . . . . . . . . . . . . . 14.6 t -131.11 137.14 48.94 Favored 'General case' 0 N--CA 1.425 -1.719 1 N-CA-C 97.868 -4.864 . . . . 0.0 97.868 -177.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 3.2 p -135.19 -129.87 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.435 -1.189 1 N-CA-C 98.027 -4.805 . . . . 0.0 98.027 164.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -78.16 -5.01 87.1 Favored Glycine 0 C--N 1.349 1.305 0 O-C-N 117.705 -3.122 . . . . 0.0 110.713 178.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 3.1 m -145.78 164.42 10.59 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.728 1 N-CA-C 99.14 -4.393 . . . . 0.0 99.14 -177.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' CYS . . . . . . . . . . . . . 93.9 m -79.07 137.64 37.61 Favored 'General case' 0 CA--C 1.495 -1.172 0 N-CA-C 108.09 -1.078 . . . . 0.0 108.09 169.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -152.11 -151.23 0.37 Allowed 'General case' 0 CA--C 1.493 -1.229 0 N-CA-C 103.985 -2.598 . . . . 0.0 103.985 -174.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.1 p30 -143.65 161.63 38.04 Favored 'General case' 0 N--CA 1.426 -1.647 1 N-CA-C 98.007 -4.812 . . . . 0.0 98.007 175.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 81.3 mt -150.43 163.96 37.07 Favored 'General case' 0 N--CA 1.423 -1.814 1 N-CA-C 94.276 -6.194 . . . . 0.0 94.276 167.212 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' NH2 . . . . . . . . . . . . . . . . . . . . 0 C--N 1.358 0.936 0 O-C-N 124.248 0.967 . . . . 0.0 . . . . . . . . . . 0 0 . 1 stop_ save_